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ABSTRACT 
Paratuberculosis (Johne's disease) is a chronic granulomatous infection of cattle, 
caused by the intracellular bacterium Mycobacterium avium subsp. paratuberculosis 
(referred to hereafter as M. paratuberculosis). Currently available vaccines are not effective 
at preventing infection or transmission of the bacterium to other animals. The objectives of 
this dissertation were to develop and test DNA vaccines that prevent M. paratuberculosis 
infection, to examine the host immune response induced by protective DNA vaccines, and to 
identify immunogenic proteins from M. paratuberculosis. In an effort to identify protective 
M. paratuberculosis sequences, a genomic DNA expression library was generated and 
subdivided into pools of clones. Eleven clone pools were evaluated to determine DNA 
vaccine efficacy by immunizing mice via gene gun delivery and challenging with live, 
virulent M. paratuberculosis. Four clone pools demonstrated a significant reduction (P < 
0.05) of M. paratuberculosis infection in mice when compared to other clone pools and non-
vaccinated, infected control mice. In a second study, one of the protective clone pools was 
partitioned into 10 new clone arrays of 108 clones each and an immunization experiment was 
performed to identify protective clone arrays. When groups of mice were immunized with 
clone array DNA via gene gun, four clone arrays provided significant protection (P < 0.05) 
from M. paratuberculosis challenge. Comparison of the nucleotide sequences from 
protective clone arrays identified 26 sequences that may have contributed to the protection 
observed in these mice. Additionally, protective clone arrays were found to induce IL-10 and 
IL-12 cytokine production, which indicated induction of both ThI and Tr2 immune 
responses. In a final experiment, the efficacy of the M. paratuberculosis 19 kDa lipoprotein 
was evaluated as an immunomodulator in cattle with Johne's disease. Control, non-infected 
ix 
cattle did not produce antibodies or cell-mediated immune responses against the 19 kDa 
protein. However, the 19 kDa protein induced cellular immune responses (IFN-y production) 
in subclinical^ infected cattle and induced humoral immune responses (19 kDa-specific 
antibody production) in clinically infected cattle. Taken together, these three studies have 
identified a number of M. paratuberculosis antigens that may aid in the development of 
vaccines to prevent Johne's disease. 
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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Johne's disease, or paratuberculosis, owes its name to H.A. Johne who in 1895, along 
with L. Frothingham, reported an association between a tuberculosis-like acid-fast bacilli and 
intestinal inflammation of cattle (Johne and Frothingham, 1895). Bang further investigated 
the disease in 1906 and determined that it was not tuberculosis, but instead named it pseudo­
tuberculous enteritis or Johne's disease (Bang, 1906). In 1912, Twort was successful at 
culturing the bacterium and in 1914 described the experimental induction of enteritis in cattle 
(Twort and Ingram, 1912; Twort, 1914). The bacterium has undergone many name changes 
since its initial discovery, with the official name now being Mycobacterium avium subsp. 
paratuberculosis. 
Paratuberculosis has been reported throughout the world and the economic losses to 
the dairy industry are significant. In the United States alone, approximately 35% of herds are 
infected with paratuberculosis, and the resulting yearly losses are estimated at 250 million 
dollars (Collins et al., 1994; Ott et al,. 1999; Stabel, 1998). It is believed that young animals 
are the most susceptible and become infected upon ingestion of contaminated milk or 
colostrum. Typically, an incubation period of 2-5 years is common before clinical symptoms 
of disease appear (Larsen et al., 1975). During the subclinical stage, animals may 
intermittently shed bacteria through their feces or milk, allowing for spread of infection 
throughout the herd. Clinical disease is characterized by chronic diarrhea, weight loss, and 
general loss of health. Although Johne's disease is primarily considered a problem for cattle, 
sheep, and goats, infection has been reported in a number of wild ruminants, including 
moose, bighorn sheep, Rocky Mountain goats, American bison, and deer, and monogastrics 
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such as horses, mules, swine, and chickens. Additionally, controversy exists over reports that 
have suggested an association between human infection with Mycobacterium avium subsp. 
paratuberculosis and Crohn's disease (Bull et al., 2003; Green et al., 1989; McFadden et al., 
1987). 
Mycobacterium avium subsp. paratuberculosis, referred to hereafter as M. 
paratuberculosis, is fastidious and extremely slow growing, hindering laboratory 
manipulations. Diagnostic tests are available, but a low bacterial load and varying immune 
response to infection often complicate identification of infected animals. Treatment options, 
such as the use of antibiotics, are expensive and often ineffective (Chiodini et al., 1984). 
While vaccines are available, they induce inflammation at the injection site, interfere with 
diagnostic tests, and do not prevent infection, but rather delay the onset of clinical disease 
(Chiodini et al., 1984; Cocito et al., 1994). Although there is a long history and great deal of 
information about paratuberculosis, much remains to be done to understand the organism, its 
intracellular survival, the host response to infection, and methods to effectively prevent 
disease. 
The use of DNA vaccines has gained favor in recent years as a safe and effective 
means of controlling a number of infectious diseases. Compared with traditional vaccines, 
DNA vaccines offer the advantage of being inexpensive and simple to produce, are stable at a 
variety of temperatures, and do not contain elements that induce allergic or hypersensitivity 
responses often associated with conventional vaccines (Babiuk et al., 2000). Advances in 
molecular biology and high-throughput technology, in conjunction with DNA vaccination, 
have made it possible to screen thousands of antigens in a relatively short period of time. 
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The objectives of this dissertation were to develop and test DNA vaccines that 
prevent M paratuberculosis infection, to examine the host immune response induced by 
protective DNA vaccines, and to identify immunogenic proteins from M. paratuberculosis. 
Dissertation Organization 
This dissertation is arranged into a series of chapters: a general introduction, a review 
of the literature, three separate scientific manuscripts, and a general conclusions chapter. The 
first manuscript, Chapter 3, entitled "Expression library immunization of mice as a potential 
vaccination strategy against Mycobacterium avium subsp. paratuberculosis infection, " has 
been submitted to Vaccine. The second manuscript, Chapter 4, entitled "Sequence analysis 
and immunological assessment of protective clones from an expression library of 
Mycobacterium avium subsp. paratuberculosishas been prepared for submission to 
Vaccine. The third manuscript, Chapter 5, entitled "Cloning, characterization, and 
antigenicity of the Mycobacterium avium subsp. paratuberculosis 19-kDa lipoprotein," has 
been prepared for submission to Microbial Pathogenesis. I, Jason F. Huntley, am primary 
author for all manuscripts listed above. Judy Stabel (co-major professor) was co-author for 
all three manuscripts. John Bannantine (POS committee member and scientific mentor at the 
National Animal Disease Center) was co-author for all three manuscripts. Tim Reinhardt 
(POS committee member) provided assistance with design of the second experiment and is 
co-author on the second manuscript. Mike Paustian provided assistance with sequence 
analysis and is co-author on the second manuscript. 
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CHAPTER 2. REVIEW OF THE LITERATURE 
Microbiology 
Mycobacterial species 
The genus Mycobacterium contains a number of pathogenic bacteria, including 
Mycobacterium leprae, Mycobacterium avium, Mycobacterium tuberculosis, Mycobacterium 
bovis, and Mycobacterium paratuberculosis, which cause leprosy, pulmonary infections in 
birds and HIV-infected individuals, tuberculosis, bovine tuberculosis, and Johne's disease, 
respectively. Mycobacteria are acid-fast, Gram-positive bacilli that are approximately 0.5 to 
1.5 (am in length (Clarke, 1997). They are intracellular pathogens and have elaborate 
mechanisms for binding to and entering host cells, avoiding degradation in the phagosome, 
and evading immune detection. The mycolic acids present on the outer membrane of the 
mycobacteria are long-chain fatty acids that may serve as a thick coat defense mechanism 
against the host immune system (Brennan and Nikaido, 1995). Mycobacteria require iron for 
growth and secrete exochelins to scavenge iron from the intracellular compartment. In an 
environment where iron is scarce, exochelins efficiently remove iron from animal transferrin 
and lactoferrin and transfer it to membrane-associated mycobactin (Cocito et al., 1994). 
As a subset of mycobacteria, the M. avium complex is composed of three closely 
related members: M. avium subsp. avium (M. avium), M. avium subsp. silvaticum (M. 
silvaticum), and M. avium subsp .paratuberculosis. This taxonomic classification has been 
based upon either biochemical or genetic analysis. In culture, M. paratuberculosis requires 
mycobactin for growth, whereas M. avium and M. silvaticum do not (Thorel et al., 1990). 
Genetically, the presence of the IS900 insertion sequence (discussed later) differentiates M. 
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paratuberculosis from M. avium and M. silvaticum (Collins et al., 1989; Green et al., 1989). 
By comparison, related insertion sequences are specific for other M. avium complex 
members: IS901 and IS11J0 for M. avium (Kunze et al., 1991; Kunze et al., 1992; 
Hernandez-Perez et al., 1994) and IS902 for M. silvaticum (Moss et al., 1992). 
Laboratory culture 
M. paratuberculosis can be cultured on a number of mediums, including Herrold's 
egg yolk medium (HEYM), Cornell media, and Lôwenstein-Jensen. These media differ in a 
number of components, including the inclusion or exclusion of antibiotics and the use of 
whole eggs or egg yolks (Kalis et al., 2000; Whipple et al., 1991). While most European 
laboratories routinely use Lôwenstein-Jensen medium, the majority of North American 
laboratories use HEYM. A recent study compared HEYM to Lôwenstein-Jensen media and 
found that HEYM supported the growth of more than twice as many M. paratuberculosis 
colonies in a shorter incubation period (Nielsen et al., 2004). As noted above, M. 
paratuberculosis requires mycobactin for growth, therefore, inclusion of mycobactin J into 
media aids in bacterial recovery and increases the growth rate of the organism (Merkal and 
McCullough, 1982). Despite decades of research to optimize growth conditions, the 
organism is extremely slow growing and requires 8 to 12 weeks of incubation before colony 
growth is visible (Stabel, 1997). Colony growth is typically small (1-5 mm) by 8-12 weeks 
and colonies appear rough, glossy, and are white. Although rare, yellow or orange-
pigmented M. paratuberculosis strains have been isolated from sheep and cattle (Chiodini et 
al., 1984; Stevenson et al., 2002). 
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Environmental survival 
M. paratuberculosis is extremely stable and can tolerate exposure to ultraviolet light 
and fluctuations in temperature and pH better than other bacterial pathogens. The majority of 
data regarding environmental survival of M. paratuberculosis was performed over 25 years 
ago, but demonstrated that the bacterium can remain viable for nine months in rivers and 
ponds and up to eleven months in soil and feces (Jorgensen, 1977; Larsen et al., 1956; Lovell 
et al., 1944). A recent study has demonstrated that the bacteria could be cultured from fecal-
contaminated soil for up to 55 weeks (Whittington et al., 2004). Additionally, moisture and 
application of lime to the soil did not affect survival of the bacteria. A separate study found a 
correlation between loamy soils with high silt or sand content and higher percentages of 
paratuberculosis-positive cattle (Ward and Perez, 2004). 
Data regarding M. paratuberculosis heat tolerance have largely been performed in 
pasteurization experiments. Two studies suggested that paratuberculosis is heat tolerant, and 
that a resistant sub-population may survive high-temperature, short-time (HTST) 
pasteurization treatment conditions (72-75°C, 15-25 sec), but not batch pasteurization (63°C, 
30 minutes) (Gao et al., 2002; Grant et al., 2002). However, two separate studies have 
demonstrated effective killing of 105 CPU of M. paratuberculosis by the batch method 
(65.5°C for 30 minutes) and 10* CPU by HTST (72°C, 15 sec) (Stabel ef a/, 1997; Stabel, 
2001). 
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Infection and Disease 
Host range 
Although primarily considered a disease of cattle, sheep, and goats, a number of other 
ruminants become infected with M. paratuberculosis, including white-tailed deer 
{Odocoileus virginianus) (Chiodini and van Kruiningen, 1983; Libke and Walton, 1975), 
Key deer (Odocoileus virginianus clavium) (Quist et al., 2002), fallow deer (Dama dama) 
(Marco et al., 2002), saiga antelope (Saiga tatarica) (Dukes et al., 1992), tule elk {Cervus 
eleaphus nannodes) (Cook et al., 1997; Jessup et al., 1981; Manning et al., 2003), bighorn 
sheep (Ovis canadensis), Rocky Mountain goats (Oreamnos americanus) (Williams and 
Spraker, 1979; Williams et al., 1983a), and bison (Bison bison) (Buergelt and Ginn, 2000; 
Buergelt et al., 2000; Whitlock et al., 1999; Whittington et al., 2001). M. paratuberculosis 
has also been isolated from monogastrics, including chickens (Larsen and Moon, 1972), 
rabbits (Angus, 1990; Greig et al., 1997; Greig et al., 1999), swine (Jorgensen, 1979; Larsen 
et al., 1971; Thoen et al., 1975), and horses (Larsen et al., 1972). The bacteria can replicate 
and persist in these hosts, but clinical disease rarely develops. Because of this, there is 
concern that wild ruminants and monogastrics serve as significant reservoirs for infection of 
domestic ruminants such as cattle. Indeed, it has been shown that wildlife isolates of M. 
paratuberculosis can infect domestic ruminants (Williams et al, 1983b). Further, one study 
showed an increased incidence of Johne's disease in dairy cattle who grazed on land where 
M paratuberculosis-positive deer also resided (Cetinkaya el al., 1997). 
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Infection of cattle 
Cattle are most likely infected as neonates through ingestion of colostrum or milk 
from infected dams (Chiodini et al., 1984; Larsen et al., 1975). Bacteria are primarily shed 
through the feces, colostrum, and milk, but have also been recovered from the uterus (Rhode 
and Shulaw, 1990), kidney (Hines et al., 1987), supramammary lymph nodes (Sweeney et 
al., 1992a), and semen (Larsen et al., 1981) of infected cattle. In addition, transplacental or 
in-utero infection of the fetus has been reported and it is estimated that between 20% to 40% 
of fetuses are infected in utero (Seitz et al., 1989; Sweeney et al., 1992b). The number of 
organisms required to establish infection in young cattle is not known, but because of the 
incomplete development of the neonate immune system, it is believed that few bacteria are 
needed for infection (Chiodini et al., 1984; Cocito et al., 1994). The bacterial load in the 
feces can exceed 1010 CFU/gram of feces, therefore fecal contamination of the udder is a 
likely route of infection (Chiodini et al., 1984). Additionally, shedding of bacteria into 
colostrum and milk has been detected from 35% of heavy shedders and as high as 9% of low 
shedders (Streeter et al., 1995; Sweeney et al., 1992a). There is an age-related susceptibility, 
as older animals are more resistant to infection or, if infected as adults, may never develop 
clinical disease (Larsen et al, 1975). 
Little information is available about breed susceptibility, but one study indicated that 
Channel Island and Shorthorn breeds have a higher incidence of paratuberculosis (Julian, 
1975). Other reports have suggested an increased susceptibility to particular cattle breeds, 
but these are more than likely due to regional differences in the number and breeds of beef or 
dairy cattle herds (Chiodini et al., 1984). The role of host genetic components in disease 
susceptibility has also been explored. Both the natural resistance associated macrophage 
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protein 1 (nrampl) (McLeod et al., 1995) and the susceptibility to tuberculosis 1 (sstl) 
(Kramnik et al., 2000) genes have been shown to play a role in resistance to intracellular 
pathogens such as mycobacteria. 
Cellular interactions 
Upon ingestion of contaminated material, M. paratuberculosis passes from the lumen 
of the small intestine into the lamina propria via M cells (Momotani et al., 1988). M cells are 
specialized cells lacking brush-border microvilli, digestive enzymes, or surface mucous and 
provide a simple route of entry for enteric pathogens (Featherstone, 1997). Alternatively, the 
bacilli may invade intestinal epithelial cells using specific virulence factors (Bannantine et 
al., 2003b). The bacteria are released on the basolateral side of the cell, where they are 
phagocytosed by resident macrophages and dendritic cells of the Beyer's patches. In vitro 
studies have shown that non-opsonized M. paratuberculosis are readily taken up by non-
activated bovine macrophages (Feola et al., 1999; Zhao et al., 1999; Zurbrick et al., 1988). It 
is not known whether the bacteria actively invade macrophages or are phagocytosed as part 
of the normal antigen sampling function of the intestinal mucosal surface. Regardless of the 
active or passive role of M. paratuberculosis, a number of macrophage receptors have been 
identified which bind to mycobacterial surface components and aid in internalization of the 
bacteria. These macrophage receptors include the mannose receptor (Schlesinger, 1993; 
Kang and Schlesinger, 1998; Astarie-Dequeker et al., 1999), complement receptors CR1, 
CR3, and CR4 (Schlesinger and Horwitz, 1991; Stokes et al., 1993; Melo et al., 2000), the 
Toll-like receptor 2 (Means et al., 1999; Underbill et al., 1999), and the fibronectin receptor 
(Kuroda etal., 1993). 
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Once inside the phagosome of the macrophage, mycobacteria interfere with 
phagosome maturation, acidification, and phagosome-lysosome fusion through mechanisms 
that are not completely understood. Phagosomes containing mycobacteria lack a proton-
ATPase in the vacuolar membrane, which normally begins the acidification process 
(Sturggill-Koszycki et al., 1994). M. paratuberculosis-containing phagosomes were shown 
to be only mildly acidified to pH 6.3, as compared to phagosomes containing dead M. 
paratuberculosis or latex beads (Kuehnel et al., 2001). Recent studies suggest that 
mycobacteria interrupt the normal trafficking of Rab proteins, which are present on the 
cytoplasmic surface of phagosomes and are involved in signaling and maturation (Clemens et 
al., 2000; Deretic et al., 1997; Via et al., 1997). It has also been shown that 
lipoarabinommannan (LAM), a mycobacterial cell wall component, blocks EEA1 and 
syntaxinô recruitment to the phagosome and inhibits Ca2+ signaling events that induce 
phagosome-lysosome fusion (Fratti et al., 2001; Fratti et al., 2003; Vergne et al., 2003). 
Mycobacteria also have the ability to escape from the phagosome into the cytosol to avoid 
lysosomal degradation (McDounought et al., 1993). 
The early stage of infection occurs without activation of the macrophage or 
generation of a host immune response (Chiodini, 1996; Coussens, 2001; Woodward et al., 
1979). During this time, mycobacteria replicate and spread to other macrophages, bacterial 
antigen is processed and presented to T cells, antigen-specific T cells clonally expand, and 
the cellular immune response is activated. Granulomas, clusters of infected macrophages 
surrounded by activated T cells, form at the infection site to contain the bacteria and 
maximize bactericidal activity. In a guinea pig model of M. tuberculosis infection, a 
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bacterial load of 103 to 104 CPU was needed before antigen presentation and cellular 
immunity begin (Smith et al., 1970). 
Disease stages 
Paratuberculosis progresses through three disease stages in cattle (Cocito et al., 
1994). During stage 1, subclinical without fecal shedding, the animal shows no signs of 
disease with little or no bacterial shedding. For animals in this stage, the immune response is 
primarily a cellular immune response that appears to control the infection (discussed in detail 
in a later section). Stage 2, subclinical with bacterial shedding, is perhaps the most important 
stage for dairy producers because animals that otherwise appear healthy are shedding 
paratuberculosis in their feces which can be ingested by other animals. Bacterial shedding in 
the feces may be intermittent, which complicates diagnosis if only one fecal sample is taken 
for culture. Immunologically, the cellular immune response may being to fade in stage 2 and 
segue to a humoral immune response. In stage 3, animals begin to show clinical signs of 
paratuberculosis, including weight loss, chronic diarrhea, decreased milk production, and 
infertility. If left untreated or if the cow is not culled and sent to slaughter, the animal will 
eventually die in a state of poor health. During the terminal stage of infection, fecal shedding 
can exceed 1010 bacteria per gram of feces (Chiodini et al., 1984). Despite high levels of M. 
paratuberculosis-specific antibody production, antibodies do not protect cattle from clinical 
disease (Stabel, 1998). 
The time between infection and development of clinical disease is variable and 
depends on a number of factors, including initial infectious dose, immune response, and 
environment. Experimental infections of cattle have shown that between 10 to 15% animals 
develop clinical disease (Lepper et al., 1989; Stuart, 1965). Typically, clinical signs do not 
appear until the animal is at least 3 to 5 years of age (Chiodini et al., 1984; Larsen et al., 
1975). Stressors such as parturition, lactation, dietary deficiencies, or parasite infection may 
induce clinical disease (Stabel, 2000). The diarrhea that develops in clinical animals is a 
result of chronic inflammation of the intestine and may be due to delayed-type 
hypersensitivity reactions to M. paratuberculosis antigens (Chiodini et al., 1984). 
Animal models 
Because clinical disease takes years to develop in ruminants, a number of small 
animal models have been developed to study M. paratuberculosis infection. Oral infection 
of rabbits has been reported, but the development of clinical signs and histopathologic lesions 
only occurs in 62 to 75% of infected animals (Mokresh et al., 1989; Mokresh and Butler, 
1990). The majority of small animal experiments that examined infection and 
immunological responses to M. paratuberculosis have been performed in mice, most notably 
in C57BL/6 and Balb/c strains (Chiodini and Buergelt, 1993; Tanaka et al., 1994; Veazey et 
al., 1995a; Veazey et al., 1995b; Veazey et al., 1996). Resistance to mycobacterial 
infections in mice, including M. paratuberculosis, is associated with the Beg locus on mouse 
chromosome 1 (Frelier et al., 1990). Resistance (Bcgr) and susceptibility (Bcgs) to 
mycobacterial infections is now known to be correlated with the nramp gene, noted 
previously. A mutation in the Nramp gene confers susceptibility to mycobacterial infection. 
Nramp is a component of the lysosomal membrane of monocytes and macrophages and 
regulates iron concentrations in the lysosome, presumably sequestering iron away from 
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intracellular pathogens (Blackwell and Searle, 1999). Both C57/B6 and Balb/c mice have the 
Bcgs allele, while C3H/HeJ mice have the Bcgr allele. 
When comparing infection of Balb/c, C57/B6, and C57/B10 mouse strains over 180 
days, Balb/c were found to maintain the highest level of M. paratuberculosis in the spleen 
and liver, with C57/B6 mice being less susceptible and C57B10 being the least susceptible to 
infection (Chiodini and Buergelt, 1993). A comparison of M paratuberculosis infection in 
Balb/c and C3H/HeJ mice demonstrated that the number and size of granulomatous lesions in 
Balb/c mice was dramatically increased as compared to C3H/HeJ mice (Tanaka et al., 1994). 
Similarly, a comparison of oral infection in C57/B6 and C3H/HeJ mice revealed that C57/B6 
mice had more granulomas in mesenteric lymph nodes and liver, whereas C3H/HeJ mice 
progressively cleared M. paratuberculosis infection during the course of the study (Veazey et 
al., 1995b). An immunologic analysis of C57/B6 and C3H/HeJ mice found that C57/B6 
mice have lower levels of CD4+ T cells but higher percentages of CD8+ and yô T cells both 
before and after M. paratuberculosis infection, as compared to C3H/HeJ mice (Veazey et al., 
1996). Together with the Nramp mutation, these differences in cell populations may account 
for increased susceptibility of C57/B6 mice to M. paratuberculosis infection. 
Among other mouse strains examined, both beige/scid and nude mice have been 
reported to develop clinical signs consistent with Johne's disease in cattle, including weight 
loss, atrophy of muscle tissue, thickening of the small intestine, and diarrhea (Hamilton et al., 
1991; Mutwiri et al., 2001). Additionally, T cell receptor (TCR)-a-deficient deficient mice 
were found to be more susceptible to M. paratuberculosis infection than TCR-8-deficient or 
C57/B6 mice, suggesting that a(3 T cells play a major role in disease resistance (Stabel and 
Ackermann, 2002). 
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Pathology 
Gross lesions, either focal or diffuse, in clinical paratuberculosis cattle are most 
common in the terminal portion of the ileum and associated lymph nodes. The intestinal wall 
is thickened, edematous, appears corrugated, and the mucosal surface has thick transverse 
folds. Mesenteric lymph nodes and associated lymphatics are likewise enlarged and 
edematous. Lesions may also occur in the liver and hepatic lymph nodes as well as kidneys, 
lungs, and other systemic lymph nodes (Buergelt et al., 1978; Chiodini et al., 1984; Hines et 
al., 1987; Whitlock and Buergelt, 1996). 
Histologically, paratuberculosis can be characterized by the presence of large 
numbers of macrophages and Langhans' giant cells in the mucosa and submucosa. A 
classification scheme was developed to grade lesions as mild, moderate, or marked (Buergelt 
et al., 1978; Clarke, 1997). "Mild" lesions are characterized by few Langhans' giant cells 
and macrophages in the intestinal mucosa, submucosa, and mesenteric lymph nodes with no 
detectable acid-fast bacilli. "Moderate" lesions are characterized by groups of macrophages 
and/or Langhans' giant cells in the intestinal mucosa, submucosa and mesenteric lymph 
nodes with some acid-fast bacilli present. "Marked" lesions contain large numbers of 
Langhans' giant cells and macrophages infiltrating all layers of the intestinal tissue and 
lymphatic vessels. Additionally, villi are blunted, intestinal crypts are distended, and large 
numbers of acid-fast bacilli are found in the giant cells and macrophages. Macrophages in 
the moderate and marked stages appeared larger than normal with a foamy, vacuolated 
cytoplasm. There is no caseous necrosis or ulceration associated with paratuberculosis. 
Lymphocytes appear as aggregates, surrounding macrophages and giant cells, and a foci of 
necrosis may occur in the center of the granuloma. 
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Immunology 
Overview 
As previously discussed, there is a lag between the time of M. paratuberculosis 
infection and the generation of an immune response. During this time, the macrophage 
attempts to kill the pathogen and process antigens for presentation to other immune cells. 
Antigen bound to MHC class I molecules is presented to CD8+ cells while antigen bound to 
MHC class II molecules is presented to CD4+ cells. Infected macrophages become activated 
and produce interleukin-1 (IL-1), which in conjunction with antigen presentation, activates T 
lymphocytes (Cohen, 1990). Activated T cells, in turn, produce interleukin-2 (IL-2), which 
stimulates the clonal expansion of M. paratuberculosis-specific CD8+ cytolytic T 
lymphocytes and CD4+ helper T lymphocytes. Helper T cells can be divided into two 
counter-regulatory subsets, Tyl and Th2, which direct different immune functions. ThI 
lymphocytes produce cytokines such as IL-2, IL-12, tumor necrosis factor-beta (TNF-(3), and 
gamma interferon (IFN-y), which are involved in cell-mediated immunity. Th2 lymphocytes 
produce cytokines such as IL-4, IL-5, IL-6, and IL-10, which induce antibody production via 
humoral immunity (Cherwinski et al., 1987; Mosmann and Coffman, 1989). 
A paradoxical immune response has been described in M. paratuberculosis-'mkctsd 
cattle, as the immune response switches during the course of infection (Stabel, 2000). 
During the subclinical stage of infection, a cell-mediated immune response predominates, as 
characterized by strong delayed-type hypersensitivity reactions, lymphocyte proliferation to 
antigens, and production of ThI cytokines by stimulated T lymphocytes. As the disease 
progresses to the clinical stage, the cell-mediated immune response fades and the humoral 
immune response, characterized by antibody production and Th2 cytokine release, 
predominates. Antibodies to M. paratuberculosis do not protect the host from disease, while 
cellular immunity appears to be critical for controlling infection and preventing clinical 
signs. 
y8 T cells 
In addition to CD4+ and CD8+ cells, yô T cells also play a major role in controlling 
mycobacterial infection. In humans, yô T cells produce nearly twice as much IFN-y in 
response to mycobacteria as CD4+ T cells (Tsukaguchi et al., 1999). Further, despite the 
ability of mycobacteria to prevent phagosome-lysosome fusion, macrophages that were pre-
activated by yô T cells secreting IFN-y demonstrated phagolysosome maturation and 
increased mycobacterial killing (Bonecini-Almedia et al., 1998; Flynn et al., 1993). In 
mouse studies, yô T cells rapidly proliferated in response to mycobacterial infection and 
played a critical role in granuloma formation (Janis et al., 1989; Tanaka et al., 2000). Taken 
together, these studies suggest that yô T cells are an important mediator of anti-mycobacterial 
activity. 
The role of yô T cells in ruminant paratuberculosis appears to be different from 
human mycobacterial infections. In contrast to humans, in which 5-10% of circulating CD3+ 
T cells are yô T cells, as many as 80% of the circulating CD3+ T cells in young calves are yô 
T cells (Hein and Mackay, 1991). These high percentages decrease in the circulation as the 
animal ages, but this decline is likely due to the preferential homing of yô T cells to the skin, 
spleen, and intestinal epithelia (Hein and Dudler, 1997; Machugh et al., 1997). However, the 
protective effect of yÔ T cells in ruminants is still controversial, as studies have found that 
cattle and sheep yô T cells proliferate in response to mycobacterial antigens but do not 
secrete IFN-y (Bassey and Collins, 1997; Hasvold et al., 2002; Smyth et al., 2001). Further, 
yô T cells are present in higher numbers in clinical cattle than subclinically-infected cattle 
(Koets et al., 2002). 
IFN-y 
In the earliest stages of mycobacterial infection, IFN-y appears to be the most critical 
cytokine for controlling bacterial growth in both humans (Cooper and Flynn, 1995; Orme, 
1993; Yamamura et al., 1991) and cattle (Stabel, 1996; Sweeney et al., 1998). As noted 
above, yô T cells are responsible for the majority of IFN-y production in humans. However, 
CD4+ T cells have been shown to secrete the major portion of IFN-y in subclinically infected 
cattle, indicating the importance of CD4+ T cells in controlling paratuberculosis (Bassey and 
Collins, 1997; Waters et al., 2003). As further proof of the importance of CD4+ T cells, 
subclinically-infected sheep were found to contain large numbers of CD4+ cells in intestinal 
tissue (Little et al., 1996). Additionally, in mice, CD4+ T cells have been shown to be 
required to control M. paratuberculosis infection (Adams et al., 1993; Stabel and 
Ackermann, 2002). In contrast, few CD4+ T cells could be found in goats and cattle in the 
advanced stages of paratuberculosis (Koets et al., 2002; Navarro et al., 1998). Finally, cell 
types such as NK cells or NK T cells have been implicated as producers of IFN-y in 
mycobacterial diseases (Emoto et al., 1999; Smith et al., 1997), although there is no evidence 
of this in ruminant paratuberculosis to date. 
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CD8+ T cells 
The role of CD8+ cytotoxic T cells in paratuberculosis remains unclear, although one 
study has shown increases in CD8+ cells in infected tissues of clinical animals (Navarro et 
al, 1998). Additionally, CD8+ cells may act as regulators of other immune cells, as the 
proliferative responses of yô T cells to M. paratuberculosis antigens were blocked by the 
presence of CD8+ cells (Chiodini and Davis, 1993). Although not necessarily true for 
paratuberculosis, CD8+ cells were shown to selectively kill M. tuberculosis-infected 
macrophages from humans (Stenger et al., 1997). 
B cells 
Little information is available about the function of B cells in paratuberculosis, 
probably due to the fact that M. paratuberculosis-specific antibodies have little effect on 
disease outcome (Stabel, 2000). In cattle with clinical signs of disease, the percentage of B 
cells in peripheral blood was significantly higher than subclinically-infected or control cattle 
(Waters et al., 1999). However, B cells from these clinical cattle were unresponsive to 
stimulation with M. paratuberculosis antigen, as compared to vigorous stimulation of B cells 
from subclinical and control animals. These data suggest that either B cells become anergic 
during the late stages of disease or antigen-specific B cells traffic to effector sites (i.e. 
intestinal lymph nodes). 
The role of other cytokines 
Gene expression profiling of peripheral blood mononuclear cells (PBMCs) from M. 
paratuberculosis-mfectcd cattle revealed an up regulation of IFN-y from subclinical cattle 
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and an upregulation of IL-10 and IFN-y from clinical cattle (Coussens et al., 2002; Coussens 
et al., 2003). A recent study examined the expression of 13 cytokines from PBMCs, ileal 
tissues, and mesenteric lymph nodes from subclinically infected cattle (Coussens et al., 
2004). They found that in PBMCs, M. paratuberculosis induced the expression of IL-10, but 
suppressed IFN-y, TNF-a, and IL-6 production, as compared to control, non-infected cattle. 
By comparison, ileal tissues responded to M. paratuberculosis infection by enhanced 
production of IFN-y, TGF-(3, IL-la, IL-1(3, IL-5, IL-6, and IL-8, but a reduced expression of 
IL-16 as compared to control cattle. Finally, mesenteric lymph node expression of IL-la, 
IL-2, IL-8, and IL-10 was enhanced by M. paratuberculosis but TGF-[3 and IL-16 expression 
was reduced in comparison to control cattle. In addition to classical ThI cytokines (IFN-y, 
IL-la, and IL-6), infected tissues secrete cytokines that selectively recruit neutrophils (via 
IL-8) and eosinophils (via IL-5). Taken together, these results suggest that the bovine 
immune system responds to paratuberculosis infection by limiting the response to the sites of 
infection. Suppression of TNF-a in PBMCs and enhanced expression IL-la in ileal tissues 
been confirmed by other studies (Buza et al., 2003; Aho et al., 2003). Additionally, PBMCs 
from naturally infected cattle were reported to express higher levels of IL-10 and TGF-(3 after 
stimulation with M. paratuberculosis than control, non-infected cattle (Khalifeh and Stabel, 
2004). The same study showed that IL-10 and TGF-(3 inhibited mycobacterial killing by 
macrophages from healthy cows. 
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Molecular Biology 
Genomics 
The genomic sequencing of M. paratuberculosis was recently completed and 
indicated that the genome is 4.83 megabases (Mb) in size and contains 4355 predicted open 
reading frames (Li et al. unpublished). This is similar to the 4.7 Mb genome of M. avium 
(sequencing recently completed by The Institute for Genomic Research; http://www.tigr.org), 
the 4.41 Mb genome of M. tuberculosis (Cole et al., 1998), and the 4.35 Mb genome of M 
bovis (Gamier et al., 2003), but larger than the 3.26 Mb degenerate genome of M. leprae 
(Cole et al., 2001). The genomes of the mycobacteria are rich in guanine (G) and cytosine 
(C), with M. paratuberculosis among the highest at 69.3% GC content (Bannantine et al., 
2002). 
The genetic relatedness of the mycobacteria has been previously determined by 
DNA-DNA hybridizations (Cocito et al., 1994). The high degree of homology between M. 
avium and M. paratuberculosis has been demonstrated by 91 to 100% DNA hybridization 
between the two subspecies. Additionally, the divergence of the mycobacteria was 
calculated by DNA hybridization, as M. paratuberculosis was predicted to 53 to 65% 
homologous to M. intracellular and 52% homologous to M. tuberculosis. A more accurate 
analysis, using genomic DNA sequence, can now be performed using sequence alignment 
software. Sequence analyses of 52 kilobases (kb) (1% of the genome) of non-contiguous 
genomic sequence by our laboratory indicated that M. paratuberculosis was 98.8% similar to 
M. avium and 84% similar to M. tuberculosis (unpublished data). A larger comparison was 
recently reported using 350 kb (7% of the genome) of non-overlapping genomic DNA and 
found 97.4% nucleotide identity between M. paratuberculosis and M. avium (Bannantine et 
al., 2003a). 
RFLP 
Molecular genetics methods, such as restriction fragment length polymorphism 
(RFLP), have been used to differentiate M. avium and M. paratuberculosis isolates (Coffin et 
al., 1992; Whipple et al, 1990). Further, RFLP has been used to distinguish between cattle 
and sheep isolates, indicating that some M. paratuberculosis strains are host adapted 
(Bauerfeind et al., 1996; Collins et al, 1990a). In order to standardize RFLP analysis of M. 
paratuberculosis isolates, a large-scale study combined previously reported RFLP typing 
methods to suggest a new RFLP analysis protocol (Pavlik et al., 1999). This protocol 
digested genomic DNA from 1008 M. paratuberculosis strains with two restriction 
endonucleases, Pstl and BstEll, and hybridized the fragments to 453 base pair (bp) fragment 
of the IS900 insertion sequence (described below). A total of 28 different RFLP types were 
reported using this standardized method. However, the problem with RFLP analysis is that it 
requires culturing of samples (8-12 weeks) to obtain sufficient amounts of bacteria to extract 
DNA. 
Insertion sequences 
The presence of a number of insertion sequences has been reported in mycobacterial 
genomes, including IS900 from M. paratuberculosis (Collins et al., 1989; Green et al., 
1989). IS900, which is present in 17 copies in the M. paratuberculosis genome (Li et al., 
unpublished data), is a 1451 bp sequence that has been reported to be species-specific for M. 
paratuberculosis. Because of the specificity and high copy number of the IS900 element, a 
number of PCR-based diagnostic tests have been developed for the detection of M. 
paratuberculosis from suspect tissues (Englund et al., 2001; Miller et al., 2002; Whittington 
et al., 1999) and feces (Collins et al., 1993; Fang et al., 2002). 
The ISP0O insertion sequence is a mobile element with a functional transposase 
(Dellagostin et al., 1993). Further, it is unique from the majority of other transposable DNA 
elements in that it lacks both terminal inverted repeats and direct repeats (Green et al., 1989). 
IS90O contains two open reading frames (ORFs), p43 and hed, encoded on opposite strands. 
The first ORF encodes the p43 transposase protein, which was found to be expressed in M. 
paratuberculosis (Tizard et al., 1992). Antibodies against the p43 protein bound specifically 
to M. paratuberculosis isolates, but not M avium or M. silvaticum. The second ORF, on the 
complement strand, encodes for the Hed (host expression-dependent) protein. The 
expression of Hed requires that IS900 be correctly inserted between the ribosome binding 
site (RBS) and start codon of a given mycobacterial gene (Bull et al., 2000a; Doran et al., 
1994). The hed gene does not contain a termination codon, therefore, the hed translation 
products from each IS900 element vary in size. Further, the hed gene contains a RBS on its 
3' end, which restores translation of the downstream target gene that was inactivated by 
insertion (Doran et al., 1997). The function of the Hed protein is unknown, but sequence 
homology suggests that the protein is involved in iron transport (Doran et al., 1994). 
However, transformation of M. smegmatis, normally mycobactin independent, with IS900 
resulted in mycobactin J dependent growth (Naser et al., 1998). Despite the requirement of 
mycobactin J for M. paratuberculosis growth in culture, recent completion and annotation of 
the M. paratuberculosis genome has revealed that mycobactin promoters and genes are 
present, suggesting that other factors exist which suppress mycobactin expression (J. 
Bannantine, personal communication). Clearly, the role of the Hed protein in mycobactin 
repression warrants further investigation. 
Another insertion element, IS/377, is present in 7 copies in the M. paratuberculosis 
genome (Li et al., unpublished data). However, this sequence is not unique to M. 
paratuberculosis, as approximately 7 to 10 copies of IS13I1 are found in both M. avium and 
M. intracellular (Collins, et al., 1997; Whittington et al., 1998a). The IS/377 sequence, 
1317 bp in size, is slightly smaller than the IS900 sequence and contains a single ORF 
encoding a putative transposase. Unlike IS900, the IS/3// sequence contains terminal 
inverted repeats. Point mutations in IS/3/ / have been used to distinguish between cattle and 
sheep isolates of M. paratuberculosis (Whittington et al., 1998a). 
Pathogenicity islands 
A 9.0 kb pathogenicity island, designated GS, was identified from M. 
paratuberculosis because its GC content (57.1%) was significantly lower than the 69.3% 
average for the M. paratuberculosis genome (Bull et al., 2000b; Tizard et al., 1998). The 
low GC content of this island and flanking inverted repeats suggested that this sequence was 
obtained through horizontal gene transfer. The GS sequence encodes for six ORFs 
homologous to extracellular lipopolysaccharide (LPS) biosynthesis genes. 
A 38 kb pathogenicity island was recently discovered which contains genes encoding 
for ABC transporters (mptA to F), iron acquisition proteins (fepB to D), siderophore 
synthases (sidA to G), and two PPE signaling membrane proteins (Stratmann et al., 2004). 
This pathogenicity island is flanked by an IS///0-like insertion sequence and the region 
encoding mptA to mptF is believed to be specific for M. paratuberculosis, as no significant 
homology was found to sequences from other bacterial genomes, including M. avium. 
M. paratuberculosis-specific sequences 
In addition to the reported specificity of the IS900 sequence and the mptA to mptF 
pathogenicity island, three genes have been reported to be specific for M. paratuberculosis. 
The first is hspX, from which a 30 bp region was selected which differentiated M. avium 
from M. paratuberculosis (Ellingson et al., 1998; Ellingson et al., 2000). Although this hspX 
region could accurately differentiate 99.2% of samples, two of the 12 M. paratuberculosis 
isolates were negative for hspX by PCR. The second gene, F57, is a 620 bp sequence of 
unknown function that does not hybridize with DNA from any other mycobacteria (Poupart 
et al., 1993). A third sequence, ISMpal, is a 1500 bp insertion element (Olsen et al., 2004). 
The sequence has one open reading frame, which encodes for a putative transposase. Three 
copies of ISMpal were found in the genome of M. paratuberculosis, but PCR analysis also 
amplified the sequence from two porcine M. avium isolates, negating its use as a diagnostic 
sequence. 
Preliminary analysis of the M. paratuberculosis genomic sequence revealed 21 
sequences that were present in M. paratuberculosis but absent from M. avium and other 
mycobacteria (Bannantine et al., 2002). Eight of these unique genes were clustered in a 4.4 
kb region, but the lack of flanking inverted repeats and GC content (66%) similar to the 
average genomic GC content (69%) indicated that this region was not horizontally acquired. 
These unique genes may be useful in the development of M. paratuberculosis-specific 
diagnostic tests. 
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immunogenic Proteins 
A number of putative antigens have been identified from M. paratuberculosis and 
their immunogenicity examined by a number of methods, including sérodiagnostic and 
lymphocyte stimulation assays (Table 1). The GroES antigen is a small (10 kDa), highly 
antigenic heat shock protein that is secreted from mycobacteria (Cobb and Frothingham, 
1999). GroES is also found in M tuberculosis and M. leprae, with over 90% identity to the 
M. paratuberculosis protein, making it unlikely to be useful as a diagnostic antigen. 
A secreted 14 kDa antigen was found to stimulate IFN-y production from both 
uninfected and M. paratuberculosis-infected calves, suggesting that certain antigens may 
interfere with IFN-y-based diagnostic tests (Olsen and Storset, 2001). In a later study, sera 
from 27% of infected cattle, but not control cattle, reacted with the 14 kDa protein (Olsen et 
a/., 2001). 
A hypothetical thiol peroxidase was identified from M. paratuberculosis because of 
its homology to a culture filtrate antigen from M. tuberculosis (Mullerad et al., 2003). This 
16.7 kDa protein was shown to induce IFN-y, IL-6, and nitric oxide production in immunized 
mice, but it is unknown if the M. paratuberculosis protein is likewise secreted from the 
bacteria. 
Two alkyl hydroperoxide reductase proteins, AhpC and AhpD, were characterized 
from M. paratuberculosis that stimulated IFN-y production from the leukocytes of infected 
goats (Olsen et al., 2000). Additionally, sera from infected goats reacted against the 45 kDa 
AhpC protein but not the 19 kDa AhpD protein. Alkyl hydroperoxide reductases are 
detoxifying enzymes that protect bacteria from reactive oxygen and nitrogen intermediates. 
Table 1. Immunogenic proteins from M. paratuberculosis. 
Antigen Description Size (kDa) Reference 
GroES Heat shock protein 10 Cobb and Frothingham, 1999 
MPP14 Secreted protein 14 Olsen and Storset, 2001 
Gene 254 M. paratuberculosis-specific 16 Bannantine et al., 2004 
MPT-TP Thiol peroxidase 16 Mullerad et al., 2003 
Gene 135 M. paratuberculosis-specific 17 Bannantine et al., 2004 
AhpD Alkyl hydroperoxide reductase 19 Olsen et al., 2000 
HspX M. paratuberculosis-specific 20 Bannantine and Stabel, 2000 
Gene 56 M. paratuberculosis-specific 21 Bannantine et al., 2004 
SodA Superoxide dismutase 23 Mullerad et al., 2002a 
Cspl Recognized inside macrophages 25 Bannantine and Stabel, 2001 
Gene 241 M. paratuberculosis-specific 30 Bannantine et al., 2004 
Antigen A Culture filtrate protein 31 Sugden et al., 1991 
3 2-kDa antigen Secreted; binds fibronectin 32 El-Zaatari et al., 1994 
Ag85B Secreted; binds fibronectin 32 Mullerad et al., 2002b 
34-kDa antigen Cell wall protein; thermostable 34 De Kesel et al., 1992 
34-kDa antigen Trypsin-like serine protein; virulence 34 Cameron et al., 1994 
3 5-kDa antigen Unknown 35 El-Zaatari et al., 1997 
Mmp Major membrane protein; virulence 35 Bannantine et al., 2003 
AhpC Alkyl hydroperoxide reductase 45 Olsen et al., 2000 
Fap Fibronectin attachment protein; cell envelope 49 Secott et al., 2001 
GroEL Heat shock protein 65 El-Zaatari et al., 1995 
Pks7 Polyketide synthase 70 Bannatine and Stabel, 2001 
Gene 218 M. paratuberculosis-specific 91 Bannantine et al., 2004 
Antigen D Culture filtrate protein 400 Sugden et al, 1991 
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Both antigens were found to be present in M. paratuberculosis, but not M. avium or other 
mycobacterial species, indicating their importance as possible diagnostic antigens. A later 
study found that 27% of infected cattle produced antibodies against AhpC while only 15% of 
infected cattle produced antibodies against AhpD (Olsen et al, 2001). 
The hspX gene, which encodes for a putative heat shock protein, was originally 
reported to contain a region that was specific for M. paratuberculosis (Ellingson et al., 1998). 
The protein contains an arginyl-glycl-aspartic acid (ROD) motif, which was proposed to 
mediate attachment to host cells and be a virulence factor. More recent studies of hspX have 
shown that the gene product, a 21 kDa protein, was present within infected macrophages but 
no changes in protein expression were observed in the presence of macrophages (Bannantine 
and Stabel, 2000). Additionally, when this gene was expressed as a recombinant protein, it 
could only be detected from 17% of sera from clinical cattle. 
A 23 kDa superoxide dismutase, SodA, was originally identified and characterized as 
a secreted protein, but its immunogenicity was not determined (Liu et al., 2001). A separate 
study found that immunization with recombinant SodA protein induced the production of a 
ThI response, which included a delayed-type hypersensitivity (DTH) response and the 
release of IFN-y, TFN-a, and IL-6 (Mullerad et al., 2002a). However, this study did not 
assess the protective effects of the SodA protein against bacterial challenge. 
A 25 kDa protein was discovered, which was recognized by sera from rabbits 
immunized with live M. paratuberculosis (Bannantine and Stabel, 2001). The 25 kDa 
protein was found to be associated with M. paratuberculosis inside macrophages. Sequence 
analysis revealed that the protein was similar to a secreted protein from Corynebacterium 
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glutamicum and was thus named Cspl. Despite this homology, signal peptide and cell 
fractionation analyses revealed that the M. paratuberculosis Cspl was not secreted. 
A 32 kDa secreted protein with fibronectin binding properties was identified by 
screening a M. paratuberculosis expression library with anti-mycobacterial antibodies and 
DNA probes (El-Zaatari et al., 1994). Fibronectin-binding proteins aid in attachment to 
macrophages and have been implicated in protective immunity from M. tuberculosis (Abou-
Zeid et al., 1991). 
The antigen 85 complex (Ag85A, B, and C) are secreted proteins that have been 
studied extensively in mycobacteria, but only recently described from M. paratuberculosis 
(Dheenadhayalan et al., 2002). In M tuberculosis, the Ag85B protein has been shown to 
bind fibronectin and is the most abundantly secreted protein from the Ag85 complex (Belisle 
et al., 1997; Thole et al., 1992). However, a DNA vaccine encoding the Ag85B gene did not 
protect mice from challenge with M. avium (Velaz-Faircloth et al., 1999). The M. 
paratuberculosis Ag85B antigen, with a molecular mass of 32 kDa, was shown to induce 
IFN-y, IL-6, IL-10, and nitric oxide production in immunized mice (Mullerad et al., 2002b). 
These results indicated that Ag85B induces both ThI and Th2 immune responses. 
Unfortunately, it has not been determined if the 32 kDa fibronectin-binding protein described 
by El-Zaatari, above, is the same as the Ag85B protein. 
A 34 kDa thermostable cell wall protein has also been identified, with B cell epitopes 
at the C-terminal end of the protein useful for the development of a M. avium complex-
specific immunohistochemical technique (Coetsier et al., 1998; De Kesel et al., 1992; De 
Kesel et al., 1993; Gilot et al., 1993). Antibodies produced against two epitopes from the 34 
kDa protein bound to M. avium and M. paratuberculosis, but not M. intracellular or M. 
bovis (Ostrowski et al., 2003). A serological screen found that the 34-kDa antigen was 
strongly recognized by 12 of 15 M paratuberculosis-infected cattle (De Kesel et al., 1992). 
Another 34 kDa has been isolated from M. paratuberculosis, which is unique from 
the 34 kDa antigen described above. This 34 kDa antigen was recognized by sera from 
infected sheep, goats, and deer (Cameron et al., 1994). The protein was found to be 
homologous to the HtrA proteins, trypsin-like serine proteases, from E. coli and S. 
typhimurium. HtrA has been linked with S. typhimurium virulence, as deletion of the gene 
rendered mutants susceptible to oxidative stress killing mechanisms inside the macrophage 
(Johnson et al., 1991). 
A 35 kDa protein was isolated which was recognized by sera from subclinically-
infected cattle and cattle, sheep and goats with clinical disease (El-Zaatari et al., 1997). No 
information was given about the sequence or proposed function of the protein. The 
specificity of this protein for the M. avium complex was demonstrated by lack of reactivity to 
sera from M. bovis BCG-vaccinated cattle. However, the gene is not specific for M. 
paratuberculosis, as DNA hybridization to M. avium isolates was reported. 
A second 35 kDa protein was described, which was homologous to the 35 kDa major 
membrane protein (Mmp) from M. leprae and M. avium (Banasure et al., 2001). In M. 
leprae, the Mmp has been shown to induce T cell responses and antibody production (Triccas 
et al., 1996; Winter et al., 1995). Further, a DNA vaccine encoding the M. leprae Mmp 
protected mice from challenge (Martin et al., 2001). A detailed analysis of the M. 
paratuberculosis Mmp found that it was, indeed, surface expressed and recognized by sera 
from clinically-infected cattle (Bannantine et al., 2003b). Further, the M. paratuberculosis 
Mmp was found to be expressed in higher amounts when the bacteria were in low-oxygen 
conditions, similar to the intestinal environment. Finally, the Mmp was reported to play a 
role in virulence, as Mmp-specific antibodies blocked M. paratuberculosis invasion of 
epithelial cells. A recent study confirmed Bannantine's results, by finding that the 35 kDa 
protein was detected in M. paratuberculosis membrane fractions and was recognized by sera 
from infected animals (Basagoudanavar et al., 2004). This latest report also found that the 35 
kDa protein induced cellular immune responses, as indicated by skin test reactions in guinea 
pigs. 
Another fibronectin binding protein, the fibronectin attachment protein (FAP), has 
been identified from M. paratuberculosis, with a molecular mass of 49.1 kDa (Secott et al., 
2001). This protein was localized to the space between the peptidoglycan layer and the cell 
envelope and was found to bind fibronectin with greater affinity at pH 3. Further analysis 
indicated that disruption of FAP expression significantly reduced attachment and uptake of 
M paratuberculosis by two epithelial cell lines (Secott et al., 2002). 
The GroEL protein, a 65 kDa heat shock protein, was identified by screening a M. 
paratuberculosis expression library with anti-mycobacterial antibodies and DNA probes (El-
Zaatari et al., 1994). In a later study, sera from 3 of 10 clinical cattle and 5 of 25 
subclinically-infected cattle reacted with a recombinant 65 kDa protein, excluding its use as a 
diagnostic antigen (El-Zaatari et al., 1995). In an M. avium infection model in mice, a DNA 
vaccine encoding the M. paratuberculosis 65 kDa gene resulted in a fourfold CFU reduction 
at four weeks post-challenge, but had no effect by eight weeks (Velaz-Faircloth et al., 1999). 
With the recent completion of the M. paratuberculosis genome, it was possible to 
identify sequences that were present in M. paratuberculosis, but not found in the other 
mycobacteria (Bannantine et al., 2002). These sequences were cloned and expressed as 
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recombinant proteins to assay for their immunogenicity against sera from infected mice, 
rabbits, and cattle (Bannantine et al, 2004). Five coding regions were identified that were 
immunogenic across the majority of infected animals: gene 56 (21 kDa); gene 135 (17 kDa); 
gene 218 (91 kDa); gene 241 (30 kDa); gene 254 (16 kDa). Although the function of these 
proteins is not known, they have the potential to be highly specific diagnostic antigens. 
Other immunogenic antigens that have been reported include a 70 kDa polyketide 
synthase protein, termed Pks7 (Bannantine and Stabel, 2001) and two culture filtrate 
proteins, a 31 kDa antigen A and a 400 kDa D (Sugden et al., 1991). Further, although 
antigenicity has not been specifically demonstrated, preliminary work has been reported for a 
number of potential antigens from M. paratuberculosis, including heat shock protein 70 
(Langelaar et al., 2002) and a secreted superoxide dismutase (SodC) (Dupont and Murray, 
2001). 
Diagnostic Tests 
Overview 
There are several methods available to diagnose M. paratuberculosis-'mfccted 
animals. Isolation and culturing of M. paratuberculosis from feces or tissue remains the 
most definitive detection method. Additionally, diagnostic tests are commercially available 
which measure cellular or humoral immune responses from suspect animals. As noted 
above, the cell-mediated immune response is strong during the early stages of infection, as 
indicated by ThI cytokines such as IFN-y. Over time, the cellular immune response fades 
and the humoral immune response predominates, as indicated by the presence of large 
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amounts of M. paratuberculosis-specific antibodies. Finally, molecular-based techniques 
exist which amplify M. paratuberculosis-specific DNA sequences from suspect samples. 
Culture 
Direct culture of M paratuberculosis from feces or tissue specimens is the most 
definitive method for determining the infection status of suspect animals (Collins, 1996a). 
However, infected animals may not shed bacteria in their feces, may shed at low levels, or 
may intermittently shed, complicating the diagnosis of infected animals. Many variables 
exist in sample preparation and culture media, which result in differences in sensitivity 
among laboratories. The use of hexadecylpyridinium chloride (HPC), at a concentration of 
0.75%, in decontamination steps is required to remove non-mycobacterial organisms and 
increases recovery of M. paratuberculosis (Chiodini et al., 1984). Additionally, 
sedimentation or concentration of samples has been reported to increase the number of 
bacteria cultured from samples (Stabel, 1997). Further, in both the Cornell and NADC 
methods, fecal samples are treated with two overnight pre-incubations, a HPC-brain heart 
infusion broth combination and an antibiotic treatment, before being inoculated onto HEYM 
containing antibiotics. As noted in a previous section, HEYM has been reported to foster the 
growth of more M. paratuberculosis colonies in a shorter amount of time. Despite the most 
optimized culture medium, 8 to 16 weeks of incubation are necessary before colony growth 
is visible. The pre-incubations described above increase the sensitivity of fecal culture and 
dramatically reduce contamination problems that are problematic during long culture 
incubation periods. 
The BACTEC system (Becton Dickinson Laboratories) is an alternative method for 
culturing M. paratuberculosis from suspect samples. M. paratuberculosis is grown in a 
liquid medium containing 14C02-labeled palmitate. Growth of the bacterium is measured by 
the BACTEC instrument, which detects the release of 14CC>2 as a metabolic breakdown 
product. When combined with concentration techniques, the BACTEC system was reported 
to identify positive samples sooner (as early as 13 days) and had a higher sensitivity 
(identified twice as many positive samples) than HEYM culturing (Collins et al., 1990b). 
More recent studies have confirmed that BACTEC is slightly more sensitive and rapid than 
conventional culture methods (Thornton et al, 2002; Whittington et al., 1998b). 
Immunomagnetic beads 
The use of immunomagnetic beads, coated with M. paratuberculosis-spQcific 
antibodies, was originally developed to isolate bacteria from milk samples (Grant, et al., 
1996). The beads have a maximum binding capacity of 103 CPU and a sensitivity threshold 
of 10 CPU of M. paratuberculosislml. Upon isolation of the beads, bacteria are released and 
DNA is extracted for PCR-based detection of M. paratuberculosis. This method is 
approximately 10-fold more sensitive than conventional culturing techniques and eliminates 
time-consuming decontamination steps. However, the test cannot differentiate between live 
or dead bacteria. This technique has been recently used to isolate and detect M. 
paratuberculosis from fecal samples with even greater sensitivity (Khare et al, 2004). 
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Skin test 
During the early stages of infection, the cell-mediated immune response is strong and 
appears to control infection. Tests for delayed-type hypersensitivity (DTH) reactions by 
intradermal injection of M. paratuberculosis antigens, called skin tests, are indicators of 
cellular immune responses. The johnin antigen that is used in skin tests is not specific for M. 
paratuberculosis because of the high degree of similarity to environmental mycobacteria 
such as M. avium. Johnin is injected in the caudal fold or neck and changes in skin thickness 
are measured 72 hours later (Chiodini et al., 1984). The effectiveness of this test diminishes 
with repeated exposure as animals become anergic to johnin. 
IFN-y assay 
A better indicator of cell-mediated immunity against paratuberculosis is an enzyme-
linked immunosorbent assay (ELISA) that measures the release of IFN-y from bovine 
lymphocytes or whole blood (Rothel et al., 1990; Stabel, 1996; Stabel and Whitlock, 2001). 
This test is now commercially available (Commonwealth Serum Laboratories, Victoria, 
Australia) and detects IFN-y production after 18 hours of stimulation with M. 
paratuberculosis sonicate. The specificity of the IFN-y ELISA has been reported to be as 
high as 99%, while the sensitivity is usually around 70% (Billman-Jacobe et al., 1992; Kalis 
et al., 2003; Stabel and Whitlock, 2001). 
Detection of antibodies 
Three different tests are available to detect M. paratuberculosis-specific antibodies 
from suspect animals: the complement fixation (CF) test; the agar gel immunodiffusion 
(AGID) test; and the ELISA. However, as noted above, antibodies usually occur in the later 
stages of disease or immediately prior to the appearance of clinical signs. Therefore, these 
tests are only able to detect infected animals after they have potentially infected other 
animals in the herd, through shedding of bacteria into the feces. The CF test is the least 
specific and sensitive of the three serologic tests. AGID is a simple procedure, which is 
based upon antigen-antibody precipitation in agar, but is less sensitive than ELISA (Collins, 
1996a; Stabel, 1998). The ELISA is the most sensitive of the three serologic tests, with 
reported sensitivities of 15 to 57% for subclinically infected cattle and an average sensitivity 
of 88% for clinically infected cattle, when compared to fecal culture (Collins and Sockett, 
1993; Reichel et al., 1999; Stabel et al., 2002; Sweeney et al., 1995). Specificity is reported 
to be 99% or greater when test sera are preabsorbed with M. phlei, an environmental 
mycobacteria (Collins and Sockett, 1993). 
fC# 
PCR-based detection of M. paratuberculosis-specific sequences is the most sensitive 
method available to identify infected animals. To date, a number of paratuberculosis-specific 
sequences and genes have been discovered, including IS90O, hspX, F57, ISMpal, and the 21 
unique sequences identified during the genomic sequencing project. The insertion element, 
IS900, is the most routinely exploited sequence for PCR-based detection of suspect samples 
because of its high copy number (Harris and Barietta, 2001). PCR amplification of 1S900 
from tissues (Englund et al., 2001; Miller et al., 2002; Whittington et al., 1999) and feces 
(Fang et al., 2002) has demonstrated that PCR is highly sensitive and specific. As proof of 
this specificity, a PCR analysis showed that IS 900 was only amplified from M. 
paratuberculosis samples, but not from over 100 M. avium, M. intracellular, or other 
Mycobacterium avium subspecies (Ellingson et al., 2000). Further, PCR has been used to 
positively identify samples that were culture negative (Miller et al., 2002) as well as detect 
femtogram (less than two genome copies) amounts of DNA (Del Prete et al., 1998; Moss et 
al., 1991). However, two studies have found that IS900 may also be present in some non-
paratuberculosis environmental mycobacteria, including M. avium subsp. avium isolates from 
HIV patients (Naser et al., 1999) and mycobactin-independent mycobacteria isolated from 
the feces of two cattle in Victoria, Australia (Cousins et al., 1999). Cousins further analyzed 
the ISPOO-positive isolates by RFLP and determined that they were distinct from M. 
paratuberculosis, suggesting that PCR amplification of IS900, alone, may not specific. In an 
effort to increase PCR specificity, a new set of IS900 primers was recently described, which 
specifically amplified 74 M. paratuberculosis isolates, but not 116 isolates from other 
mycobacteria (Vansnick et al., 2004). 
In summary, the intermittent shedding of bacteria in the feces, the variable host 
response to infection, and the wide range of sensitivities and specificities for available 
diagnostic tests suggest that no one single test should be used to identify M. 
paratuberculosis-infected animals. Suspect animals should be tested at multiple time points 
with the appropriate diagnostic test to confirm infection status. 
Paratuberculosis Vaccines 
Vaccination against paratuberculosis was first described in 1926 by Vallee and 
Ringhard, who injected cattle with a subcutaneous inoculation of M. paratuberculosis. Since 
that initial report, a number of vaccine preparations have been tested in ruminants, including 
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live virulent strains suspended in olive oil, attenuated strains that grow without mycobactin, 
and heat-killed strains (Chiodini, 1996; Cocito et al., 1994). The protective effects of 
vaccine preparations were compared and revealed that virulent strains provided better 
protection than attenuated strains (Larsen et al., 1978). 
The vaccine that is currently approved for use in the United States is a heat-killed 
bacteria, whereas a live vaccine is primarily used in Europe. Although paratuberculosis 
vaccination is restricted in the United States, calves are vaccinated when they are less than 
one month of age. Studies for paratuberculosis have shown that vaccines induce both 
cellular and humoral immune responses (Kohler et al, 2001; Muskens et al., 2002). 
Nevertheless, currently available vaccines are not effective at preventing infection or the 
transmission of the disease to other animals (Chiodini et al., 1984; Cocito et al., 1994). 
Under the best conditions, vaccines have been reported to reduce fecal shedding, although 
changes in management practices cannot be ruled out (Kormendy, 1994; Kalis et al., 2001). 
One study found that vaccination reduced the number of fecal shedders up to 7% (Kalis et 
al., 2001) while a second study reported a reduction of 46% (Kormendy, 1994). Further, 
vaccines do not prevent infection, but rather, delay the onset of clinical disease (Kormendy, 
1994; Larsen et al., 1978; Uzonna et al., 2003; Van Schaik et al., 1996; Wentink et al., 
1994). Studies have shown that boosting does not appear to provide additional protection 
from infection or delay clinical disease (Gilmour and Angus, 1973; Stuart, 1965). 
One potential reason for the ineffectiveness of the U.S. vaccine is that the heat-killed 
strain 18 vaccine is now known to be a strain of M. avium subsp. avium, not M. avium subsp. 
paratuberculosis (Chiodini, 1993). Use of current vaccines are unfavorable because of their 
adverse reactions, including severe inflammation and granuloma formation at the injection 
40 
site. In addition, vaccination interferes with bovine tuberculosis skin testing and serologic 
detection of paratuberculosis infected cattle (Collins, 1996b; Muskens et al., 2002). The 
vaccine also poses a health risk to veterinarians who administer the vaccine, as adverse 
reactions to accidental self-injection have been documented (Patterson et al., 1988). 
A study using the heat-killed vaccine demonstrated that calves mount an immediate 
(within one month), strong and long-lasting (six to seven years) cell-mediated immune 
response against M. paratuberculosis antigens (Johnin PPD), as measured by the IFN-y assay 
(Muskens et al., 2002). However, this response was not specific to M. paratuberculosis, as 
vaccinated cattle were positive for M. bovis PPD for two years after vaccination. Muskens 
also examined the percentages of ELISA-positive cattle over time and found that only 18 -
26% of cattle were ELISA-positive by the end of the first year, but 51 - 80% were ELISA-
positive by the second year. However, the levels of M. paratuberculosis antibody fell over 
time, as 28 - 31% were positive by the third year and only 8 - 18% were positive by year 
four. Unfortunately, the author did not report the percentage of cattle that mounted cellular 
immune responses over time. In summary, these results demonstrated that vaccination 
interferes with M. bovis testing and that humoral immunity is delayed and transient. 
In a separate vaccine trial, use of the attenuated vaccine was shown to induce hand-
sized nodule formation at the injection site of all immunized cattle (Kohler et al., 2001). 
Although IFN-y production to Johnin PPD was induced as early as 1 - 2 weeks after 
immunization and persisted during the 2-year study, over 60% of the animals also responded 
to stimulation with either avian or bovine PPD. By comparison, antibody responses were not 
detected until 16 weeks after vaccination and dropped to undetectable levels by 60 weeks 
post-vaccination. 
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As a result of M. paratuberculosis infection, economic losses to dairy producers are 
mainly attributed to loss of milk production and premature culling of infected animals. A 
cost-benefit analysis demonstrated that economic losses could be significantly reduced with 
vaccination (van Schaik et al., 1996). Vaccination of young calves with a heat-killed vaccine 
reduced the number of subclinically infected animals by 40% and reduced the number of 
clinically infected animals by 86% over an eight-year period. Although vaccination did not 
prevent decreased milk production, the benefits ($142 per cow) outweighed the costs of 
vaccination ($15 per cow). 
DNA Vaccines 
Overview 
In 1990, an experiment was performed in which the quadricep muscles of mice were 
injected in vivo with plasmid DNA encoding either chloramphenicol acetyltransferase, 
luciferase, or P-galactosidase (Wolff et al., 1990). Protein expression was detected for all 
three plasmids, with luciferase activity still present two months post-injection. This 
experiment proved that foreign proteins could be expressed in mammalian cells in vivo and 
suggested that immune responses should be generated against those proteins. Following the 
success of that initial experiment, three new DNA immunization experiments soon followed. 
In these subsequent experiments, both mice and cattle were immunized with various DNA 
vectors and immune responses were generated, including protection against viral challenge 
(Cox et al, 1993; Tang et al., 1992; Ulmer et al., 1993). 
DNA vaccines are advantageous because they are inexpensive and simple to produce, 
are stable at a variety of temperatures, and do not contain elements that induce allergic or 
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hypersensitivity responses often associated with conventional vaccines (Babiuk et al., 2000). 
Additionally, the persistence of plasmid and expressed protein for over a year indicates that 
DNA vaccines can act as self-boosters for continued immune stimulation and enhancement 
(Wolff et al., 1992). Presently, experimental evidence has demonstrated that DNA 
immunization can protect animals from a number of bacterial, viral, and parasitic diseases, as 
well as cancer (Babiuk et al, 2000; Huygen, 2003; Manickan et al., 1997; Shedlock and 
Weiner, 2000). 
The risks associated with foreign DNA inoculation are not completely known, but the 
possibility does exist for integration into the host chromosome or induction of an anti-DNA 
autoimmune response. Despite 14 years of DNA immunization trials, no evidence has been 
reported for either event. In fact, three separate studies have found no evidence of 
chromosomal integration, noting that the spontaneous mutation rate for mammalian cells is 
much higher than the calculated risk of chromosomal integration using DNA immunization 
(Ledwith et ai, 2000; Martin et al., 1999; Nichols et al., 1995). 
Delivery methods 
DNA can be delivered by intramuscular or intradermal injection with a needle or by 
gene gun delivery. Intramuscular (IM) and intradermal (ID) DNA vaccinations have a low 
transaction efficiency and require between 100 (ag to 10 mg of DNA to induce an immune 
response. The inefficiency of needle delivery is due to the delivery of the majority of the 
DNA into the extracellular space where it is likely degraded by nucleases. DNA that is not 
directly injected into host cells can be internalized through unknown mechanisms. There is 
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speculation that Toll-like receptor 9 may be involved in signaling for the transport or 
phagocytosis of extracellular DNA into the cell (Medzhitov, 2001). 
Gene gun-mediated DNA vaccination is needle-free and nanogram quantities of DNA 
can effectively induce both humoral and cell-mediated immune responses. Preparation for 
gene gun vaccination is more complicated than needle injection, as DNA is coated onto 
microcarrier beads (i.e. gold or tungsten) before being propelled into the skin by pressurized 
helium or carbon dioxide. However, vaccination via gene gun directly transfects host cells, 
including professional antigen presenting cells and subsequently mimics the endogenous 
antigen production of intracellular pathogens such as mycobacteria. 
As compared to conventional or subunit vaccines, the protein encoded by plasmid 
DNA is produced intracellularly and is available for both MHC-I and MHC-II processing and 
presentation. Induction of the immune response type depends mainly on the features of the 
encoded antigen, but it is possible to influence either a cellular or humoral immune response 
by the route of delivery, addition of co-stimulatory sequences, or alteration of the coding 
sequence to produce secreted or transmembrane antigens (Babiuk et al., 2000). In general, 
needle injection induces a ThI response and gene gun immunization induces a Th2 response. 
Cytotoxic T cell responses can be induced by both delivery methods. 
DNA vaccines in veterinary medicine 
Practical applications of DNA vaccination in veterinary medicine have been 
demonstrated by protection against feline, canine, avian, porcine, equine, and bovine diseases 
(Dunham, 2002). Among the most encouraging vaccine trials, IM injection of a DNA 
vaccine encoding the rabies virus glycoprotein G gene has been shown to protect dogs from 
44 
lethal challenge with rabies virus (Perrin et al., 1999). Protection from rabies is believed to 
be due to neutralizing antibodies, as this DNA vaccine construct was reported to induce high 
levels of neutralizing antibody from cats, dogs, and horses (Fischer et al., 2003; Osorio et al., 
1999). In dogs, IM injection induced higher levels of antibody production than ID injection. 
However, ID injection of cats induced more neutralizing antibody than IM injection, 
emphasizing the need to optimize the route of DNA vaccine delivery. 
A replication defective feline immunodeficiency virus (FIV) in combination with the 
coding region of IFN-y has been shown to protect cats from FIV infection (Flynn et al., 2000; 
Hosie et al., 1998). In that study DNA vaccination induced strong cytotoxic T lymphocyte 
(CTL) responses against FIV, but no FIV-specific antibody was detected. Additional studies 
have demonstrated that plasmid DNA encoding IL-12 or IL-18, with either the FIV provirus 
DNA vaccine or the FIV envelope gene, enhanced cell-mediated immune responses and 
protected cats from FIV infection (Dunham et al., 2002; Leutenegger et al., 2000). 
Protection against feline leukemia virus (FeLV) was shown to be enhanced by the 
addition of plasmids encoding IL-12 and IL-18 (Hanlon et al., 2001). A DNA vaccine 
construct encoding the FeLV gag/pol and env genes in combination with IL-12 and IL-18 
completely protected 12-week old kittens from viral challenge. Protection against FeLV was 
associated with virus-specific CTL responses, as vaccinated kittens did not produce 
antibodies against viral proteins (Hanlon et al., 2001). 
DNA vaccines to mycobacterial diseases 
Several DNA vaccines encoding a single mycobacterial antigen have been developed 
and tested against Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium 
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leprae, and Mycobacterium avium (Huygen, 2003). Nearly half of these mycobacterial DNA 
vaccines protected animals from bacterial challenge and elicited strong humoral, CTL, and/or 
ThI immune responses. These studies have demonstrated the potential for safe, effective 
DNA vaccines that limit mycobacterial infection and disease progression. 
DNA vaccines for M. tuberculosis have largely been based upon previously 
characterized antigens that induce IFN-y production, an indicator of protective immunity 
(Kumar et al., 2003; Lima et al., 2003; Skinner et al., 2003a). The earliest DNA vaccination 
studies demonstrated that plasmids encoding the 65 kDa heat shock protein and antigen 85 A 
protein induced both cellular and humoral immune responses and protected mice from M. 
tuberculosis challenge (Huygen et al., 1996; Tascon et al., 1996). In a more recent study 
confirmed the protective effects of the 65 kDa heat shock protein, and found that IM 
injection of DNA was effective in protecting mice against challenge with M. tuberculosis, 
reducing infection in the lung by 2 logio (Lima et al., 2003). Other studies have successfully 
demonstrated reduced tissue infection after challenge in mice or guinea pigs immunized 
either with Hsp65, Apa, or a combination of ESAT-6 plus Ag85A coding sequences (Kumar 
et al., 2003; Lowrie et al., 1999; Skinner et al., 2003a). 
Mice immunized with a plasmid encoding the 35 kDa protein from M. avium were 
found to have a 2-fold increase in the number of IFN-y secreting T cells and a 1 logio 
reduction in bacterial load after challenge, as compared to control mice (Martin et al., 2003). 
By comparison, mice immunized with both the 35 kOa-encoding plasmid and a plasmid 
containing the IL-12 gene had a 4-fold increase in the number of IFN-y secreting T cells and 
a 2 logio reduction in bacterial load after challenge. Together, DNA vaccination with the 35 
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kDa gene and the IL-12 gene was more effective at preventing M. avium infection than BCG 
vaccination. 
Although most mycobacterial DNA vaccine studies have been performed in mice, 
there is evidence that DNA immunization of larger mammals, such as cattle, can effectively 
induce cellular and humoral immune responses. IM injection of a DNA vaccine encoding the 
M. bovis MPB83 antigen was shown to induce a 5-fold increase in bovine T cell stimulation, 
as compared to non-vaccinated cattle (Chambers et al., 2000). Unfortunately, the protective 
effects of the MPB83 DNA vaccine were not directly tested in cattle, but mice immunized 
with the same plasmid were protected from IV challenge with M. bovis. A later study 
immunized groups of cattle IM with three different plasmids encoding either the MPB70, 
MPB83, or Ag85A antigens (Vordermeier et al., 2001). DNA encoding the Ag85A antigen 
did not induce any immune responses, while the MPS70 plasmid induced a moderate level of 
lymphocyte proliferation. However, DNA vaccination with MPB83 induced strong CD4+ T 
cell proliferation, IFN-y production, and IgGl antibodies against the MPB83 protein, but did 
not interfere with bovine tuberculin skin testing. In contrast, DNA immunization of cattle 
with a plasmid encoding the Hsp65 antigen resulted in lymphocyte proliferation and IFN-y 
production, but no antibody production to the Hsp65 (Tollefsen et al., 2003). Additionally, 
the Hsp65-encoding plasmid did not interfere with bovine tuberculin skin testing. 
In order to enhance the effectiveness of DNA vaccination in cattle, some investigators 
have reported a procedure of DNA priming, followed by a recombinant protein or BCG 
boost. In one study, cattle were primed with a combination of plasmids encoding for Hsp65, 
Hsp70, and Apa, followed by a boost with BCG prior to challenge with virulent M. bovis 
(Skinner et al., 2003). As compared to BCG-vaccinated cattle, the DNA prime-BCG boost 
cattle had lower numbers of lesions in the lungs and lymph nodes and fewer numbers of M. 
bovis were isolated from tissues. A separate study demonstrated that ID injection of cattle 
with a plasmid encoding the M. tuberculosis Ag85A antigen, followed by a boost with 
recombinant Ag85A protein induced both CD4+ and CD8+ T cell proliferation and IFN-y 
production, but protection against M. bovis was not assessed (Taracha et al., 2003). Finally, 
immunization of cattle with a plasmid encoding for the M. bovis Hsp65, followed by a boost 
with recombinant Hsp65 in adjuvant, resulted in strong lymphocyte proliferation, IFN-y 
production, and Hsp65-specific antibody production (Vordermeier et al., 2003). Neither 
vaccination with DNA alone nor DNA prime-protein boost resulted in interference with 
bovine tuberculin testing. Taken together, the results of M. bovis DNA vaccination studies in 
cattle suggest that plasmid-encoded antigens can effectively induce protective bovine 
immune responses and prevent mycobacterial infection without interfering with skin testing. 
As reviewed in the "Immunogenic Proteins" section above, many antigens have been 
described from M. paratuberculosis. However, only one protein, a 65kDa heat shock 
protein, has been tested for its use as a potential vaccine (Velaz-Faircloth et al., 1999). In 
that study, a DNA vaccine encoding the M. avium subsp. paratuberculosis 65kDa antigen 
failed to protect mice after challenge with live M. avium subsp. avium. The advent of DNA 
vaccination makes it possible to quickly evaluate all of these antigens, either separately or in 
groups. 
Expression library immunization 
One technique that was previously described to identify novel protective antigens 
from bacterial pathogens is expression library immunization (Barry et al., 1995). In theory, 
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all of the antigens encoded by a pathogen can be cloned into an expression vector and 
screened simultaneously in an infection model. This high-throughput DNA immunization 
technique, as described, proceeds through successive rounds of immunization and library 
segregation, into smaller pools of clones, to ultimately isolate a single protective sequence 
(Johnston and Barry, 1997). In these studies, a genomic expression library of Mycoplasma 
pulmonis was generated and segregated into nine groups of 3000 clones each. Upon 
vaccination and challenge in mice, protection was observed for two of the groups, proving 
that a large number of potential antigens can be screened simultaneously in vivo. 
Given the safety and efficacy of DNA vaccines, together with the ineffectiveness and 
complications of the current paratuberculosis vaccine, expression library immunization 
shows great promise. 
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CHAPTER 3. EXPRESSION LIBRARY IMMUNIZATION OF MICE AS A 
POTENTIAL VACCINATION STRATEGY AGAINST MYCOBACTERIUM AVIUM 
SUBSP. PARA TUBERCULOSIS INFECTION 
A manuscript submitted to Vaccine 
Jason F.J. Huntley, Judith R. Stabel, and John P. Bannantine 
Abstract 
Paratuberculosis (Johne's disease) is a chronic granulomatous infection of cattle, caused by 
the intracellular bacterium Mycobacterium avium subsp. paratuberculosis, for which there is 
no effective vaccine. In an effort to identify protective M. avium subsp. paratuberculosis 
sequences, a genomic DNA expression library was generated and subdivided into pools of 
clones. Eleven of the clone pools were evaluated to determine DNA vaccine efficacy by 
immunizing mice via gene gun delivery and challenging with live, virulent M. avium subsp. 
paratuberculosis. Four clone pools demonstrated a significant reduction (P < 0.05) of M. 
avium subsp. paratuberculosis infection in mice when compared to other clone pools and 
nonvaccinated, infected control mice. This study demonstrates that M. avium subsp. 
paratuberculosis DNA sequences, when delivered by a gene gun, can protect mice against 
paratuberculosis infection. 
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Introduction 
For more than a century, paratuberculosis (Johne's disease) has been recognized as a 
devastating, chronic infection of ruminant animals worldwide. Paratuberculosis is caused by 
the acid-fast bacilli Mycobacterium avium subsp. paratuberculosis. The bacteria are shed 
through the feces, colostrum, and milk of infected animals. Calves less than nine months of 
age are most susceptible to infection [1] and are most likely to become infected after 
ingestion of contaminated milk or colostrum. M. avium subsp. paratuberculosis passes from 
the lumen of the small intestine through the M cells [2] or epithelial cells [3] and becomes 
engulfed by macrophages in the Peyer's patches. It is within the macrophage that M. avium 
subsp. paratuberculosis replicates and establishes a persistent infection. During the 
subclinical stage of infection, the host cell-mediated immune response is robust and appears 
to control the infection. As the disease progresses from the subclinical to the clinical stage, 
the cell-mediated response diminishes, and a humoral immune response predominates [4], 
As is apparent in clinical animals, antibodies to M. avium subsp. paratuberculosis are not 
effective in controlling Johne's disease [4]. An incubation period of 2-5 years is common 
before clinical signs appear [1], which include progressive weight loss, diarrhea, emaciation, 
and eventual death of the animal [5, 6]. Stress factors such as parturition, lactation, 
nutritional deficiencies, or parasitic infections may trigger the progression to clinical disease 
[7]. 
Vaccine studies for paratuberculosis have shown induction of both cellular and 
humoral immune responses [8, 9] but were not effective at preventing infection or the 
transmission of the disease to other animals. Under the best conditions, vaccines have been 
reported to reduce fecal shedding and delay the onset of clinical disease [10-15], The heat-
76 
killed strain 18 vaccine that is approved for use in the United States is now known to be a 
strain of M. avium subsp. avium, not M. avium subsp. paratuberculosis [16]. Use of this 
vaccine is unfavorable because of its adverse reactions, including severe inflammation and 
granuloma formation at the injection site. In addition, vaccination interferes with bovine 
tuberculosis skin testing and serologic detection of paratuberculosis infected cattle [9, 17]. 
The vaccine also poses a health risk to veterinarians who administer the vaccine, as adverse 
reactions to accidental self-injection have been documented [18]. 
A number of putative antigens have been identified from M. avium subsp. 
paratuberculosis and their immunogenicity examined by sérodiagnostic and lymphocyte 
stimulation assays [3, 19-24], However, only one protein, a 65kDa heat shock protein, has 
been tested for its use as a potential vaccine [25], In that study, a DNA vaccine encoding the 
M. avium subsp. paratuberculosis 65kDa antigen failed to protect mice after challenge with 
live M. avium subsp. avium. Additionally, several DNA vaccines encoding a single antigen 
have been developed and tested against Mycobacterium tuberculosis, Mycobacterium bovis, 
Mycobacterium leprae, and Mycobacterium avium [26]. Nearly half of these mycobacterial 
DNA vaccines elicited strong levels of protection and demonstrate the potential for safe, 
effective DNA vaccines that limit mycobacterial infection and disease progression. 
DNA vaccines offer the advantage of being inexpensive and simple to produce, are 
stable at a variety of temperatures, and do not contain elements that induce allergic or 
hypersensitivity responses often associated with conventional vaccines [27]. A number of 
DNA delivery methods exist, but gene gun-mediated DNA vaccination is needle-free and 
nanogram quantities of DNA can effectively induce both humoral and cell-mediated immune 
responses. One technique that was previously described to identify novel protective antigens 
of bacterial pathogens is expression library immunization [28]. In theory, all of the antigens 
encoded by a pathogen can be cloned into an expression vector and screened simultaneously 
in an infection model. 
Although sequencing of the genome of M. avium subsp. paratuberculosis strain K-10 
was recently completed, few of the over 4300 genes or gene products have been 
characterized. Data from the genome project will greatly facilitate a directed approach to 
identify antigens that can be used as vaccine candidates. However, until these data are more 
fully annotated, the expression library immunization technique was applied in this study to 
identify protective sequences. To accomplish this, a representative genomic library of M. 
avium subsp. paratuberculosis DNA was cloned into a mammalian expression vector and 
tested for its protective effects in vivo against challenge with live, virulent M. avium subsp. 
paratuberculosis in mice. 
Materials and Methods 
Bacterial strains 
M. avium subsp. paratuberculosis strains 19698-1974 (originally isolated in 1974 
from a clinical cow at the National Animal Disease Center, Ames, I A) and 5007 and 6112 
(both recently isolated from cows with clinical infection at the National Animal Disease 
Center) were grown in Middlebrook 7H9 liquid media (pH 6.0) supplemented with 10% oleic 
acid albumin dextrose complex (Becton Dickinson Microbiology, Sparks, MD), 0.5% Tween 
80 (Becton Dickinson Microbiology), and 2 mg/ml mycobactin J (Allied Monitor Inc., 
Fayette, MO). M avium subsp. paratuberculosis cultures were grown to log phase at an 
optical density 540 nm (OD540) of 0.4, at 37°C without shaking. All bacterial strains were 
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minimally passaged to maintain virulence. Bacteria were pelleted by centrifugation at 10,000 
X g for 30 minutes and washed twice with phosphate-buffered saline (PBS). The bacteria 
were resuspended in PBS and the concentration was adjusted to 109 CFU/ml as determined 
by OD540. The final concentration of bacteria was confirmed by serial dilution onto agar 
slants of Herrold's Egg Yolk Medium (HEYM) containing 2 mg/L of mycobactin J (Allied 
Monitor, Fayette, MO). Escherichia coli ElectroMAX (Gibco BRL, Rockville, MD) cells 
were routinely grown in Luria-Bertani (LB) broth or LB agar plates at 37°C supplemented 
with kanamycin (50 pg/ml) for selection. 
Mice 
Six week old C57BL/6J-Lystbg"j/J and Balb/cJ female mice were purchased from 
Jackson Laboratories (Bar Harbor, ME). Mice were housed in a temperature and humidity 
controlled room at the National Animal Disease Center and were maintained in disposable 
plastic cages with free access to water and standard mouse chow during the course of this 
study. The National Animal Disease Center Animal Care and Use Committee approved all 
animal procedures described below. 
Expression vector 
The mammalian expression vector, pVAXl (Invitrogen Corporation, Carlsbad, CA) 
was modified for use in this study. In order to enhance mammalian translation initiation and 
expression, a Kozak translation initiation sequence (consensus sequence: ANNATGG; with 
ATG initiation codon) was inserted into the multiple cloning site of pVAXl. Briefly, 
oligonucleotides Koz-1 and Koz-2 (Table 1) were denatured by heating to 85°C for 5 minutes 
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and then annealed to each other by slowly cooling to 37°C. The resulting double stranded 
DNA and pVAXl vector were double-digested for 1 hour with Hind III and Bam HI 
restriction endonucleases (New England Biolabs, Beverly, MA) at 37°C. Digested products 
were purified from agarose gels using Geneclean III (Biol01, Inc., Carlsbad, CA) and ligated 
with T4 DNA Ligase (Gibco BRL) to create pVAX-Koz. Following ligation, pVAX-Koz 
was transformed into competent E. coli cells, clones were selected for plasmid purification 
(Midi kit, Qiagen, Inc., Valencia, CA), and correct orientation of the Kozak sequence was 
confirmed by DNA sequencing. 
Expression oflacZ in mice 
As a preliminary experiment, the lacZ gene, which codes for p-galactosidase, was 
cloned to examine in vivo expression of an assayable, prokaryotic gene in mice via gene gun-
mediated delivery. PCR amplification of lacZ was performed using the primers lacZ5' and 
lacZ3' (Table 1). The resulting amplicon and pVAX-Koz were double digested for 1 hour at 
37°C with Bam HI and Xba I restriction endonucleases (New England Biolabs), purified as 
described above, and ligated in-frame to create pVAX-lacZ. Following ligation, pVAX-lacZ 
was transformed into E. coli and kanamycin-resistant clones were selected for plasmid 
purification. DNA sequencing was used to confirm that lacZ was in-frame and in the correct 
orientation. DNA was prepared for Helios Gene Gun immunization as described by the 
manufacturer (Bio-Rad Laboratories, Hercules, CA). Briefly, 15 fig of pVAX-Koz or 
pWAX-lacZ plasmid DNA was precipitated onto 7.5 mg of 1 (im gold beads and loaded into 
tubing for preparation of 15 vaccine "bullets". Each resulting DNA vaccine bullet contained 
1 jxg of DNA that was delivered by 0.5 mg of gold microcarrier beads. Balb/cJ mice, n=20, 
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were obtained for lacZ transfection. The mice were randomly segregated into 2 groups of 10 
mice. The first group was immunized with pVAX-Koz as a negative control and the second 
group was immunized with pVA X-lacZ. In order to increase the efficiency of DNA 
transfection, the abdomens of the mice were shaved with surgical clippers and wiped with 
70% ethanol prior to immunization. Mice were anesthetized by inhalation of isoflurane prior 
to immunization to aid in handling. A total of 1 gg of DNA was delivered by gene gun at a 
discharge pressure of 300 p.s.i. to the abdomen of each mouse. Two mice from each group 
were sequentially euthanized on days 1, 2, 4, 6, and 140 post-immunization and tissues 
(abdominal epidermis, abdominal muscle, spleen, inguinal lymph node, mesenteric lymph 
node) were collected for detection of b-galactosidase expression. Tissue samples were 
embedded in Tissue-Tek Optimal Cutting Temperature (O.C.T.) compound (Sakura Finetek, 
Torrance, CA), snap frozen in liquid nitrogen, and stored at -80°C until processed. Sections 
were cut at 10 pm and placed on poly-lysine coated glass slides. Tissue sections were 
washed twice in PBS for 5 minutes each and then incubated overnight at 37°C in X-gal 
staining solution (0.1 M sodium phosphate buffer (pH 7.3), 1.3 mM MgClz, 3 mM 
KjFe(CN)6, and 1 mg/ml 5-bromo-4-chloro-3-indolyl-(3-D-galactopyranoside). The sections 
were counter-stained with nuclear fast red stain solution (0.35 M nuclear fast red, 50 mM 
AHC(SO^) for 5 minutes prior to visualization. For each tissue section, multiple fields were 
examined microscopically and (3-galactosidase expression was noted, positive or negative, 
for each time point. 
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Genomic DNA library 
Genomic DNA was extracted from M. avium subsp. paratuberculosis strain 19698-
1974 as previously described [29]. A genomic expression library was constructed by 
partially digesting 55 pg of M avium subsp. paratuberculosis genomic DNA with 4 units of 
Sau2>A I restriction endonuclease (New England Biolabs) for 1 hour at 37°C to yield 1-3 Kb 
fragments. The resulting genomic fragments were gel purified using Geneclean III as 
described above. pVAX-Koz was digested with Bam HI, gel purified, and the 5' and 3' ends 
were dephosphorylated with calf intestinal alkaline phosphatase (Gibco BRL), to prevent 
vector self-ligation. Following the dephosphorylation reaction, pVAX-Koz was 
phenol/chloroform extracted and ethanol precipitated. Genomic fragments were ligated into 
the pVAX-Koz vector in 10 independent reactions. Aliquots from each ligation reaction 
were transformed into competent E. coli cells multiple times to yield independent 
transformations. The transformed cells were plated on LB-kanamycin agar media so that an 
average of 1500 colonies grew per 50 mm plate. A total of 11 plates, termed "clone pools", 
were selected for this study and numbered sequentially. Colonies from each clone pool were 
harvested from each plate and frozen at -80°C in LB storage media containing 20% glycerol. 
Plasmids were purified from each clone pool using the EndoFree Plasmid Maxi Kit (Qiagen, 
Inc.) and quantitated by spectrophotometry at 260 nm. 
Analysis of clone pools 
PCR analysis was performed in order to determine the percentage -of clones that 
contained genomic DNA inserts. Two clone pools, #3 and #11, were randomly selected and 
50 clones from each of these 2 pools were randomly selected for plasmid purification. PCR 
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reactions were designed to amplify across the multiple cloning site using primers pVAX-
MCS5' and pVAX-MCS3' (Table 1). Amplicons were visualized on 1.2% agarose gels and 
sizes were estimated based upon a 100 bp DNA ladder size standard (MBI Fermentas, 
Hanover, MD). Additionally, all clone pools were examined by PCR for the presence of 9 
known M. avium subsp .paratuberculosis genes: alkA [30], cspl [19], groES [31], gsbB [32], 
hsp65 [20], hspX [33], IS900 [34], mi g [35], pks [19]. The DNA sequences for each primer 
set used to detect these 9 genes are listed in Table 1. 
Evaluation of mouse and bacterial strains 
In order to determine the optimal model for evaluating infection of mice, an 
experiment was performed which tested 2 mouse strains (C57BL/6J-Lystbg"j/J and Balb/cJ) 
against 3 strains of M. avium subsp. paratuberculosis (clinical isolates 19698-1974, 5007, 
and 6112). C57BL/6J-Lystbg"j/J mice were randomly segregated into 1 negative control 
group of 4 mice and 3 groups of 7 mice for infection with each of the 3 bacterial isolates. 
Balb/cJ mice were randomly segregated into 1 negative control group of 6 mice and 3 groups 
of 14 mice for infection with each of the 3 bacterial isolates. Non-infected control mice were 
mock-challenged by an intraperitoneal (IP) injection of 100 |aL with sterile PBS. 
Experimentally infected mice were inoculated IP with the appropriate bacterial strain (log-
phase, 108 bacteria per mouse in 100 (J,L volume). After three months of infection, mice 
were anesthetized by inhalation of isoflurane and were decapitated by a guillotine. Spleen 
and mesenteric lymph node were removed from each mouse, weighed, homogenized in 
0.75% hexadecylpyradinium chloride solution by use of a stomacher for one minute, and 
allowed to sit overnight for decontamination. Serial dilutions (10°, 10"', 10"2, 10"3, 10"4) of 
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each tissue homogenate from individual mice were inoculated (100 pL per slant) onto 
HEYM slants and incubated at 37°C for 8 weeks. The number of colony forming units per 
slant was counted for each dilution and an average recovery of bacteria was calculated for 
each mouse tissue based upon mg of wet tissue weight. The culture data (CFU/mg of tissue) 
was averaged for each infection group in order to compare mouse and bacterial strains. 
DNA vaccine trial 
Results from the mouse and bacterial strain experiment demonstrated that a high level 
of infection with little variation was obtained with Balb/cJ mice and bacterial strain 6112. 
Therefore, in a DNA vaccine trial, BALB/cJ mice were obtained and randomly partitioned 
into immunization groups of 10 mice as follows: 1. no DNA - non-infected; 2. no DNA -
infected; 3. microcarrier - infected; 4. vector DNA - infected; 5. clone pool DNA - infected. 
For control group 3 (microcarrier - infected), mice were immunized with 0.5 mg of gold 
microcarrier beads, without any plasmid DNA. For control group 4 (vector DNA - infected), 
mice were immunized with 0.5 mg of gold microcarrier beads carrying 1 pig of pVAX-Koz. 
Eleven clone pools (#1 - #11) were tested in mice in this experiment. Clone pool #1 was 
used to immunize a group of 10 mice, clone pool #2 was used to immunize a second group of 
10 mice, and so on. DNA for immunization was prepared and delivered as described for the 
lacZ expression experiment except that a total of 2 jo.g of clone pool DNA was delivered to 
each mouse. Each group of mice was boosted with the same DNA vaccine 3 weeks after the 
initial immunization. Two weeks after boosting, mice were IP inoculated with live, virulent 
M. avium subsp. paratuberculosis strain 6112 (log-phase, 108 bacteria per mouse in 100 pL 
volume). No DNA - non-infected control mice were given a mock-challenge by an IP 
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injection of 100 gL with sterile PBS. After 3 months of infection, mice were anesthetized 
and tissue samples were collected and processed as described in the mouse and bacterial 
strain evaluation experiment. Additionally, blood was immediately collected into sterile 
glass tubes and pooled according to immunization treatment. Blood was allowed to clot 
overnight at 4°C and then serum was harvested and frozen at -20°C. Serial dilutions of each 
tissue homogenate from individual mice were inoculated onto HEYM slants and incubated at 
37°C for 8 weeks. The number of colony forming units per slant was counted for each 
dilution and an average recovery of bacteria was calculated for each mouse tissue based upon 
mg of wet tissue weight. The culture data (CFU/mg of tissue) was averaged for each 
immunization group for comparison and statistical analysis. 
Electrophoresis and immunoblot analysis 
Preparation of M. avium subsp. paratuberculosis sonicate, polyacrylamide gel 
electrophoresis, and electrophoretic transfer of M. avium subsp. paratuberculosis proteins 
onto pure nitrocellulose membranes was described previously [36]. Pooled sera (according 
to immunization group) from vaccinated mice were individually diluted 1:500 with 
phosphate-buffered saline (PBS; 150 mM NaCl, 10 mM NaPC>4, pH 7.4) plus 2% bovine 
serum albumin (BSA) and 0.1% Tween-20, referred to hereafter as PBS-BSA. Diluted sera 
were sequentially added to isolated rows of a slot-blot apparatus (Bio-Rad Laboratories) 
containing a blot of M. avium subsp. paratuberculosis proteins and a molecular weight 
standard (Precision plus protein standard, Bio-Rad Laboratories). Sera were incubated at 
room temperature for 2 hours. After 3 washes with PBS plus 0.1% Tween-20, the blot was 
incubated for 1.5 hours with goat anti-mouse IgG+IgM conjugated peroxidase (Pierce, 
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Rockford, IL) diluted 1:20000 in PBS-BSA. The blot was again washed 3 times with PBS 
plus 0.1% Tween-20 and developed for chemiluminescent detection using the Supersignal 
detection reagents (Pierce). 
Statistical analysis 
The permutation test was performed to compare differences between the mean values 
for control infected mice and immunization groups. Differences were considered significant 
when P was <0.05. 
Results 
Expression of lacZ in mice 
A preliminary experiment was performed to test the duration and efficiency of 
prokaryotic gene expression in mice. Mice were transacted by gene gun delivery in the 
abdomen with either pVAX-Koz or pVAX-/acZ and multiple tissue samples were taken from 
mice at days 1,2, 4, 6, and 140 post-immunization. Incubation of tissues with X-gal staining 
solution revealed transfected cells that expressed (3-galactosidase, as indicated by intense 
blue color (Figure 1). No (3-galactosidase expression was observed in the tissues of control 
mice that received only the pVAX-Koz vector (without the lacZ gene). Expression of (3-
galactosidase was observed in abdominal epidermis, inguinal lymph node, and mesenteric 
lymph node as early as 1 day post-immunization for pVA X-lacZ immunized mice (Table 2). 
Additionally, expression of (3-galactosidase was detected in muscle by 2 days post-
immunization and in spleen by 6 days post-immunization. (3-galactosidase was detected in 
all tissues of pVA X-lacZ immunized mice at 140 days post-immunization. This experiment 
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demonstrated that a prokaryotic sequence could be successfully expressed in mouse tissues 
using the modified pVAX-Koz vector. In addition, these results demonstrated that 
expression occurred in sites other than those directly transacted and that expression occured 
for an extended period of time. 
Analysis of clone pools 
A M. avium subsp. paratuberculosis genomic DNA expression library was generated 
and a total of 11 clone pools were selected for this study, with an average of 1500 clones per 
pool. PCR analysis of 50 clones from each of the 2 randomly selected clone pools revealed 
that 80.4% (clone pool #3) and 75% (clone pool #11) of clones contained inserts (data not 
shown). Given the percentage of recombinant clones, average insert size, and number of 
clone pools, we calculated that all genes are represented in the expression library 1-fold. 
This calculation took into account that one-third of the inserts were in-frame and, of those, 
one-half were in the correct orientation. A crude survey was performed which analyzed the 
11 clone pools for 9 known M. avium subsp. paratuberculosis genes by PCR amplification. 
Genes were present in different percentages across the clone pools as follows: alkA 9.1%; 
cspl 0%; groES 0%; gsbB 18.2%; hsp65 45.5%; hspX 45.5%; IS 900 100%; mi g 9.1%; pks 
54.5%. No single clone pool contained all 9 of the assayed genes. The highest number of 
selected genes present in a single clone pool was 5, and only 1 clone pool contained 5 of 
those genes (data not shown). As expected, the IS 900 insertion sequence, which is present in 
17 copies in the M. avium subsp. paratuberculosis genome, was detected most frequently 
among the clone pools at 100%. In contrast, neither the cspl nor the groES sequence was 
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detected in any of the clone pools. Taken together, these data demonstrate that the clone 
pools contained some overlaps as well as some differences when compared with other clone 
pools. 
Evaluation of mouse and bacterial strains 
In order to determine the optimal model for evaluating M. avium subsp. 
paratuberculosis infection of mice, 2 mouse strains (C57BL/6J-Lystbg"j/J and Balb/cJ) were 
IP challenged with 3 strains of M. avium subsp .paratuberculosis (clinical isolates 19698-
1974, 5007, and 6112) to compare infection levels. IP challenge was selected because of 
ease of administration and reproducibility of infection. Two recent clinical isolates of 
bacteria, 5007 and 6112, were chosen to test their virulence in mice when compared to the 
older isolate 19698-1974. Only the recent isolates were recovered from C57BL/6J-Lystbg"j/J 
mice, while strain 19698-1974 was not recovered (Table 3). By comparison, greater numbers 
of bacteria from isolates 5007 and 6112 were recovered from the spleens and mesenteric 
lymph nodes of Balb/cJ mice compared to C57BL/6J-Lystbg"j/J mice. Similarly, strain 
19698-1974 was not recovered in reproducible numbers from the tissues of Balb/cJ mice. In 
summary, bacterial isolate 6112 infected Balb/cJ mice in higher numbers and with less 
variation than isolate 5007 (Table 3). As a result of this experiment, Balb/cJ mice and 
bacterial isolate 6112 were selected for DNA vaccine studies. 
DNA vaccine trial 
Balb/cJ mice were immunized and boosted with clone pools #1 - #11 and IP 
challenged with M. avium subsp .paratuberculosis isolate 6112. The protective effect of 
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each DNA vaccine was evaluated by comparing the number of viable bacteria recovered 
from the spleens and mesenteric lymph nodes of immunized mice to no DNA - infected 
control mice after challenge. PBS mock-infected (no DNA - non-infected) mice were 
negative for M. avium subsp. paratuberculosis infection, whereas no DNA - infected mice 
had an average of 2047 CFU/mg of spleen and 1240 CFU/mg of mesenteric lymph node 
(Table 4). Two other control groups (microcarrier - infected and vector DNA - infected) also 
had high levels of bacterial infection (Table 4), indicating that IP infection of Balb/cJ mice 
with bacterial isolate 6112 was very effective and reproducible. Clone pools #1, #2, and #10 
substantially reduced the numbers of bacteria recovered from the spleens of mice, with 27 
CFU/mg, 11 CFU/mg, and 144 CFU/mg of spleen, respectively. Statistical analysis indicated 
that these 3 clone pools provided significant protection, P < 0.01, against M. avium subsp. 
paratuberculosis infection (Table 4). Although less dramatic, clone pools #7 and #8 reduced 
bacterial infection in the spleen at least 2-fold when compared to no DNA - infected control 
mice and P values for these 2 clone pools were less than 0.05 (Table 4). By comparison, 
clone pools #1, #2, #8, and #10 significantly reduced (P < 0.01) the number of bacteria 
isolated from the mesenteric lymph nodes of immunized mice (Table 4). Clone pool #5 also 
reduced the number of bacteria isolated from the mesenteric lymph nodes of immunized 
mice, but its P value was marginal. Taken together, protection data from the spleens and 
mesenteric lymph nodes of immunized mice indicate that clone pools #1, #2, #8, and #10 
significantly protected mice from bacterial infection. More importantly, clone pools #1 and 
#2 provided almost complete protection of mice from both spleen and mesenteric lymph 
node infection, as there was a negligible recovery of organisms. 
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Serological analysis of immunized mice 
Immunoblot analysis was performed to confirm that mice were mounting a humoral 
immune response against M. avium subsp. paratuberculosis proteins after DNA 
immunization and bacterial challenge. Although not a complete immunological analysis, this 
experiment was performed to confirm that antibody reactivity differed between protective 
and non-protective clone pools (Figure 2). Serum from the no DNA - non-infected group did 
not recognize any M. avium subsp. paratuberculosis proteins, as expected. Sera from all 
groups of infected mice reacted strongly with 15kDa and 65kDa proteins. Subtle reactivity 
profiles were observed for each clone pool, indicating that each clone pool produced a unique 
set of mycobacterial proteins to which antibodies were produced. Sera from the control-
infected groups (no DNA - infected; microcarrier - infected; vector DNA - infected) reacted 
in a similar manner as sera from the non-protective clone pools (#3, #4, #5, #6, #9, #11). 
Mice that were protected from infection (clone pools #1, #2, #7, #8, #10) exhibited sera 
reactivities different from clone pools that did not protect mice from challenge. For example, 
sera reactivities at the 35kDa, 50kDa, and 90kDa regions directly correlate with high levels 
of bacterial infection (Table 4). 
Discussion 
The bovine paratuberculosis vaccine (Mycopar, Solvay Animal Health, Mendota 
Heights, MN) that is currently licensed for use in the United States has a number of side 
effects and its efficacy is variable. Vaccination interferes with bovine tuberculosis and 
paratuberculosis diagnostic testing, may induce granulomatous inflammation at the injection 
site, and accidental self-inoculation can pose a serious health risk to veterinarians who 
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administer the vaccine. Although some studies have reported that vaccines decrease fecal 
shedding and reduce clinical episodes [37], the current vaccines do not protect animals from 
infection or disease. Clearly, a safe and effective vaccine must be developed that not only 
prevents infection of calves, but also eliminates shedding of M. avium subsp. 
paratuberculosis through the feces, colostrum, and milk of infected cows. If this is 
accomplished, the spread of Johne's disease will be significantly curtailed. 
DNA vaccines offer the advantage of being inexpensive and simple to produce, are 
stable at a variety of temperatures, and do not contain elements that induce allergic or 
hypersensitivity responses often associated with conventional vaccines [27]. Gene gun-
mediated DNA vaccination is needle-free and nanogram quantities of DNA can effectively 
induce both humoral and cell-mediated immune responses. Additionally, vaccination via 
gene gun directly transfects professional antigen presenting cells and subsequently mimics 
the endogenous antigen production of intracellular pathogens such as mycobacteria. 
Our results demonstrated that we could deliver and express a known prokaryotic gene 
in mice. Expression of (3-galactosidase was observed in all tissues examined, including those 
peripheral to the transfection site (i.e. spleen, inguinal lymph node, and mesenteric lymph 
node). This suggested that antigen presenting cells were directly transacted with plasmid 
and migrated throughout the body, an essential component for generating a systemic immune 
response. In addition, detection of (3-galactosidase up to 140 days post-immunization 
demonstrated that antigens encoded by DNA vaccines are not immediately cleared, but are 
available for immune stimulation for prolonged periods of time. These data are supported by 
a previous study, which reported that plasmid-encoded luciferase was expressed for at least 
19 months after intramuscular injection in mice [38]. Taken together, the systemic and 
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prolonged antigen expression demonstrated that our pVAX-Koz vector and gene gun 
delivery method was effective at expressing a cloned gene in mice. 
In contrast to the present study, DNA vaccines for M. tuberculosis have largely been 
based upon one or more specific genes encoding proteins that induce IFN-y secretion [39-
41]. Lima et al. found that a single antigen, mycobacterial heat shock protein hsp65, was 
effective in protecting mice against challenge with M. tuberculosis, reducing infection in the 
lung by 2 logio. Other studies have successfully demonstrated reduced tissue infection after 
challenge in mice or guinea pigs immunized either with Hsp65, Apa, or a combination of 
ESAT-6 plus Ag85A coding sequences [39, 41-42], Although the complete sequence of the 
4.8 megabase M. avium subsp. paratuberculosis genome has recently been completed it has 
not been fully annotated. From the genomic sequence, M. avium subsp. paratuberculosis-
specific genes have been identified, but few of these are antigenic [43]. Individual 
immunologic analysis of the estimated 4300 proteins would be difficult and laborious. The 
advantage of expression library immunization is that every antigen encoded within a 
pathogen's genome can be screened simultaneously to identify protective sequences. 
A number of analyses were performed in this study to verify that our genomic 
expression library was representative of the whole M. avium subsp. paratuberculosis genome 
and that each clone pool was unique. Based on the average insert size, the number of clones 
per pool, the total number of clone pools, and assuming that one out of every 6 clones 
contains an in-frame, correctly oriented insert, our genomic expression library was calculated 
to have complete genome coverage. PGR amplification for 9 known M. avium subsp. 
paratuberculosis genes from each clone pool suggests that each pool is unique and that 
genomic sequences were randomly distributed among the 11 clone pools. The insertion 
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sequence, IS900, is present in 17 copies in the M. avium subsp. paratuberculosis genome, 
and was thus over-represented in our clone pools. 
In order to determine the optimum mouse infection model, an experiment was 
performed that examined IP infection of 3 bacterial isolates in 2 mice strains. C57BL/6J-
Lystbg"j/J mice were selected because they are homozygous for the beige-J mutation and are 
lysosomal trafficking deficient. Previous studies found that both Balb/cJ mice [44] and mice 
with the beige-J mutation [45] were susceptible to M. avium subsp. paratuberculosis 
infection. Oral infection of mice was not tested in the present study because a previous 
report found that mice were more susceptible to infection, had histopathologic changes, and 
exhibited clinical signs when infected IP, not orally [46]. IP infection had been successfully 
used in our laboratory previously and is easier and more reproducible than IV infection, 
although infection levels are generally lower [45]. Also, previous experiments in our 
laboratory were unable to obtain reproducible oral infection of neonatal and weanling mice. 
In the present study, we determined that the highest and most consistent level of infection 
was obtained in BALB/cJ mice IP challenged with strain 6112. Results from this experiment 
also suggest that isolate 19698-1972, although minimally passaged in our lab, has lost 
virulence since its original isolation in 1972. 
In the DNA vaccine trial, similar levels of infection were observed in all 3 control-
infected groups (no DNA - infected; microcarrier - infected; and vector DNA - infected), 
discounting the possible immunostimulatory effects of vector DNA or gold microcarriers. 
More importantly, we demonstrated that mice were protected against challenge with M. 
avium subsp. paratuberculosis when immunized with 4 different clone pools of naked DNA. 
Bacterial infection was dramatically and significantly (P < 0.02) reduced in both the spleen 
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and mesenteric lymph nodes of mice immunized with DNA from clone pools #1, #2, #8, and 
#10. 
Because of the large number of mice that were needed to perform this study, detailed 
analyses of the immune responses generated by DNA vaccination were not possible. 
Immunoblot analysis confirmed that mice generated humoral immune responses to 
vaccination and challenge (Figure 2). Reactivity to 15kDa and 65kDa M. avium subsp. 
paratuberculosis proteins is consistently observed among all groups of challenged mice. 
While the size and identity of the 15kDa protein is speculative, it is quite possible that the 
65kDa protein is a homologue of the M. tuberculosis heat-shock protein, hsp65 [40]. More 
importantly, similar patterns of sera reactivity to M. avium subsp. paratuberculosis proteins 
are observed among protective clone pools and are unique from reactivities seen among non-
protective clone pools. Sera from non-protective groups recognized 35kDa, 50kDa, and 
90kDa proteins, while sera from protective groups did not recognize, or weakly recognized, 
the same proteins. The identity of these proteins are not known and whether or not these 
differences in immune responses were a direct result of protection from challenge remains to 
be determined. Additionally, it was demonstrated that each clone pool DNA vaccine induced 
unique antibody reactivity profiles to M. avium subsp. paratuberculosis proteins. To further 
characterize the immune responses that offer protection in mice, future experiments are 
planned to assay for ThI (IFN-y, IL-2, and IL-12) and Th2 (IL-4 and IL-10) cytokines after 
immunization and M. avium subsp. paratuberculosis challenge. Analyses of humoral and 
cellular immune responses are essential to understand why these DNA vaccines are 
protective and to aid in the development and testing of future paratuberculosis vaccines. 
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Future efforts will be directed toward further division of the 4 protective clone pools 
and subsequent retesting in mice. In addition, protective DNA vaccines must be tested in 
cattle to evaluate and confirm protection. Although immunologic responses are quite 
different between cattle and mice, mice are the ideal model system to screen vaccine 
candidates before proceeding to cattle vaccine trials. 
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Table 1. Oligonucleotide primers used in this study. 
Name Restriction Site Nucleotide Sequence3 
Koz-I Hind III and Bam HI 5'-GCGCTAAGCTTGGTACCGAGCTCACTATGGGATCCGCGC-3' 
Koz-2 Hind III and Bam HI 5'-CGCGATTCGAACCATGGCTCGAGTGATACCCTAGGCGCG-3' 
lacZy Bam HI 5'-GCGCGGATCCATAGATCCCGTCGTTTTACAACG-3' 
lacZy Xba I 5'-ACGGGCCCTCTAGACTCGAGCG-3' 
pVAX-MCS5' 5'-CGAAATTAATACGACTCACT-3' 
pVAX-MCS3' 5'-TGGCAACTAGAAGGCACAG-3' 
alkA-5' 5'-CGCGCCGTGCTGGGCCAGCAG-3' 
alkA-V 5'-CTACCGCGGCGGCTTGACAAC-3' 
cspI-5' 5'-GCGCCAGCTGCCGGTGATGGGGGTCACAAAC-3' 
cspl-y 5'-GCGCAAGCTTACTGGTTCCACTTGTCGCGGATCTT-3' 
groES-5' 5'-GTGGCGAAGGTGAACATCAAG-3' 
groES-y 5'-TTACTTGGAGACGACAGCCAG-3' 
gsbB-5' 5'-TCCACGAGAGTGCTTTATTGACTG-3' 
gsbB-y 5'-TCACGGCATCGGCATTTGTG-3' 
hsp65-5' 5'-CCACGATCACCAACGATGGTG-3' 
hsp65-y 5'-CCCTTGTCGAACCGCATACCC-3' 
hspX-5' 5'-GCGCGGATCCTCTGAACCCGGCTACACACCG-3' 
hspX-y 5'-CGCGCTCTAGATCATGCCGGTGTGAGTACAAC-3' 
IS900-5' 5'-AATCAACTCCAGCAGCGCGGCCTCG-3' 
IS900-3' 5'-CCGCT AATTGAGAGATGCGATTGG-3' 
mig- 5' 5'-GCCTGATGGTCCGCCTGCTA-3' 
mig-y 5'-GACACGTCGGCGATCCCCTTCT-3' 
pks-5' 5'-GCGCAAGCTGACCGCGGTGCCGCCGGGTC-3' 
pks-y 5'-GCGCAAGCTTAGTTGGCCTGACCGGGCGTG-3' 
"Restriction sites encoded by primers are listed and underlined in the primer sequence. 
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Table 2. |3-galactosidase expression in mice tissues at days 1, 2,4, 6, and 140 post-
immunization." 
Day 1 
Day 2 
Day 4 
Day 6 
Day 140 
Abdominal Abdominal Inguinal Mesenteric 
epidermis muscle lymph node lymph node Spleen 
+ - + + -
+ + + + -
+ + + + -
+ + + + + 
+ + + + + 
a +, the tissue was positive for (3-galactosidase expression; -, no (3-galactosidase expression 
was detected. 
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Table 3. Evaluation of infection of 2 mouse strains with 3 different M. avium subsp. 
paratuberculosis isolates. 
Spleen Mes LN 
Mouse strain n= Bacteria CFU/mga SEM CFU/mgb SEM 
C57BL/6J-Lyst 4 None 0.0 0.0 0.0 0.0 
C57BL/6J-Lyst 7 5007 2.9 1.6 0.1 0.1 
C57BL/6J-Lyst 7 6112 4.6 1.6 2.3 0.7 
C57BL/6J-Lyst 7 19698-1974 0.0 0.0 0.0 0.0 
Balb/cJ 6 None 0.0 0.0 0.0 0.0 
Balb/cJ 14 5007 366.6 366.1 22.8 22.3 
Balb/cJ 14 6112 108.9 64.6 123.1 93.4 
Balb/cJ 14 19698-1974 0.0 0.0 0.0 0.0 
a The average number of colony forming units per mg of homogenized spleen from a group 
of mice. 
b The average number of colony forming units per mg of homogenized mesenteric lymph 
node (Mes LN) from a group of mice 
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Table 4. Summary of average number of bacteria recovered from mice that were vaccinated 
with clone pool DNA and/or challenged with live M. avium subsp. paratuberculosis. 
Spleen Mes LN 
Immunization Group CFU/mg" SEM P value0 CFU/mgb SEM P value" 
No DNA - non-infected 0.0 0.0 0.0 0.0 
No DNA - infected 2047.3 478.2 1240.1 218.0 
Microcarrier - infected 1422.6 264.6 1538.5 298.5 
Vector DNA - infected 1604.6 268.0 1246.5 270.2 
Clone pool 1 27.2 26.3 0.0000 63.5 62.4 0.0000 
Clone pool 2 11.4 8.9 0.0000 41.2 33.1 0.0000 
Clone pool 3 1470.0 253.6 0.1717 948.7 231.1 0.1821 
Clone pool 4 2377.7 628.2 0.6626 911.4 270.4 0.1745 
Clone pool 5 1436.7 452.9 0.1941 714.6 201.0 0.0465 
Clone pool 6 1578.9 224.2 0.2156 1543.7 392.5 0.7503 
Clone pool 7 793.6 432.2 0.0319 1057.2 885.6 0.4856 
Clone pool 8 724.4 385.5 0.0189 281.5 162.7 0.0010 
Clone pool 9 1130.3 416.7 0.0834 1441.9 771.9 0.5627 
Clone pool 10 144.2 93.7 0.0000 247.4 174.7 0.0007 
Clone pool 11 2754.2 399.5 0.8643 3239.0 729.4 0.9932 
a The average number of colony forming units per mg of homogenized spleen from an 
immunization group of 10 Balb/cJ mice. 
b The average number of colony forming units per mg of homogenized mesenteric lymph 
node (Mes LN) from an immunization group of 10 Balb/cJ mice. 
c P values for each clone pool as compared to no DNA - infected control group. P < 0.05 are 
in bold. 
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Figure 1. Expression of P-galactosidase in mouse epidermal cells. Mice were immunized 
with the control pVAX-Koz plasmid (A) or pVAX-/acZ (B, C). No |3-galactosidase is 
detected in the control pVAX-Koz transfected mice at day one post-immunization (A). 
Expression of (3-galactosidase, as indicated by a blue color, was observed as early as one day 
post-immunization (B) and as late as 140 days post-immunization (C). Gold microcarriers 
can be visualized as small black dots (A and B). 
Figure 2. Immunoblots from control, vaccinated, and challenged mice from DNA vaccine 
trial. Sera from mice were incubated with M. avium subsp. paratuberculosis proteins to 
assay for reactivity. Lanes - Ng: No DNA - non-infected; Ps: No DNA - infected; Gd: 
microcarrier - infected; pV: vector DNA - infected; clone pools as numbered. Brackets 
above the lane numbers cluster the vaccination groups into infected control groups, protected 
groups, and non-protected groups (from left to right). 
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CHAPTER 4. SEQUENCE ANALYSIS AND IMMUNOLOGICAL ASSESSMENT 
OF PROTECTIVE CLONES FROM AN EXPRESSION LIBRARY OF 
MYCOBACTERIUM A VIUM SUBSP. PARA TUBERCULOSIS. 
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Abstract 
Paratuberculosis (Johne's disease) is a chronic granulomatous infection of cattle, caused by 
the intracellular bacterium Mycobacterium avium subsp. paratuberculosis, for which there is 
no effective vaccine. In a previous study, we identified four genomic DNA expression 
library clone pools that protected mice from challenge with live, virulent M. avium subsp. 
paratuberculosis. Here, we describe the partitioning of one of the protective clone pools into 
10 new clone arrays of 108 clones each and an immunization experiment to identify 
protective clone arrays. When groups of mice were immunized with clone array DNA via 
gene gun, four clone arrays provided significant protection from both spleen and mesenteric 
lymph node colonization with M. avium subsp. paratuberculosis. The nucleotide sequence 
of each clone was determined and coding region functions were predicted by computer 
analysis. Comparison of the protective clone arrays implicated 26 antigens that may be 
responsible for protection in mice. In addition, the effect of DNA immunization dose on 
immune stimulation (Thl w. Th2) was examined. DNA immunization with protective clone 
I l l  
arrays, via gene gun, induced M. avium subsp. paratuberculosis-specific IL-10 and IL-12p70 
cytokine production. This study has identified a less complex pool of antigens from M. 
avium subsp. paratuberculosis that induce both Thl and Th2 responses in mice. 
Introduction 
Paratuberculosis (Johne's disease) is a chronic gastroenteritis caused by the acid-fast bacilli 
Mycobacterium avium subsp. paratuberculosis. Calves less than nine months of age are 
most susceptible to infection [1] and are most likely to become infected after ingestion of 
contaminated milk or colostrum. During the subclinical stage of infection, the host cell-
mediated immune response is robust and appears to control the infection. As the disease 
progresses from the subclinical to the clinical stage, the cell-mediated response diminishes, 
and a humoral immune response predominates [2], An incubation period of 2-5 years is 
common before clinical signs appear [1], which include progressive weight loss, diarrhea, 
emaciation, and eventual death of the animal [3,4]. Stress factors such as parturition, 
lactation, nutritional deficiencies, or parasitic infections may trigger the progression to 
clinical disease [5]. The most recent studies have estimated that paratuberculosis is prevalent 
in 35% of U.S. herds [6], 
The bovine paratuberculosis vaccine (Mycopar, Solvay Animal Health, Mendota 
Heights, MN) that is currently licensed for use in the United States has a number of side 
effects and its efficacy is variable. Vaccination interferes with bovine tuberculosis and 
paratuberculosis diagnostic testing [7, 8], may induce granulomatous inflammation at the 
injection site, and accidental self-inoculation can pose a serious health risk to veterinarians 
who administer the vaccine [9], Paratuberculosis vaccines have been shown to induce both 
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cellular and humoral immune responses [7, 10] but are not effective at preventing infection 
or the transmission of the disease to other animals. Under the best conditions, vaccines have 
been reported to reduce fecal shedding and delay the onset of clinical disease [11-16]. 
Although sequencing of the genome of M. avium subsp. paratuberculosis strain K-10 
was recently completed, few of the over 4300 genes or gene products have been 
characterized. A small number of putative antigens have been identified from M. avium 
subsp. paratuberculosis and their immunogenicity examined by sérodiagnostic and 
lymphocyte stimulation assays [17-24]. However, only one protein, a 65kDa heat shock 
protein, has been tested for its use as a potential vaccine [25]. In that study, a DNA vaccine 
encoding the M. avium subsp. paratuberculosis 65kDa antigen failed to protect mice after 
challenge with live M. avium subsp. avium. Data from the genome project will greatly 
facilitate a directed approach to identify antigens that can be used as vaccine candidates. 
However, until these data are more fully annotated, one technique that was previously 
described to identify novel protective antigens from bacterial pathogens is expression library 
immunization [26]. In theory, all of the antigens encoded by a pathogen can be cloned into 
an expression vector and screened simultaneously in an infection model. 
DNA vaccines offer the advantage of being inexpensive and simple to produce, are 
stable at a variety of temperatures, and do not contain elements that induce allergic or 
hypersensitivity responses often associated with conventional vaccines [27]. A number of 
DNA delivery methods exist, but gene gun-mediated DNA vaccination is needle-free and 
nanogram quantities of DNA can effectively induce both humoral and cell-mediated immune 
responses. Additionally, vaccination via gene gun directly transfects professional antigen 
presenting cells and mimics the endogenous antigen production of intracellular pathogens 
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such as mycobacteria. Several DNA vaccines encoding a single antigen have been developed 
and tested against Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium 
leprae, and Mycobacterium avium [28]. Nearly half of these mycobacterial DNA vaccines 
elicited strong levels of protection and demonstrate the potential for safe, effective DNA 
vaccines that limit mycobacterial infection and disease progression. 
Previously, we used the expression library immunization technique to identify pools 
of genomic DNA clones that protected mice from M. avium subsp. paratuberculosis infection 
[29]. In this study, we performed nucleotide sequencing to determine the genomic sequences 
that offered protection. Further, we partitioned the protective clones into smaller groups 
(clone arrays) for an immunization and challenge experiment. Clone arrays that protected 
mice from bacterial challenge were compared to reveal sequences most likely responsible for 
protection. Finally, we evaluated the immune responses generated in response to protective 
clone arrays. 
Materials and methods 
Bacterial strains 
M. avium subsp. paratuberculosis strains 19698 (laboratory strain) and 6112 (recently 
isolated from a cow with clinical infection at the National Animal Disease Center) were 
grown in Middlebrook 7H9 liquid media (pH 6.0) supplemented with 10% oleic acid albumin 
dextrose complex (Becton Dickinson Microbiology, Sparks, MD), 0.05% Tween 80 (Becton 
Dickinson Microbiology), and 2 mg/ml mycobactin J (Allied Monitor Inc., Fayette, MO). M. 
avium subsp. paratuberculosis cultures were grown to log phase at an optical density 540 nm 
(OD540) of 0.4, at 37°C without shaking. All bacterial strains were minimally passaged to 
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maintain virulence. Bacteria were pelleted by centrifugation at 10,000 X g for 30 minutes 
and washed twice with phosphate-buffered saline (PBS). The bacteria were resuspended in 
PBS and the concentration was adjusted to 109 CFU/ml as determined by OD540. The final 
concentration of bacteria was confirmed by serial dilution onto agar slants of Herrold's Egg 
Yolk Medium (HEYM) containing 2 mg/L of mycobactin J (Allied Monitor, Fayette, MO). 
Escherichia coli ElectroMAX (Gibco BRL, Rockville, MD) cells were routinely grown in 
Luria-Bertani (LB) broth or LB agar plates at 37°C supplemented with kanamycin (50 pg/ml) 
for selection. 
Mice 
Six-week-old Balb/cJ female mice were purchased from Jackson Laboratories (Bar 
Harbor, ME). Mice were housed in a temperature and humidity controlled room at the 
National Animal Disease Center and were maintained in disposable plastic cages with free 
access to water and standard mouse chow during the course of this study. The National 
Animal Disease Center Animal Care and Use Committee approved all animal procedures 
described below. 
Expression library 
The mammalian expression vector, pVAXl (Invitrogen Corporation, Carlsbad, CA) 
was modified by the insertion of a Kozak translation initiation sequence and named pVAX-
Koz as previously described [29]. Using pVAX-Koz, a genomic expression library was 
generated with DNA from M. avium subsp. paratuberculosis as previously described [29]. A 
total of 11 "clone pools", were selected for that study and numbered sequentially. Colonies 
from each clone pool were frozen at -80°C in LB storage media containing 20% glycerol. 
Plasmids were purified from each clone pool using the EndoFree Plasmid Maxi Kit (Qiagen, 
Inc.) and quantitated by spectrophotometry at 260 nm. 
Nucleotide sequence analysis of protective clone pools 
DNA vaccination and challenge results [29] demonstrated that four clone pools 
significantly protected mice from M. avium subsp. paratuberculosis challenge. In order to 
determine the coding sequence of each clone from a protective clone pool, DNA sequence 
analysis was performed. One protective clone pool was randomly selected from the frozen 
stock and clones were grown overnight on LB/kanamycin plates. Individual clones were 
picked and transferred to 96 well plates containing LB/kanamycin by a BioRobotics BioPick 
colony picker (Genomic Solutions, Ann Arbor, MI). Plates of clones were incubated 
overnight at 37°C in a GeneMachines HiGro incubator (Genomic Solutions) at 480 orbits per 
minute with oxygen supplementation. From each overnight culture, lOpL was inoculated 
into fresh, sterile 96-well 1.5ml deep-well plates containing LB/kanamycin. The original 
culture plates were preserved by adding 20% glycerol to each well and storing at -80°C 
while the new deep-well plates were incubated overnight as before. Plasmids were extracted 
from deep-well overnight cultures using QIAprep 96 turbo miniprep kits (Qiagen Inc, 
Valencia, CA). Plasmid DNA was quantitated using pico-green double-stranded DNA kit 
(Molecular Probes, Eugene, OR) and sequencing reactions were performed using Big Dye 
terminator chemistry v2.0 (Applied Biosystems, Foster City, CA). The insert sequences for 
each clone were obtained by sequencing across the vector multiple cloning site using primers 
T7 (5 ' - A AT ACG ACT C ACT AT AG- 3 ' ) and Rev (5 ' -TAG A AGGC AC AGT CG AGG- 3 ' ). A 
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total of 2496 clones were selected for sequencing. Nucleotide sequence data was obtained 
with an ABI Prism 3700 DNA Analyzer (Applied Biosystems). DNA sequence data was 
edited, aligned, and analyzed using Mac Vector and AssemblyLIGN (Genetics Computer 
Group, Madison, WI). Comparison of non-repetitive clone coding sequence to the M. avium 
subsp. paratuberculosis genome was performed using Artemis 
(http://www.sanger.ac.uk/Software/Artemis/). 
Clone arrays 
Nucleotide sequence analysis revealed that from the total number of sequenced 
clones, 581 contained genomic inserts that were not repeated within the clone pool. Of those, 
536 clones contained a M. avium subsp. paratuberculosis séquence that coded for an open 
reading frame larger than seven amino acids. These 536 clones were sequentially numbered 
by open reading frame size, from smallest (#1) to largest (#536), and individually transferred 
and ordered in new 96-well master plates, termed "non-repetitive clones", from smallest to 
largest open reading frame. The non-repetitive clones were incubated as before and clone 
growth was visually confirmed the following morning. From the master plates of non-
repetitive clones, 10 new clone pools were generated with 108 clones each. The 10 new 
clone pools, termed "clone arrays", were specifically designed so that each clone array 
contained an equal distribution of open reading frame sizes. This was accomplished by a 
complex clone selection method such that clone arrays #1 - #5 contained every 5th clone 
while clone arrays #6 - #10 contained every 6th clone. Briefly, clone array #1 contained 
clones 1,6, 11, 16,..., 536, clone array #2 contained clones 2, 7, 12, 17,..., 532, clone array 
#3 contained clones 3, 8, 13,18,..., 533, etc. By comparison, clone array #6 contained 
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clones 1,7, 13, 19,535, clone array #7 contained clones 2, 8, 14, 20 536, clone array 
#8 contained clones 3, 9, 15, 21,..., 531, etc. This configuration of clones resulted in 17 
shared clones between any 2 clone arrays while assuring that open reading frame sizes were 
equally distributed among the new clone arrays. Each clone array was grown overnight in 
96-well plates and culture growth was visually confirmed for each clone. The 108 clones 
from each clone array were pooled and grown overnight for EndoFree plasmid DNA 
purification as described above. In addition, the parent protective clone pool (1500 clones 
that offered protection in our previous study) and the non-repetitive clones larger than 7 
amino acids (536 clones) were grown and plasmid DNA was purified. 
DNA vaccine trial 
DNA was prepared for Helios Gene Gun immunization as described by the 
manufacturer (Bio-Rad Laboratories, Hercules, CA). Briefly, 40 gg of plasmid DNA was 
precipitated onto 10 mg of 1 |am gold beads and loaded into tubing for preparation of 20 
vaccine "bullets". Each resulting DNA vaccine bullet contained 2 fig of DNA that was 
delivered by 0.5 mg of gold microcarrier beads. BALB/cJ mice were obtained and randomly 
partitioned into immunization groups of 10 mice as follows: 1. no DNA - non-infected; 2. 
no DNA - infected; 3. parent protective clone pool DNA - infected; 4. non-repetitive clones 
DNA - infected; 5. clone array DNA - infected. Ten clone arrays (#1 - #10) were tested in 
mice in this experiment. Clone array #1 was used to immunize a group of 10 mice, clone 
array #2 was used to immunize a second group of 10 mice, and so on. Mice were 
anesthetized by inhalation of isoflurane to aid in handling during the immunization protocol. 
Prior to immunization, abdomens of the mice were shaved with surgical clippers and wiped 
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with 70% ethanol to increase DNA transaction efficiency. A total of 2 of DNA was 
delivered by gene gun at a discharge pressure of 300 p.s.i. to the abdomen of each mouse. 
Each group of mice was boosted with the same DNA vaccine 3 weeks after the initial 
immunization. Two weeks after boosting, mice were IP inoculated with live, virulent M. 
avium subsp. paratuberculosis strain 6112 (log-phase, 10s bacteria per mouse in 100 pE 
volume). No DNA - non-infected control mice were given a mock-challenge by an IP 
injection of 100 pL with sterile PBS. After three months of infection, mice were 
anesthetized by inhalation of isoflurane and were decapitated by a guillotine. Spleen and 
mesenteric lymph node were removed from each mouse, weighed, homogenized in 0.75% 
hexadecylpyradinium chloride solution by use of a stomacher for one minute, and allowed to 
sit overnight for decontamination. Serial dilutions (10°, 10"', 10'2, 10"3, 10"4) of each tissue 
homogenate from individual mice were inoculated (100 pL per slant) onto HEYM slants and 
incubated at 37°C for 8 weeks. The number of colony forming units per slant was counted 
for each dilution and an average recovery of bacteria was calculated for each mouse tissue 
based upon mg of wet tissue weight. The culture data (CFU/mg of tissue) was averaged for 
each immunization group for comparison and statistical analysis. 
DNA vaccine dilution and immunologic response 
In order to assess the immunologic response of mice in response to DNA vaccination 
and to determine whether the amount of DNA delivered via gene gun affects the immune 
response, mice were vaccinated and boosted with dilutions of a protective DNA vaccine and 
the immune responses were analyzed. One of the protective clone arrays was randomly 
selected and DNA was purified as described above. Gene gun bullets were prepared as 
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described above, except that 5 dilutions of clone array DNA were prepared as follows: 5 ng 
DNA/builet; 2 ng DNA/bullet; 200 ng DNA/bullet; 20 ng DNA/bullet; 2 ng DNA/bullet, 
Plasmid DNA from the pVAX-Koz vector (20 ng) and the protective clone array dilutions 
(100 ng, 40 ng, 4 ng, 400 ng, and 40 ng) were separately precipitated onto 10 mg of 1 pm 
gold beads and loaded into tubing for preparation of 20 vaccine "bullets". Each resulting 
bullet contained 0.5 mg of gold microcarrier beads with either 1 ng of pVAX-Koz DNA or 5 
ng, 2 ng, 200 ng, 20 ng, or 2 ng of DNA from the protective clone array. The 5 ng 
DNA/bullet group was prepared twice so that a group of mice could be immunized twice for 
a total of 10 ng of DNA per vaccination. BALB/cJ mice were obtained and randomly 
par t i t i oned  in to  immuniza t ion  g roups  o f  10  mice  a s  fo l lows :  1 .  no  DNA;  2 .  pVAX;  3 .10  
ng DNA; 4. 2 ng DNA; 5. 200ng DNA; 6. 20ng DNA; 7. 2ng DNA. Mice were 
immunized as described above and were boosted 3 weeks after the initial immunization, with 
the exception that the 10 ng DNA mice were immunized twice with 5 ng of DNA for a total 
of 10 ng of clone array DNA. Two weeks after boosting, mice were anesthetized by 
inhalation of isoflurane and were decapitated by a guillotine. Spleens were aseptically 
removed from each mouse and placed in 10ml of RPMI 1640 medium (Gibco BRL, Grand 
Island, NY). Spleens were thoroughly minced and then passed through a 20-gauge needle 
attached to a 10 ml syringe at least 5 times to attain a single-cell suspension. Cell viability 
was determined using propidium iodine exclusion. Splenocytes, consisting of a mixed 
population of mononuclear cells, were plated in 48-well culture plates at a concentration of 4 
x 105 viable cells/well in complete medium (RPMI 1640 containing 10% fetal bovine serum 
(HyClone, Logan UT), 2 mM L-glutamine, 100 U of penicillin/ml, and 100 ng of 
streptomycin/ml (Gibco BRL). Cells were either cultured with medium alone (non-
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stimulated), 10 pg of concanavalin A/ml (ConA, Sigma Chemical Co., St. Louis, MO), or 10 
gg of M. avium subsp. paratuberculosis whole-cell sonicate (MPS)/ml. The MPS was 
prepared by sonication of 1 ml volumes of M. avium subsp. paratuberculosis at 25 W for 25 
minutes. Splenocyte supernatants were harvested 24 hours after stimulation and were frozen 
at -20°C until analyzed for IL-2, IL-4, IL-10, IL-12 p70, IFN-y, and RANTES production 
using Quantikine Mouse Cytokine ELI SA kits (R&D Systems, Inc., Minneapolis, MN). 
Statistical analyses 
A two-way ANOVA was performed to compare differences between the mean values 
for control infected mice and immunization groups. Differences were considered significant 
when P was < 0.05. 
Results 
Nucleotide sequencing of a protective clone pool 
A previous study in our laboratory demonstrated that four pools of M. avium subsp. 
paratuberculosis genes protected mice from bacterial challenge [29]. In this study, one of 
these four protective pools was characterized by sequencing all of the clones present in that 
pool. A total of 1766 clones were present in this pool and their sequences were aligned to 
determine the number of repeat clones. Sequence alignment revealed that there were 581 
non-repetitive sequences within this clone pool (32.9% of the total). The genomic insert 
sizes ranged from 14 base pairs to 3548 base pairs with a mean insert size of 285 base pairs. 
Analysis of coding regions revealed that open reading frame sizes ranged from 2 amino acids 
to 423 amino acids, with a mean open reading frame of 40 amino acids. A total of 174350 
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base pairs of M. avium subsp. paratuberculosis DNA are present in the protective clone pool, 
representing 3.9% of the genome. 
Generation of clone arrays 
Sequence data from the non-repetitive 581 clones was screened for open reading 
frame sizes of 8 amino acids or larger by sequence analysis software. Clones that contained 
open reading frames smaller than 8 amino acids (n=45) were excluded from further analysis 
because they cannot be loaded onto MHC molecules. The resulting 536 clones were 
transferred from their original culture plates into new culture plates, being arranged from 
smallest to largest open reading frame. Ten clone arrays were generated as described in the 
materials and methods, with 108 clones per clone array. 
DNA vaccine trial 
Groups of Balb/cJ mice were immunized and boosted with the parent protective clone 
pool, the non-repetitive clones, and clone arrays #1 - #10 and IP challenged with M. avium 
subsp. paratuberculosis isolate 6112. The protective effect of each DNA vaccine was 
evaluated by comparing the number of viable bacteria recovered from the spleens and 
mesenteric lymph nodes of immunized mice to no DNA - infected control mice after 
challenge. PBS mock-infected (no DNA - non-infected) mice were negative for M. avium 
subsp. paratuberculosis infection, whereas no DNA - infected mice had an average of 242 
CFU/mg of spleen and 804 CFU/mg of mesenteric lymph node (Table 1). Clone arrays #1 
and #2 dramatically reduced the number of bacteria isolated from the spleens of mice, as 
compared to the no DNA - infected group, with less than 5 CFU (Table 1). In total, 7 of 10 
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clone arrays (#1, #2, #4, #5, #8, #9, #10) provided significant levels of protection from 
bacterial colonization in the spleen, with P values less than 0.05 (Table 1). Clone arrays #2 
and #4 were the most effective at preventing bacterial colonization in the mesenteric lymph 
nodes of mice (< 10 CFU/mg of tissue), with 4 of 10 clone arrays (#1, #2, #4, #9) providing 
significant levels of protection (P < 0.05; Table 1). Mice that were immunized with either 
the parent protective clone pool or the non-repetitive clone pool had higher levels of bacteria 
recovered from their spleens than the no DNA - infected group, with 723 CFU/mg and 764 
CFU/mg of spleen, respectively. Additionally, protection was not observed in the mesenteric 
lymph nodes of mice immunized with the parent protective clone pool or the non-repetitive 
clone pool, although the non-repetitive clones afforded a five-fold reduction in bacterial 
colonization (Table 1). Protection data from the spleens and mesenteric lymph nodes of 
immunized mice indicated that clone arrays #1, #2, #4, and #9 significantly protected mice 
from bacterial infection, with clone array #2 provided almost complete protection of mice 
from both spleen and mesenteric lymph node infection, as there was a negligible recovery of 
organisms from these tissues. 
Genes that offer protection 
In order to determine the genes that provided protection from infection, the open 
reading frames from each non-repetitive clone (n=536) were compared to the M. avium 
subsp. paratuberculosis genome and predicted gene functions were assigned to each clone. 
As indicated above, clone arrays #1, #2, #4, and #9 significantly protected mice from 
bacterial infection in both the spleens and mesenteric lymph nodes, therefore, this analysis 
focused on those protective clone arrays. Because each clone array contained 108 clones, 
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the coding sequence of each clone was known, and there were 17 shared clones between any 
two clone arrays, an analysis was performed to compare sequences among clone arrays that 
may confer protection. Predicted gene functions were separated into 7 major categories: 
transport/binding proteins; membrane proteins; macromolecular metabolism (i.e. 
macromolecule degradation/synthesis, nucleotide-associated enzymes, polysaccharide 
degradation/synthesis); IS-like elements; virulence proteins; small-molecular metabolism 
(i.e. amino acids, co-factors, regulators, fatty acids, energy); mycobactin/polyketide synthase. 
Each of the coding regions from the four protective clone arrays was separated into 
categories for comparison (Table 2). A list of individual genes shared among protective 
clone arrays is presented in Table 3. Most notable are members of the pro line-rich antigens, 
PPE-family proteins, macrophage cell entry proteins, and mycobactin/exochelin proteins, 
which were identified in 3 of 4 protective clone arrays. 
DNA vaccine dilution and immunologic response 
In order to determine the immune response that was induced by vaccination with a 
protective clone array and to determine if the amount of DNA affects the immune response, 
groups of mice were immunized and boosted with dilutions of a protective clone array. 
Splenocytes were isolated from the mice 2 weeks post-boost and analyzed for the production 
of ThI (IL-2, IL-12p70, IFN-y, and RANTES) or Th2 (IL-4 and IL-10) cytokines in response 
to stimulation. In general, a DNA dilution effect was observed, as the amount of cytokine 
production was reduced with decreasing amount of DNA vaccine with the highest cytokine 
secretion noted for mice immunized with 10 |ig of DNA, followed by 2 pg of DNA, and then 
a plateau response for the other 3 doses (200 ng, 20 ng, 2 ng of DNA). 
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Stimulation of splenocytes by either ConA or MPS resulted in greater secretion of all 
cytokines compared to the non-stimulated cultures (Figure 1). A significant (P < 0.05) 
increase in ConA-stimulated secretion of IL-2, IL-4, IL-10, IFN-y, and RANTES was noted 
by splenocytes from mice immunized with 10 jag of DNA compared to the negative control, 
non-vaccinated mice or the pVAX vaccinated mice (Figure 1). In contrast, priming mice 
with 200 ng, 20 ng, or 2 ng of DNA resulted in reduced ConA-stimulated IL-10 secretion by 
splenocytes compared with the no DNA control groups (Figure 1C). Stimulation of 
splenocytes with MPS resulted in no differences in IL-2 or IL-4 across treatment groups, 
with negligible levels of these cytokines secreted after 24 hours of stimulation (Figure 1A 
and B). However, immunization of mice with 10 jag of DNA resulted in increased (P < 0.05) 
secretion of IL-10, IL12p70, and IFN-y by MPS-stimulated splenocytes compared to the 
control groups. Overall, cytokine secretion induced by ConA or MPS was somewhat 
intermediate in the mice immunized with 2 pg and less of DNA compared to the highest 
levels of cytokine secretion achieved with 10 pg of DNA. 
Discussion 
Previous studies in our laboratory demonstrated that DNA vaccination with subpools 
of a M avium subsp. paratuberculosis genomic expression library protected mice after 
bacterial challenge [29]. Using expression library immunization [26], a high-throughput 
DNA immunization technique, thousands of bacterial genes were screened simultaneously to 
identify protective sequences. The immunization technique, as described, proceeds through 
successive rounds of immunization and library segregation to ultimately isolate a single or 
select group of protective sequences. Because M. avium subsp .paratuberculosis infection 
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experiments are expensive and time-consuming, we decided to deviate from the expression 
library immunization protocol, and instead, completely sequence every clone in a protective 
clone pool. Rapid and efficient sequencing of a large number of clones was possible with 
high-throughput nucleotide sequencing instruments on-site. We previously calculated that 
each clone pool contained 1500 clones and estimated that 25% of clones did not contain 
genomic inserts. Here, sequencing results demonstrated that there were 581 different clones 
(32.9% of the total clones sequenced) in the protective clone pool. While this represents a 
smaller portion of the genome than previously calculated, it reduced the complexity of the 
clone pool and provided a smaller group of protective clones to segregate and test. 
Sequencing results found that 543 (21.8%) of the clones did not contain inserts, which 
confirms our previous estimate [29]. 
Because high-throughput sequencing is performed in a 96-well format, every 
sequence can be traced back to its original clone for further manipulation. In the context of 
this study, we chose to remove duplicated clones, clones without genomic inserts, and clones 
with poor sequence data. Additionally, clones that contained open reading frames of 7 amino 
acids or smaller were removed because they could not be loaded and presented on host cell 
MHC molecules. The in silico screening accomplished by nucleotide sequencing resulted in 
two important results. First, a 64% reduction in clone number was achieved in less than 2 
weeks. This level of clone reduction would have otherwise required an eight month 
immunization and challenge experiment in a group of 150 mice. Second, because we 
obtained the nucleotide sequence of every clone in a protective clone pool, subsequent 
experiments could be directed with specific knowledge of which genes offered protection. 
Using the nucleotide sequence data, non-reptetitive clones (n=536) were arranged according 
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to open reading frame size, from smallest to largest, and 10 new clone arrays were generated 
with 108 clones each. In order to assure a true, random distribution of clones, clone arrays 
were manually generated so that there was no size-bias. Additionally, the 10 new clone 
arrays were generated so that any two clone arrays had 17 shared clones. This was essential 
to account for the possible additive effects of multiple clones in providing protection. 
Although, ideally, expression library immunization aims to identify one protective sequence, 
it is more likely that multiple coding regions will provide protection and their combined use 
would provide even greater levels of protection. 
The DNA vaccination experiment demonstrated that four clone arrays significantly 
protected mice from both spleen and mesenteric lymph node challenge with M. avium subsp. 
paratuberculosis. However, the parent protective clone pool did not reduce bacterial 
infection in mice, as compared to the no DNA - infected group. This may be due to a 
technical failure to isolate and purify the same clones as our previous DNA vaccine 
experiment. As noted in the materials and methods, the parent protective clone pool used in 
this study was grown from frozen stock. It is possible that some clones lost viability during 
storage or were inadvertently excluded when a portion of the stock was selected for growth 
and DNA purification. It is also possible that the relative abundance of particular plasmids 
may play a role in protection and these subtle differences were not replicated in the new 
DNA purification. As noted above, sequencing results showed that there was repetition of 
clones within the parent protective clone pool. Upon purifying clone pool DNA for this 
experiment, it is possible that some clones were present in higher percentages than the 
previous experiment, while other clones may have been present in lower percentages than the 
previous experiment. Likewise, the non-repetitive clone pool, which excluded clones 
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without inserts, clones encoding for 7 amino acids or fewer, or clones that did not generate 
usable sequence data, did not protect mice from challenge when compared to the no DNA -
infected group. The lack of protection from the non-repetitive clone pool may be due to the 
relative abundance of particular clones, the absence of small peptide-producing clones, or the 
exclusion of clones for which we had no sequence data. Poor sequence data can result as a 
consequence of many factors, including high GC content, secondary structure, or poor 
template preparation. The exclusion of this small minority of clones (7.5%) was 
unavoidable. However, because of the number of repeated clones (67%), we were confident 
that very few clones were excluded. Regardless, results from this study demonstrated 
significant protection when mice were vaccinated with four different clone arrays. Since 
these clone arrays were derived from the parent protective clone pool, these results validate 
that protective sequences do exist in the parent protective clone pool. The protective effects 
of clone arrays #1, #2, #4, and #9 may be due to the reduced complexity of clones (n=108) 
versus the parent protective clone pool (n=1500) or the non-repetitive clone pool (n-536). 
The protective effects of the four clone arrays may also be due to the removal of a clone or 
group of clones that facilitated infection in the parent protective clone pool or the non-
repetitive clone pool. 
The coding sequences that were shared among the four protective clone arrays were 
determined and a detailed list was prepared of the 26 proteins that protect mice from M. 
avium subsp. paratuberculosis challenge (Table 3). The list of protective antigens was 
assembled based upon predicted surface expression, virulence, or previous reports of 
antigenicity in mycobacteria. The mycobacterial cell membrane-associated protease, FtsH, 
has been shown to induce antibody production in M. tuberculosis patients [30]. The 
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mycobacterial major membrane protein, MMP, has been reported to induce both cellular and 
humoral immune responses from M leprae-infected individuals [31-32] and a DNA vaccine 
study showed that MMP protects mice from leprosy challenge [33]. In addition, the MMP 
has recently been shown to play a role in invasion of macrophages by M. avium subsp. 
paratuberculosis [34]. Proline-rich antigens have been described, which induce both T and 
B cell responses in M. tuberculosis and M, leprae [35-37]. Further, a DNA vaccine encoding 
the M tuberculosis 36kDa proline-rich antigen protected mice from challenge with live 
bacteria [36]. The PE family of antigens is named after their proline and glutamic acid-rich 
N-terminal ends. They are highly antigenic, located on the cell wall and cell membrane, and 
are involved in macrophage infection and cell-to-cell interactions [38-40]. The macrophage 
cell entry protein, Mce, is a virulence factor involved in macrophage entry and survival [41-
43]. The polyketide synthase family of genes produces lipid-like molecules with a wide 
variety of functions, including iron acquisition and virulence [18, 44]. 
Analysis of the immune response to genomic DNA vaccination was performed and 
revealed that a protective clone array induced M. avium subsp. paratuberculosis-spQcWic IL-
10, IL-12p70 and IFN-y production (Figure 1). Because cellular immunity is vital in 
protection from paratuberculosis [2], it is fitting that we detected high levels of IL-12p70 and 
IFN-y, both Thl cytokines. MPS stimulated high levels of IFN-y production, but not 
significantly different from ConA stimulation. RANTES, another Thl cytokine, was also 
expressed at high levels in response to MPS stimulation, but negative control, non-vaccinated 
mice also produced high levels of this cytokine in response to stimulation with MPS antigen 
preparation. As anticipated, we observed a dilution effect with DNA immunization, as 
decreasing amounts of immunization DNA translated into decreasing immune responses for 
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all cytokines examined. With the exception of IL-12p70 production after ConA stimulation, 
similar levels of cytokine production were observed for both non-vaccinated and pVAX 
vaccinated mice, indicating that plasmid DNA, alone, does not significantly induce cytokine 
production. Although we obtained significant levels of protection from challenge with 2 pg 
of clone array DNA, the results of this immunological analysis suggest that future DNA 
vaccine experiments in mice should utilize the 10 ng dose of clone array DNA to achieve 
optimal cytokine responses. While there is debate whether the amount of DNA affects the 
immune response [45-47], results from this study suggest that DNA dose directly correlates 
with cytokine induction. In a previous study, we noted specific patterns of M. avium subsp. 
paratuberculosis-specific antibody production in response to expression library 
immunization that correlated with protection from bacterial challenge [29]. Here, we 
demonstrated that expression library immunization induced both Thl (IL-12p70) and Th2 
(IL-10) responses. Indeed, the protective effect of this clone array may be the combined 
result of both Thl and Th2 responses. 
We have demonstrated that expression library immunization and high-throughput 
sequencing are effective techniques to rapidly identify protective sequences. Future efforts 
will be directed toward characterizing and testing the protective effects of the 26 antigens 
identified in this study. Additionally, the DNA dose will be varied to determine if stronger 
and more consistent levels of protection can be obtained. Ultimately, these antigens must be 
tested in cattle to evaluate and confirm protection. Until this point, however, cattle infection 
studies were cost-prohibitive because of the large number of antigens that had to be screened. 
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Table 1. Summary of average number of bacteria recovered from mice that were vaccinated 
with clone array DNA and/or challenged with live M. avium subsp. paratuberculosis. 
Spleen Mesenteric Lymph Node 
Immunization Group CFU/mg' SEM P value0 CFU/mg" SEM P value0 
No DNA - non-infected 0 0 0 0 
No DNA - infected 242.49 93.51 804.21 638.61 
Parent clone pool 723.41 199.83 0.1257 649.91 228.32 0.5896 
Non-repetitive clones 764.88 363.74 0.6272 142.52 38.31 0.0776 
Array 1 2.74 0.68 0.0007 15.89 8.23 0.0106 
Array 2 1.34 0.33 0.0003 0.28 0.13 0.0003 
Array 3 453.08 411.48 0.5599 39.29 36.13 0.0548 
Array 4 28.88 27.76 0.0144 10.89 3.91 0.0044 
Array 5 10.91 10.5 0.0029 49.9 32.69 0.0636 
Array 6 422.96 182.77 0.8027 700.37 471.77 0.4425 
Array 7 407.82 240.27 0.6697 336.98 83.79 0.4665 
Array 8 61.47 32.78 0.0379 46.94 27.11 0.0534 
Array 9 13.43 11.83 0.0024 18.65 12 0.0116 
Array 10 31.61 15.53 0.0118 89.95 54.76 0.1212 
a The average number of colony forming units per mg of homogenized spleen from an 
immunization group of 10 Balb/cJ mice. 
b The average number of colony forming units per mg of homogenized mesenteric lymph 
node from an immunization group of 10 Balb/cJ mice. 
c P values for each clone pool as compared to no DNA - infected control group. P < 0.05 are 
in bold. 
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Table 2. Distribution of protective sequences into functional categories. 
Category 
Transport/ Membrane Macromolecular IS-Like Virulence Small- Mycobactin/ 
Binding Proteins Metabolism Elements Proteins molecule Polyketide 
Proteins Metabolism Synthase 
Array 1 
Array 2 
Array 4 
Array 9 
10 
5 
6 
7 
33 
24 
35 
32 
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Table 3. Genes present in protective clone arrays that are predicted to be antigenic. 
1 Designation of the gene in the M. avium subsp. paratuberculosis genome (L. Li et al., 
unpublished data). 
Category Array Array 2 Array 4 Array 9 Genome Hit 
Transport/ 
Binding 
Proteins 
ftsH membrane chaperone 
Igt lipoprotein transferase 
ctpl magnesium transport 
ftsH membrane chaperone MAP0448 
chaA calcium/proton antiporter chaA calcium/proton antiporter MAP 1301 
Igt lipoprotein transferase MAP 1308 
oppA oligopeptide transport oppA oligopeptide transport MAP2491 
ctpl magnesium transport MAP3498c 
Membrane 
Proteins 
membrane protein 
membrane protein 
mmpL2 membrane protein 
membrane protein 
mmpL2 membrane protein 
ftsX membrane protein 
mmpL4.2 membrane protein 
membrane protein 
membrane protein 
ftsX membrane protein 
mmpL4.2 membrane protein 
membrane protein 
membrane protein 
membrane protein 
MAP 1239c 
MAP 1493c 
MAP1912 
MAP2239 
MAP3049C 
MAP3131 
MAP3171c 
Virulence proline rich antigen proline rich antigen proline rich antigen MAP0047c 
Proteins PE/PPE-family protein PE/PPE-family protein MAP 1003c 
mce4 macrophage cell entry mce4 macrophage cell entry MAP2191 
mce4 macrophage cell entry mce4 macrophage cell entry mce4 macrophage cell entry MAP2192 
PPE-family protein PPE-family protein PPE-family protein MAP3737 
Mycobactin/ pksl2 polyketide synthase pksl2 polyketide synthase MAP 1796c 
Polyketide polyketide synthase polyketide synthase MAP1871c 
Synthase mbtF mycobactin/exochelin mbtF mycobactin/exochelin MAP2171c 
Proteins mbtD mycobactin/exochelin mbtD mycobactin/exochelin mbtD mycobactin/exochelin MAP2174c 
mbtC mycobactin/exochelin mbtC mycobactin/exochelin MAP2175c 
polyketide synthase polyketide synthase polyketide synthase MAP2230c 
polyketide synthase polyketide synthase MAP2604C 
polyketide synthase polyketide synthase MAP3742 
pks2 polyketide synthase pks2 polyketide synthase MAP3764c 
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Figure 1. Immunologie responses of mice after gene gun immunization with varying 
amounts of DNA from a protective clone array. Groups of mice (n=10) were immunized and 
boosted with the vector alone (pVAX) or with dilutions of a protective clone array (10 jig, 2 
jig, 200 ng, 20 ng, and 2 ng). Negative control, non-vaccinated mice (Neg Ctl) were not 
immunized with any DNA. Splenocytes were cultured for 24 hours in triplicate: non-
stimulated (NS), conconavalin A (ConA) stimulated, or M. avium subsp. paratuberculosis 
sonicate (MPS) stimulated. Supernatants were harvested and IL-2 (A), IL-4 (B), IL-10 (C), 
IL-12p70 (D), IFN-y (E), and RANTES (F) cytokine production was measured by ELISA. 
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CHAPTER 5. CLONING, CHARACTERIZATION, AND ANTIGENICITY OF THE 
MYCOBACTERIUM A VIUM SUBSP. PARATUBERCULOSIS19-KDA 
LIPOPROTEIN 
A manuscript prepared for submission to Microbial Pathogenesis 
Jason F.J. Huntley, Judith R. Stabel, and John P. Bannantine 
Abstract 
The Mycobacterium tuberculosis 19-kDa lipoprotein has been reported to stimulate both T 
and B cell responses as well as induce the release of a number of Thl cytokines. In order to 
evaluate the efficacy of the Mycobacterium avium subsp. paratuberculosis (M. avium subsp. 
paratuberculosis) 19-kDa lipoprotein as an immunomodulator in cattle with Johne's disease, 
the gene encoding the 19-kDa protein was analyzed. A majority of the coding region was 
cloned, expressed, and purified as a fusion protein with the maltose-binding protein (MBP-
19kDa) in Escherichia coli. To assess the ability of the 19kDa protein to induce cellular 
immune responses, IFN-y production was measured from 21 naturally infected cattle after 
whole blood was stimulated with a sonicate of M. avium subsp. paratuberculosis or the 
recombinant MBP-19kDa. Overall, the mean response to MBP-19kDa was as strong as the 
mean response to the paratuberculosis sonicate. By comparison, cells from control, non-
infected cattle did not produce IFN-y after stimulation with either protein preparation. To 
assess the humoral immune response to the 19kDa protein, sera from cattle with clinical 
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Johne's disease were used in immunobiot analysis to test for antibodies against the 19kDa 
protein. Reactivity to the 19kDa protein, but not the MBP, was observed in 9 of 10 infected 
cattle. Finally, immunoelectron microscopy examination with 19kDa-specific antibodies 
demonstrated cytoplasmic localization of the 19kDa protein, indicating that it is not 
specifically surface localized. Taken together, these results demonstrate that the 19kDa 
protein from M. avium subsp. paratuberculosis stimulates both humoral and cell-mediated 
immune responses in infected cattle. 
Introduction 
Paratuberculosis (Johne's disease) is caused by Mycobacterium avium subsp. 
paratuberculosis (referred to hereafter as M. avium subsp. paratuberculosis) and induces a 
chronic enteritis in ruminants. The disease is characterized by weight loss, diarrhea, and 
decreased milk production and is estimated to result in over $200 million of lost revenue 
yearly to the dairy industry in the U.S. alone [1], Prevalence studies in the U.S. have 
estimated that between 22 to 40% of dairy herds are infected with M. avium subsp. 
paratuberculosis [2-3]. Neonatal calves are most susceptible to infection and are likely to 
become infected after ingestion of contaminated milk or colostrum [4-5]. During the 
subclinical stage of infection, the host cell-mediated immune response is robust and appears 
to control the infection. As the disease progresses from the subclinical to the clinical stage, 
the cell-mediated response diminishes, and a humoral immune response predominates [6]. 
Vaccines are not completely protective, but have been reported to reduce fecal shedding and 
delay the onset of clinical disease [7-9]. 
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Despite decades of research, little is known about the M. avium subsp. 
paratuberculosis proteins involved in metabolism, cell wall synthesis, macrophage entry and 
survival, disease pathogenesis, or host immune evasion. However, several antigens have 
recently been identified and their immunogenicity examined by sérodiagnostic and 
lymphocyte stimulation assays [10-17], With the genome sequence of M. avium subsp. 
paratuberculosis recently defined (Li et al., unpublished), all the proteins produced by this 
pathogen should be available for characterization. 
The 19kDa lipoprotein from Mycobacterium tuberculosis has been previously studied 
and has been shown to be immunogenic in mice [18-20] and humans [21-22], Homologues 
of the 19kDa lipoprotein have been reported from M. bovis, M. avium, and M. intracellulare 
but are absent from M. phlei, M. smegmatis, M. fortuitum, M. gordonae, and M. leprae [23]. 
The M. tuberculosis precursor protein is 159 amino acids long [24], including a 21 amino 
acid hydrophobic leader that is cleaved, exposing an N-terminal triacylated region that is 
immunogenic [25]. Lipoylation near the N-terminal portion of the 19kDa protein is believed 
to occur at amino acids 19-24 and contributes to membrane association and its 
immunogenicity [20]. Experimental infection and staining of macrophages has shown that 
the 19kDa protein can traffic separately from live mycobacteria, indicating that the 19kDa 
protein can be anchored in the outer bacterial cell wall or secreted across the mycobacterial 
cell membrane and released [26]. Glycosylation of the 19kDa protein is believed to inhibit 
innate immune responses, such as the release of TNF-a, IL-6, and IL-10 from macrophages, 
but does not affect antibody binding [27-29]. 
The M. tuberculosis 19kDa protein has been shown to stimulate CD4+ T cell 
proliferation, including the release of IL-2, IFN-y, and IL-12 [25, 30]. More specifically, 
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peptides from amino acids 45-64 and 61-80 of the 19kDa protein were shown to be 
responsible for CD4+ stimulation [21,31]. The 19kDa protein was also shown to induce 
CD8+ cells to secrete IFN-y and specifically lyse M. tuberculosis-infected monocytes [32]. 
The peptides responsible for the activation of cytotoxic T cells spanned amino acids 69-78, 
88-97, 100-110, 102-110, 139-148, and 145-154 of the M. tuberculosis 19kDa protein [18, 
19; 22, 32]. Finally, B cell epitopes have been described that localize to the linear sequences 
of amino acids 11-30, 29-47, 61-80, and 140-159, as well as a conformation-dependent 
epitope at the amino and carboxy-terminal ends because of intramolecular disulfide bonding 
of cysteine residues [20,24]. 
Novel opportunities arising from the recently completed genome sequence of M. 
avium subsp. paratuberculosis now enable us to select and characterize genes of interest. 
The goal of this study was to identify immunoreactive proteins that may be involved in 
pathogenesis or aid in the diagnosis of Johne's disease. Diagnostic methods that measure 
host immunity to M. avium subsp. paratuberculosis have been thwarted by the lack of 
reagents that can detect infection in both the subclinical and clinical stages of disease. In this 
study, the 19kDa lipoprotein from M. paratuberculosis was cloned, expressed, and 
characterized. In addition, the purified recombinant protein was used to assess cellular 
immune responses in subclinically infected cattle as well as humoral immune responses in 
cattle with clinical Johne's disease. 
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Results 
Comparison of the mycobacterial 19kDa coding regions 
In order to determine the nucleotide sequence of the M. avium subsp. paratuberculosis 
19kDa coding region, primers were designed based upon sequence of M. avium subsp. 
avium. The 19kDa coding region of M. avium subsp. paratuberculosis was amplified, 
sequenced, and features were defined (Figure 1). A putative Shine-Dalgarno ribosome 
binding site (AAAGGAG) was identified 5 base pairs upstream of the vV-formylMet initiation 
codon (GTG), based upon the NNAGGAG consensus Shine-Dalgarno sequence [33]. GTG 
initiation codons have been identified in 34% of the M. avium subsp. paratuberculosis 
genome (Bannantine and Kapur, unpublished). The open reading frame has a G+C content 
of 66.2% and encodes for 161 amino acids with a predicted molecular mass of 15.2 kDa. A 
12 base pair inverted repeat was identified 14 base pairs downstream of the translation 
termination codon (Figure 1). 
The first 22 amino acids of the M. tuberculosis 19kDa protein are hydrophobic and 
were previously noted to represent a signal peptide which is post-translationally cleaved to 
expose an N-terminal cysteine (Figure 2) [34]. In order to determine if the M. avium subsp. 
paratuberculosis 19kDa protein contained a signal peptide, we performed signal peptidase 
cleavage analysis (SignalP3.0; http://www.cbs.dtu.dk/services/SignalP/). Analysis revealed a 
putative cleavage site between amino acids 34 and 35, to expose an N-terminal serine (Figure 
2). The SignalP-NN (neural networks) model assigned the highest cleavage probability 
values to amino acid 35 (C score = 0.324; Y score = 0.439) with the predicted length of the 
signal peptide being 34 amino acids. 
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Comparison of amino acid sequences (Figure 2) revealed some subtle differences 
among the 19kDa coding regions. The open reading frame of the M. avium subsp. 
paratuberculosis 19kDa protein encodes for 161 amino acids, as does the open reading frame 
for the M. avium subsp. avium 19kDa gene. By comparison, the M. intracellular 19kDa 
gene encodes for 162 amino acids, while both M. tuberculosis and M. bovis encode for 159 
amino acids. 
Cloning and expression of the M. avium subsp. paratuberculosis 19kDa protein 
In order to perform immunoassays using the purified 19kDa protein, a majority of the 19kDa 
coding region was cloned into the pMal-c2 expression vector (Figure 1). The MBP-19kDa 
fusion protein was over-expressed and affinity-purified from E. coli lysates. MBP-19kDa 
was analyzed by SDS-PAGE (Figure 3) to assess purity and confirm size. The predicted 
mass of the MBP alone was 42 kDa, while the predicted mass of the MBP-19kDa fusion was 
56 kDa. Both the purified MBP and MBP-19kDa were separated by SDS-PAGE and 
transferred to nitrocellulose for immmunoblot analysis. 
Immunoblot analysis of the 19kDa protein 
Because of the numerous reports of the B cell antigenicity of the M. tuberculosis 19kDa 
protein, immunoblot analysis was performed to determine if cattle naturally infected with M 
avium subsp. paratuberculosis produced antibodies against the 19kDa protein. Blots were 
probed with sera from 9 non-infected and 14 clinically infected cattle. Sera from 7 of 9 non-
infected cattle did not react with either MBP or MBP-19kDa, while 2 non-infected cattle 
weakly recognized the MBP-19kDa protein, but not the MBP protein (data not shown). By 
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comparison, sera from 9 of 14 infected cattle reacted specifically with the 19kDa protein, but 
not the MBP protein alone. The serum from 1 clinically-infected cow recognized both MBP 
and MBP-19kDa proteins and sera from 4 clinically-infected cattle reacted with the MBP 
protein. An example of specific reactivity to the 19kDa protein with sera from 3 clinical 
cows is shown in Figure 4. 
Immunoelectron microscopy 
To directly determine the subcellular location of the 19kDa protein, we performed 
immunoelectron microscopy analysis on M. avium subsp. paratuberculosis cells using 
19kDa-specific antibodies. Transmission electron microscopy revealed that most of the 
19kDa protein is located cytoplasm!cally (Figure 5), suggesting that it is not surface localized 
or secreted. It was previously determined in our laboratory that MBP monoclonal antibodies 
do not bind to M. avium subsp. paratuberculosis in immunoblot and immunoelectron 
microscopy experiments [11]. 
IFN-y responses of infected cattle to the 19kDa protein 
In order to analyze the cellular immune responses of infected cattle to the 19kDa protein, 
whole blood containing unfractionated PBMCs from 9 non-infected and 21 infected cows 
was stimulated with M. avium subsp. paratuberculosis sonicate (MPS), MBP, or MBP-
19kDa and IFN-y production was assayed. IFN-y production in response to MPS stimulation 
allowed for the segregation of infected cattle into three groups: suspect, positive, and high 
positive. After subtracting the IFN-y responses of non-stimulated cells, suspect animals had 
less than 0.1 absorbance units of IFN-y production, positive animals had 0.1 - 0.3 absorbance 
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units of IFN-y production, and high positive animals had more than 0.3 absorbance units of 
IFN-y production. Whole blood from control, non-infected animals did not respond to either 
MPS or 19kDa stimulation, while MPS and 19kDa stimulation induced IFN-y production 
from infected cattle (Figure 6). Significant differences (P < 0.05) were found between 
control and high positive groups for both MPS and 19kDa protein stimulation. In addition, 
the mean stimulation value for MPS and 19kDa was not significantly different for any group 
of cattle. In suspect animals, the 19kDa protein induced higher IFN-y production than MPS 
from 3 of 9 animals. In both the positive and high positive cattle, the 19kDa protein induced 
higher IFN-y production than MPS from 1 of 6 animals. 
Discussion 
Slow-growing mycobacteria cause a number of diseases, including leprosy, human 
and bovine tuberculosis, avian pneumonia, and bovine paratuberculosis. A majority of the 
research on individual mycobacterial proteins has been performed in M. tuberculosis, 
whereas little is known about the M. avium subsp. paratuberculosis proteome. Indeed, all 
currently available antigen-based diagnostic tests for Johne's disease use an undefined 
mixture of proteins, such as purified protein derivative (PPD), that may not be specific for M. 
avium subsp. paratuberculosis. Recent completion of the M. avium subsp. paratuberculosis 
genome will dramatically advance efforts to identify paratuberculosis proteins. Through the 
power of proteomics, we can now begin to identify many of the components of PPD. 
The present study was performed in order to identify and characterize the M. avium 
subsp. paratuberculosis 19kDa protein, as well as assess its antigenicity in cattle. 
Previously, the 19kDa protein from M. tuberculosis was characterized and reported to induce 
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both cellular and humoral immune responses from mice and humans [18; 21]. Here, the gene 
encoding the 19kDa protein from M. avium subsp. paratuberculosis was sequenced and 
compared to other mycobacterial 19kDa sequences. We identified an AAAGGAG ribosome 
binding site 5 base pairs upstream of the GTG initiation codon in M. avium subsp. 
paratuberculosis, based upon the consensus sequence NNAGGAG that was previously 
derived from 325 E. coli genes [33]. This is in comparison to previous 19kDa studies which 
reported a putative ribosome binding site, AAAGGAG, 6 base pairs upstream of the N-
formylMET GTG initiation codon in M. bovis [35] and a GGAGA ribosome binding site 4 
base pairs upstream of the initiation codon for M. intracellular [36]. Taken together, the 
exact match to the E. coli consensus sequence, the appropriate spacing upstream of the 
putative translation initiation codon, and the presence of a mycobacterial GTG initiation 
codon all suggest that this is N-terminus of the M. avium subsp. paratuberculosis 19kDa 
protein. 
The M. tuberculosis 19kDa protein was reported to contain a 21 amino acid N-
terminal signal peptide [34], however our Signal? analysis for M. avium subsp. 
paratuberculosis identified a putative 34 amino acid N-terminal signal sequence. This 
discrepancy is probably due to advances in computer prediction algorithms, rather than 
differences in coding sequences, as few differences were found between the two N-terminal 
sequences (Figure 2). If the cleavage sites are truly different, the secreted M. avium subsp. 
paratuberculosis 19kDa protein would be 13 amino acids shorter than the M. tuberculosis 
and M. bovis 19kDa secreted protein. Future N-terminal peptide sequencing of the M avium 
subsp. paratuberculosis 19kDa protein will be required to confirm this signal sequence. 
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In the M. avium subsp. paratuberculosis sequence, a 12 base pair inverted repeat was 
identified 14 base pairs downstream of the translation termination codon (Figure 1). Inverted 
repeats have been previously identified downstream of other mycobacterial genes and it is 
likely that these sequences form hairpin loops to terminate translation [35, 37-38]. 
Previously, an 8 base pair inverted repeat was detected 78 base pairs downstream of the 
translation termination site for the M. bovis 19kDa gene [35], while a 10 base pair inverted 
repeat was detected 15 base pairs downstream of the translation termination site for the M. 
intracellular 19kDa gene [36]. 
Recombinant expression and purification of the 19kDa protein allowed for a detailed 
analysis of bacterial surface localization and antigenicity in infected cattle. We generated 
19kDa protein-specific antibodies and used them in immunoelectron microscopy binding 
studies. The M. avium subsp. paratuberculolsis 19kDa protein was localized throughout the 
bacilli, not just at the cell surface (Figure 5). There is disagreement in the literature about the 
true location of the 19kDa protein, as previous studies have reported that the M. tuberculosis 
19kDa protein is both surface bound and released from bacteria [26-27, 39]. 
In this study, we demonstrated that the M. avium subsp. paratuberculosis 19kDa 
protein stimulated both cellular and humoral immune responses in infected cattle. In order to 
measure cellular immune responses, cells from infected cattle were stimulated with both the 
19kDa protein and a whole-cell sonicate of M. avium subsp. paratuberculosis (MPS), 
commonly used in many sérodiagnostic tests for bovine paratuberculosis, and IFN-y 
production was measured. Results from this study suggest that the 19kDa protein is as good 
a stimulator of IFN-y production as MPS, as the mean stimulation value between the two 
protein preparations was not significantly different, regardless of the cattle group examined. 
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Additionally, we found that a majority (9 of 14) of infected cattle produced antibodies to the 
19kDa protein, as determined by immunoblot analysis. By comparison, sera from the 
majority (7 of 9) of control, non-infected cattle did not react to the 19kDa protein. Two non-
infected cows produced antibodies to the 19kDa protein, which may be due to cross-
reactivity with environmental mycobacteria such as M. avium subsp. avium, which also 
produce the 19kDa protein. Sera from four clinical cows reacted to the MBP protein, but this 
reactivity was extremely weak. The MBP is found in environmental E. coli and likely 
accounts for reactivity seen in some cattle. In order to avoid potential cross-reactivity with 
MBP, we attempted to cleave the MBP portion from the MBP-19kDa fusion protein, but 
cleavage was not successful (data not shown). 
In conclusion, while the 19kDa protein is not specific for M. avium subsp. 
paratuberculosis, results from this study show that the 19kDa protein stimulates both cellular 
and humoral immune responses in infected cattle. Results from this study suggest that the 
19kDa protein, alone, can be used to identify cattle in the early and late stages of infection. 
Materials and Methods 
Bacterial strains and culture 
M. avium subsp. paratuberculosis strain 19698-1974 (originally isolated in 1974 from a 
clinical cow at the National Animal Disease Center, Ames, IA) was grown in Middlebrook 
7H9 liquid media (pH 6.0) supplemented with 10% oleic acid albumin dextrose complex 
(Becton Dickinson Microbiology, Sparks, MD), 0.05% Tween 80 (Becton Dickinson 
Microbiology), and 2 mg/ml mycobactin J (Allied Monitor Inc., Fayette, MO). M. avium 
subsp. paratuberculosis cultures were grown to log phase at an optical density 540 nm 
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(OD540) of 0.4, at 37°C without shaking. Escherichia coli DH5a cells were routinely grown 
in Luria-Bertani (LB) broth or LB agar plates at 37°C supplemented with ampicillin (100 
|ig/ml) for selection. 
Animals 
Rabbits were purchased from Harlan Sprague Dawley (Indianapolis, IN). Rabbits were 
housed in a temperature and humidity controlled room at the National Animal Disease Center 
and had free access to water and standard rabbit chow during the course of this study. The 
Johne's Disease Research Project at the National Animal Disease Center has a repository of 
sera from cattle that were euthanized with clinical signs of Johne's disease, including weight 
loss and diarrhea. Fecal samples from each of these clinical cattle were found to contain 
more than 100 CFU per gram of feces as determined by colony counts on Herrold's egg yolk 
media (HEYM) agar slants by standard culture methods [40]. Sera from 14 clinical cattle 
were selected for immunoblot analysis. The Johne's Disease Project maintains a herd of 
non-infected cattle as well as a herd of cattle naturally infected with M. avium subsp. 
paratuberculosis. The animals used in this study were placed in four groups consisting of 9 
non-infected healthy cows, 9 suspect subclinical cows (IFN-y responses < 0.1), 6 positive 
subclinical cows (IFN-y responses 0.1 - 0.3), and 6 high-positive cows (IFN-y responses > 
0.3). The non-infected control cows were characterized by repeated negative fecal cultures 
performed quarterly over a 3- to 5-year period. In addition, these animals were negative on 
any serologic assays (i.e. production of antibody specific for M. avium subsp. 
paratuberculosis and IFN-y) performed during that period. Subclinical cattle (suspect, 
positive, and high-positive) were characterized by shedding less than 10 CFU/g of feces and 
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were intermittently positive by IFN-y assays (response >0.1) performed quarterly over a 3-
to 5-year period. The National Animal Disease Center Animal Care and Use Committee 
approved all animal procedures described in this study. 
Comparison of mycobacterial 19 kDa coding regions 
The nucleotide sequences for the 19kDa coding regions from M. tuberculosis (X07945), M. 
bovis (XI5803), and M. intracellular e (L12235) were obtained from the GenBank/EMBL 
nucleotide sequence data library. The sequences were assembled and compared with 
MegAlign software (DNASTAR, Inc., Madison, WI). The homologous 19kDa coding region 
from M. avium subsp. avium, TIGR_243243 contig 3273, was identified by BLASTn 
analysis using the GenBank database (http://www.ncbi.nlm.nih.gov/Blast.cgi). M. avium 
subsp. avium strain 104 is currently being sequenced by The Institute for Genomic Research 
(TIGR; http://www.tigr.org/cgi-bin/BlastSearch/blast.cgi?organism=m_avium). To amplify 
the 19kDa coding region from M. avium subsp. paratuberculosis, primers were designed 
using M. avium subsp. avium sequence because of the strong nucleotide identity between the 
two subspecies [41-43], Oligonucleotide primers, 19kDa-5' (5'-
CCGGGCTGGGAGGTTTGTGG-3') and 19kDa-3' (5'-
ACAACGGGACGATCTCGGTGAACA-3') were designed by PrimerSelect software 
(DNASTAR, Inc.) to flank the 19kDa region of M. avium subsp. avium. Primer 19kDa-5' is 
located 166bp upstream of the proposed start codon and primer 19kDa-3' is located 96bp 
downstream of the proposed termination codon. DNA was extracted from M. avium subsp. 
paratuberculosis as previously described [41]. PCR amplification was performed in 200 |iL 
tubes and cycled in a GeneAmp PCR System 9700 thermocycler (Applied Biosystems; 
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Foster City, CA). Each 50 p,L reaction contained 5 |iL of 10X Expand High Fidelity Buffer 
(Roche Diagnostics Corp., Indianapolis, IN), 1 p,L of dNTP (10 mM each dNTP; Roche 
Diagnostics), 0.5 |iL of 19kDa-5' and 19kDa-3' oligonucleotide primers (100 pmol/p,L each), 
1.7 U of Expand High Fidelity DNA polymerase (Roche Diagnostics), 42 of ultrapure 
distilled water, 2.5 pL of 5% DMSO, and 0.1 fag of M. avium subsp .paratuberculosis 
genomic DNA. Amplification conditions were as follows: 94°C for 2 min, followed by 50 
cycles at 94°C for 15 sec, 55°C for 30 sec, and 72°C for 2 min, with a final 
extension/termination of 72°C for ten minutes and holding at 4°C. PCR amplified products, 
747 bp in size, were visualized on 1.2% agarose gels stained with ethidium bromide. PCR 
products were sequenced at the National Animal Disease Center Genomics Facility using 
19kDa-5' and 19kDa-3' primers. M. avium subsp. paratuberculosis 19kDa nucleotide 
sequences were edited and aligned using EditSeq and MegAlign software (DNASTAR, Inc.). 
Cloning and expression of the M. avium subsp. paratuberculosis 19kDa gene 
Following determination of the M avium subsp. paratuberculosis 19kDa coding region, a 
maltose binding protein (MBP) fusion of 19kDa (MBP-19kDa) was constructed using the 
pMAL-c2 vector (New England Biolabs, Beverly, MA). The 19kDa coding region was 
amplified with Expand High Fidelity PCR system, as described above, but the primers used 
for this amplification were 19kDa-pMal5' (5'-
GCGCCAGCTGACGATCGCGGTCGCGGGCGCGGC-3') and 19kDa-pMal3' (5'-
GCGCAAGÇTTCAGGTCACATCGATCTCGAAC-3 '). The 19kDa-pMal5' and 19kDa-
pMal3' primers contained Pvu II and Hind III restriction sites (underlined) for cloning, 
respectively. This primer set amplified the 19kDa coding sequence minus the N-terminal 4 
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amino acids and the C-terminal 3 amino acids. The pMal-c2 vector was digested with Xmn I 
and Hind III and the PCR amplicon was digested with Pvu II and Hind III. The two products 
were ligated overnight at 12°C with T4 DNA ligase (Life Technologies Inc., Rockville, MD), 
which resulted in an in-frame fusion between the vector-encoded malE gene and a majority 
of the 19kDa gene. The resulting recombinant plasmid, designated pMal-19kDa, was 
transformed into E. coli DH5a competent cells. Recombinant clones were selected by 
plating on LB-ampicillin plates overnight at 37°C. Individual clones were picked and inserts 
were confirmed by DNA sequencing. The resulting fusion protein was overexpressed and 
purified by maltose affinity chromatography using amlyose resin (New England Biolabs). A 
detailed expression and purification protocol has been published previously [44]. Expression 
and purification of the MBP-19kDa fusion protein was monitored by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gels stained with GelCode Blue (Pierce 
Biotechnology Inc., Rockford, IL) and immunoblot analysis with a monoclonal antibody 
against MBP developed at the National Animal Disease Center. Expression and purification 
of the MBP alone (without 19kDa) was previously described [12]. 
Antibody production and purification 
Two New Zealand White rabbits were immunized with the affinity purified MBP-19kDa 
using an immunization protocol previously described [45]. TiterMax (CytRx Corp., Los 
Angeles, CA) adjuvant was mixed 1:1 with MBP-19kDa prior to immunization. Following 
the initial immunization and two subsequent boosts, rabbits were terminally bled and sera 
were collected. 19kDa-specific antibodies were affinity purified from sera using AminoLink 
columns (Pierce Chemical Company). Sera from immunized rabbits were individually 
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passed over columns, followed by three washes and elution according to the manufacturer's 
instructions. Eluted fractions were evaluated for reactivity against MBP-19kDa by 
immunoblot analysis. 
SDS-PAGE and immunoblotting 
E. coli lysates expressing MBP-19kDa were prepared as previously described [46]. PAGE 
was performed using 12% (wt/vol) polyacrylamide gels. Proteins were electrophoretically 
transferred onto nitrocellulose membranes (Schleicher and Schuell, Keene, NH) using the 
Trans Blot Cell (Bio-Rad Laboratories, Hercules, CA) in sodium phosphate buffer (25mM; 
pH7.8) at 0.9 amps for 90 minutes. After transfer, the blots were blocked overnight with 
PBS plus 2% bovine serum albumin (BSA) and 0.1% Tween 20 (PBS-BSA). For 
immunoblots, serum from cattle with clinical Johne's disease were diluted 1:500 in PBS-
BSA. Sera were incubated on the blots at room temperature for 2 hours. After 3 washes in 
PBS plus 0.1% Tween 20, blots were incubated for 1.5 hours in anti-goat peroxidase-
conjugated secondary antibody diluted 1:20,000 in PBS-BSA (Pierce Biotechnology Inc.). 
After secondary antibody incubation, the blots were washed 3 times as described above and 
were developed for chemiluminescent detection using Supersignal detection reagents (Pierce 
Biotechnology Inc.). 
Immunoelectron microscopy 
All fixation and staining procedures were performed at room temperature. M. avium subsp. 
paratuberculosis bacteria were fixed for 2-4 hours in 2.5% glutaraldehyde in 0.1 M 
cacodylate buffer, pH 7.4. Fixed cells were washed 0.1 M cacodylate buffer three times and 
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postfixed in 1% OsC>4 in cacodylate buffer for 2 hours. After washing in cacodylate buffer, 
cells were incubated with 30% ethanol for 10 minutes. The cells were further dehydrated 
with a graded series of ethanol washes before being embedded in epoxy resin (Embed 812, 
Electron Microscopy Sciences, Fort Washington, PA). Ultrathin sections for 
immunoelectron microscopy were washed three times in buffer for 15 minutes and then 
etched with saturated sodium metaperiodate for 15 minutes. The sections were blocked with 
5% BSA for 30 minutes, followed by treatment with affinity purified 19kDa-specific 
antibodies (diluted 1:100 in 5% BSA) for 2 hours. The sections were washed in Tris buffer 
containing 0.1% Tween 20 and 0.1% BSA four times for 10 minutes each and then incubated 
with goat anti-rabbit IgG conjugated to colloidal gold (lOnm diameter) in Tris buffer for 2 
hours. Immunolabelled sections were washed in Tris buffer four times and then fixed with 
1% glutaraldehyde in Tris buffer for 10 minutes. All ultrathin sections were double stained 
with uranyl acetate and Reynolds lead citrate before being observed under a Philips 410 
electron microscope. 
IFN-y assays 
Blood was collected from the jugular vein of subclinically-infected cattle into sodium heparin 
vacutainer blood collection tubes. One ml aliquots of whole blood from each animal were 
plated into 4 wells of 24-well culture plates and cultured alone (non-stimulated) or with 
lOpg/ml of M. avium subsp. paratuberculosis sonicate (MpS), lO^g/ml of MBP, or 10|ig/ml 
of MBP-19kDa. The MpS was prepared by sonication of 1 ml volumes of M avium subsp. 
paratuberculosis in PBS at 25 W for 25 minutes, after which protein concentration was 
determined. Cultures were incubated for 18 hours at 39°C in a 5% CO2 humidified 
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atmosphere. Plates were centrifuged at 500 x g for 15 minutes and the plasma was harvested 
from each well. Plasma samples were frozen at -20°C until being analyzed for IFN-y 
concentration by enzyme-linked immunosorbent assay (ELISA) using a commercial kit 
(Bovigam, BioCor, Omaha, NE) as recommended by the manufacturer. Samples were 
analyzed in duplicate and were determined to be positive for IFN-y production if the 
absorbance of the stimulated sample (MpS, MBP, MBP-19kDa) was 0.1 units greater than 
the absorbance of the nonstimulated well for that animal. This classification of IFN-y 
positive samples has been previously reported by our laboratory as well as others [47-50], 
Statistical analysis 
ANOVA and unpaired t tests were performed to analyze the IFN-y stimulation data. 
Analyses were performed to compared average stimulation of control, non infected cattle to 
the infected cattle groups (suspect, positive, high positive). Differences were considered 
significant when P < 0.05. 
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Figure 1. Nucleotide sequence of the M. avium subsp .paratuberculosis 19kDa coding 
region with corresponding upstream and downstream sequences. The open reading frame 
begins at nucleotide position 1 and terminates at nucleotide position 486. A Shine-Dalgarno 
ribosome binding site (boxed and indicated by S.D.) was located 5 base pairs upstream of the 
initiation codon. A majority of the 19kDa open reading frame was cloned into the pMal-c2 
vector, as indicated by the black bar above the nucleotide sequence. A signal sequence was 
identified near the N-terminal end, with cleavage predicted between amino acids 34 and 35. 
The putative cleavage site is indicated by a double arrow (-11). Two 12 base pair inverted 
repeats were identified downstream of the translation termination site (boxed with arrows and 
indicated by I.R.). 
Figure 2. Amino acid comparison of five mycobacterial 19kDa proteins. Non-conserved 
residues are shaded in black and gaps in amino acid sequence are indicated by hyphens (-). 
M.paratb = M. avium subsp. paratuberculosis; M.avium = M. avium subsp. avium; M.intracel 
= M. intracellulars; M.bo vis = M. bovis; M.tuberc = M. tuberculosis. The predicted signal 
peptidase cleavage site for M. tuberculosis is indicated by a single arrow (i), while the site 
for M. avium subsp. paratuberculosis is indicated by a double arrow (-11). 
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Figure 3. SDS-PAGE analysis of recombinant expression and purification of the MBP-
19kDa fusion protein. The 19kDa protein from M. avium subsp .paratuberculosis was 
cloned into the pMal-c2 expression vector, expressed as a fusion protein with MBP in E. coli, 
and purified by affinity chromatography. MW: molecular weight marker; Lane 1 : un-
induced E. coli; Lane 2: IPTG induced E. coli; Lane 3: affinity purified MBP-19kDa. 
Figure 4. Immunoelectron microscopy with 19kDa-specific antibodies shows cytoplasmic 
localization of the 19kDa protein in M. avium subsp. paratuberculosis. A thin section of 
three bacteria is shown with antibodies bound. The antibodies are labeled with lOnm 
colloidal gold particles to aid in visualization. Magnification 104,000 x. 
Figure 5. Immunonoblot analysis using serum from infected cattle. MBP (lane 1) and 
MBP-19kDa (lane 2) were transferred onto membranes in equal amounts and probed with 
sera from three clinically infected cattle: (A) clinical cow 107; (B) clinical cow 116; (C) 
clinical cow 167. Reactivity was observed for the 19kDa protein but not the MBP protein. 
Figure 6. IFN-y production in response to stimulation with MPS (closed circles) or MBP-
19kDa (open circles). Infected cattle were separated into groups based upon their IFN-y 
responses to MPS: suspect; positive; high positive. The mean IFN-y response to stimulation 
was calculated for each group of cattle (horizontal bar). No statistical difference was 
calculated for MPS or MBP-19kDa stimulation within a group of cattle. A significant 
difference was observed between control, non-infected cattle and high positive, infected 
cattle, P < 0.05, for both MPS and MBP-19kDa. 
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CHAPTER 6. GENERAL CONCLUSIONS AND FUTURE STUDIES 
Conclusions 
The goal of the first study was develop and test a DNA vaccine against 
paratuberculosis in a mouse infection model. As a preliminary experiment, the lacZ gene 
was cloned into a mammalian expression plasmid and in vivo expression of (3-galactosidase 
was analyzed after immunization of mice with naked DNA. This initial experiment 
demonstrated that a known prokaryotic gene could be expressed in tissues of mice via gene 
gun transaction. Next, a mouse infection study was performed with three M. 
paratuberculosis strains and two mouse strains to determine which model provided the 
highest and most consistent level of infection, Balb/cJ mice IP infected with M. 
paratuberculosis strain 6112 were found to be the best infection model. Finally, a M. 
paratuberculosis genomic DNA expression library was generated and subdivided into pools 
of clones. Eleven clone pools were evaluated to determine DNA vaccine efficacy by 
immunizing Balb/cJ mice via gene gun delivery and challenging with live, virulent M 
paratuberculosis strain 6112. Four clone pools demonstrated a significant reduction (P < 
0.05) of M. paratuberculosis infection in spleens and mesenteric lymph nodes when 
compared to other clone pools and nonvaccinated, infected control mice. 
In the second study, one of the protective clone pools was partitioned into 10 new 
clone arrays of 108 clones each. A second DNA immunization experiment was performed to 
identify clone arrays that protected groups of mice from M. paratuberculosis challenge. Four 
clone arrays provided significant protection (P < 0.05) from bacterial challenge. Comparison 
of the nucleotide sequences from protective clone arrays revealed 26 antigens that 
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contributed to protection in mice. The proteins most commonly shared among protective 
arrays were major membrane proteins, proline-rich antigens, PPE-family proteins, and 
mycobactin/exochelin synthesis proteins. Additionally, cytokine production was analyzed 
after DNA immunization with protective clone arrays to assess the immunologic response. A 
protective DNA vaccine induced IL-10, IL-12, and IFN-y cytokine production, which 
indicates induction of both ThI and Th2 immune responses. Additionally, the optimum ThI 
cytokine production was induced after vaccination with 10 ng of DNA, as compared to 2 fig, 
200 ng, 20 ng, or 2 ng of DNA. 
In a final experiment, we evaluated the efficacy of the M paratuberculosis 19 kDa 
lipoprotein as an immunomodulator in cattle with Johne's disease. Control, non-infected 
cattle did not produce antibodies or cell-mediated immune responses against the 19 kDa 
protein. However, the 19 kDa protein induced cellular immune responses (IFN-y production) 
in subclinically infected cattle and induced humoral immune responses (19 kDa-specific 
antibody production) in clinically infected cattle. This study demonstrated that the 19 kDa 
protein stimulates both cellular and humoral immune responses in naturally-infected cattle 
and suggests that the 19 kDa protein may be useful as a sérodiagnostic tool. 
Taken together, these three studies have identified a number of M. paratuberculosis 
antigens that are immunogenic and, in the case of the two DNA vaccine trials, protective. 
Additionally, the immunological responses have been characterized for both mice and cattle 
in response to these proteins. 
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Future Studies 
It is extremely important that the second DNA vaccination experiment be repeated to 
further support the data presented in this dissertation. In particular, the four protective clone 
arrays need to be re-tested in mice to confirm their protective effects. Additionally, the 26 
proteins that were identified by sequence analysis of the protective clone arrays should be 
assembled into a new DNA vaccine to determine if these proteins do, in fact, protect mice 
from infection. Because this series of experiments has dramatically reduced the number of 
M. paratuberculosis sequences, it may now be possible to proceed to a calf-infection model 
(Stabel et al., 2003). This was the ultimate goal at the start of this experiment and it will be 
interesting to see if protection in mice correlates with protection in cattle. It will also be 
extremely useful to perform detailed immunologic studies of cattle prior to vaccination, 
during vaccination and boost, and during the initial stages of infection. When this data is 
compared with non-vaccinated, infected cattle, this may provide important clues to disease 
prevention and improved vaccine development. 
A number of hypothetical and unknown proteins are also encoded in the protective 
clone arrays (data not presented), but it is not possible to determine what role these may play 
in protection from bacterial infection. It is important that these sequences not be discarded 
without further evaluation. Indeed, a recent study in our laboratory has shown that five 
sequences unique to M. paratuberculosis, but without proposed function, are immunogenic in 
clinical Johne's cattle (Bannatine et al., 2004). 
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APPENDIX A. PRELIMINARY DNA VACCINATION EXPERIMENT 
Materials and Methods. As a preliminary experiment, 26 clone pools were generated and 
selected as described in Chapter 3. Each clone pool had an average of 1500 clones. These 
26 clone pools were named from "A" to "Z", sequentially, and are distinct from clone pools 1 
to 11 described in Chapter 3. C57BL/6J mice were randomly partitioned into immunization 
groups of 5 as follows: 1. no DNA - non-infected; 2. no DNA - infected; 3. microcarrier-
infected; 4. vector DNA - infected; 5. clone pool DNA - infected. For control group 3 
(microcarrier - infected), mice were immunized with 0.5 mg of gold microcarrier beads, 
without any plasmid DNA. For control group 4 (vector DNA - infected), mice were 
immunized with 0.5 mg of gold microcarrier beads carrying 1 p,g of pVAX-Koz. Twenty-six 
clone pools (A - Z) were tested in mice in this preliminary trial. Clone pool A was used to 
immunize a group of 5 mice, clone pool B was used to immunize a second group of 5 mice, 
and so on. DNA for immunization was prepared and delivered as described in Chapter 3. 
Each clone pool-immunized mouse was transfected with 0.5 mg of gold microcarrier beads 
carrying 2 fig of clone pool DNA. Each group of mice was boosted with the same DNA 
vaccine 3 weeks after the initial immunization. Two weeks after boosting, mice were 
inoculated intravenously (IV) in the tail vein with live M. avium subsp. paratuberculosis 
strain 19698-1974 (log-phase, 108 bacteria per mouse in 100 yiL volume of PBS). Control 
group 1 (no DNA - non-infected) mice were given a mock-challenge by intravenous injection 
of 100 piL with sterile PBS. After three months of infection, blood was taken for serum 
isolation and tissues were taken for culture as described in Chapter 3. 
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Results. The protective effect of each DNA vaccine was correlated with a lower recovery of 
bacteria from the spleens and mesenteric lymph nodes of mice immunized with clone pools 
relative to the vector DNA control mice (Table 1). PBS mock-infected mice (no DNA - non-
infected) were negative for M. avium subsp. paratuberculosis infection while the vector 
DNA - infected mice had an average of 218 CFU/mg of spleen and 95 CFU/mg of mesenteric 
lymph node. Two other infected control groups (no DNA - infected; microcarrier - infected) 
had a low level of infection, when compared to the vector DNA - infected control group, and, 
thus, were not used for protection analysis. Three clone pools (U, W, and X) offered 
significant levels of protection, P < 0.05 (Table 1), from spleen infection, with less than 1 
CFU/mg of spleen. Clone pools C, E, and F also substantially reduced bacterial infection in 
the spleen, with less than 10 CFU/mg of spleen, but the P values for these clone pools were 
0.12, 0.12, and 0.09, respectively. Interestingly, clone pool N appeared to enhance M. avium 
subsp. paratuberculosis infection 5-fold in the spleens of immunized mice versus vector 
DNA - infected mice. Clone pools C, E, W, and X offered significant levels of protection 
from bacterial infection in the mesenteric lymph node (Table 1), with less than 1 CFU/mg of 
mesenteric lymph node. Substantial reductions in mesenteric lymph node bacterial infection 
were also observed from clone pools A, H, K, and U. In general, higher numbers of bacteria 
were consistently recovered from the spleens of infected mice in our model, therefore, we 
based our claim of protection upon the data from spleens. 
Additionally, immunoblot analysis was performed to confirm that mice were 
mounting a humoral immune response against M. avium subsp. paratuberculosis proteins 
after DNA immunization and bacterial challenge. Although not a complete analysis of all 
clone pool sera, this experiment was also performed to confirm that each clone pool induced 
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a different immune response, thus validating that every clone pool was unique. Serum from 
the no DNA - non-infected group did not recognize any M. avium subsp. paratuberculosis 
proteins, as expected. Sera from all groups of infected mice reacted strongly with 15kDa and 
70kDa proteins (Figure 1). Additionally, different reactivity profiles were observed for each 
clone pool, indicating that each clone pool produced a unique set of mycobacterial proteins to 
which antibodies were produced. Sera from the control-infected groups (no DNA - infected; 
microcarrier - infected; vector DNA - infected) reacted with many bacterial proteins. In 
particular, the no DNA - infected group strongly reacted with 30kDa and 37kDa proteins 
(Figure 1), despite the fact that fewer bacteria were recovered from these mice than the 
vector DNA - infected group (Table 1). Sera from mice that were protected from infection 
(clone pools C, F, U, W, and X) exhibited some subtle reactivity differences from clone 
pools that did not protect mice from challenge (Figure 1). For example, a 90kDa protein was 
recognized by the sera of non-protected mice that was absent from the protective clone pools. 
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Table 1. Preliminary vaccine trial bacterial infection data. 
Immunization Group 
Spleen Mes LN 
CFU/mg' SEM P value0 CFU/mgb SEM P value0 
No DNA - non-infected 0.0 0.0 0.0 0.0 
No DNA - infected 13.7 12.4 14.4 14.0 
Microcarrier - infected 21.1 14.6 13.7 12.9 
Vector DNA - infected 218.8 177.3 95.3 87.6 
Clone pool A 15.6 13.7 0.1557 3.9 3.8 0.1461 
Clone pool B 153.1 84.5 0.4195 61.5 45.4 0.4152 
Clone pool C 6.3 4.4 0.1237 0.0 0.0 0.0447 
Clone pool D 36.4 21.9 0.2180 122.5 72.9 0.5441 
Clone pool E 4.4 1.3 0.1235 0.1 0.1 0.0461 
Clone pool F 3.4 3.2 0.0972 13.9 13.5 0.2507 
Clone pool G 40.3 37.2 0.2854 275.9 275.9 0.5301 
Clone pool H 27.7 18.6 0.1797 4.8 4.4 0.1905 
Clone pool I 132.4 121.0 0.3319 125.3 124.9 0.5386 
Clone pool J 237.9 206.1 0.5651 10.2 7.9 0.2461 
Clone pool K 17.3 8.0 0.1944 4.5 4.2 0.1635 
Clone pool L 269.0 233.4 0.6247 1007.5 998.2 0.6603 
Clone pool M 167.4 95.5 0.4112 107.5 106.8 0.5372 
Clone pool N 1123.0 486.3 0.9417 49.2 22.0 0.4681 
Clone pool 0 25.8 12.6 0.1859 11.7 7.4 0.3223 
Clone pool P 419.8 225.5 0.7473 225.1 194.4 0.7395 
Clone pool Q 67.5 28.4 0.3474 120.2 48.9 0.5727 
Clone pool R 473.2 436.8 0.5713 37.9 34.3 0.2840 
Clone pool S 70.6 67.4 0.2614 28.0 27.9 0.2440 
Clone pool T 47.7 43.2 0.3035 30.8 30.8 0.2455 
Clone pool U 1.0 0.6 0.0351 0.1 0.0 0.0910 
Clone pool V 72.9 45.8 0.2866 36.6 28.5 0.3685 
Clone pool W 0.4 0.2 0.0188 0.3 0.3 0.0245 
Clone pool X 0.1 0.0 0.0180 0.0 0.0 0.0000 
Clone pool Y 70.8 63.7 0.2894 66.7 66.7 0.2151 
Clone pool Z 181.8 83.1 0.4388 53.6 33.2 0.3757 
a The average number of colony forming units per mg of homogenized spleen from an immunization group of 5 
C57BL/6J mice. 
b The average number of colony forming units per mg of homogenized mesenteric lymph node (Mes LN) from 
an immunization group of 5 C57BL/6J mice. 
c P values for each clone pool as compared to vector DNA - infected control group. P < 0.05 are in bold. 
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Figure 1. Immunoblots from control, vaccinated, and challenged mice from preliminary 
vaccine trial. Sera from mice were incubated with M. avium subsp. paratuberculosis proteins 
to assay for reactivity. Lanes - Ng: No DNA - non-infected; Ps: No DNA - infected; Gd: 
microcarrier - infected; pV: vector DNA - infected; clone pools as lettered. Brackets above 
the lane numbers cluster the vaccination groups into infected control groups, protected 
groups, and non-protected groups (from left to right). 
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APPENDIX B. CLONING AND EXPRESSION OF SEVEN IMMUNOGENIC 
PROTEINS FROM MYCOBACTERIUM A VIUM SUBSP. PARA TUBERCULOSIS 
Materials and Methods 
Random shotgun sequencing of M. paratuberculosis library clones revealed several 
sequences with similarity to virulence genes in other mycobacteria. Seven M. 
paratuberculosis coding sequences (19 kDa lipoprotein, exiT, mce, mig, mmp, sec A, and 
sugl) were selected based on homology to known membrane or secreted proteins in other 
mycobacteria. The proposed function of each protein is listed in Table 1. PGR primers used 
to amplify potential immunogenic genes are shown in Table 2. PCR amplification, cloning 
into the pMAL-c2 expression vector, expression, and purification was performed as 
described in Chapter 5. The purified proteins were analyzed by SDS-PAGE to assess purity 
and confirm size (Figure 1). 
Immunoblot analysis, as described in Chapter 5, was performed to determine if cattle 
naturally infected with M. paratuberculosis produced antibodies against any of the seven 
purified proteins. Blots were probed with sera from 8 clinically-infected cattle and 4 non-
infected cattle. Additionally, the cellular immune responses of 8 subclinically-infected cattle 
and 5 non-infected cattle to each protein of interest was determined by stimulation of whole 
blood with purified protein. Whole blood stimulation and IFN-y production was assayed as 
described in Chapter 5. 
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Results 
The seven purified proteins were transferred to blots and probed with serum from 8 
clinically-infected (Figure 2) and 4 non-infected (Figure 3) cattle. Although 8 of 8 clinically-
infected cattle produced antibody to the SecA protein, 4 of 4 non-infected cattle also 
recognized the SecA protein. Sera from 5 of 8 clinically-infected cattle reacted with the ExiT 
protein, whereas sera from 4 of 4 non-infected cattle also recognized the ExiT protein. Sera 
from 5 of 8 clinically-infected cattle reacted with the 19kDa protein, while 2 of 4 non-
infected cattle produced antibodies against the 19kDa protein. 
Whole blood from 8 subclinically-infected and 5 non-infected cattle was stimulated 
with the M. paratuberculosis sonicate, the MBP fusion protein, and seven purified M. 
paratuberculosis proteins. IFN-y production in response to 24 hour incubation was assayed 
and the response from non-stimulated cells was subtracted from each value (Table 3). 
Overall, the majority of subclinically infected cattle produced the highest amount of IFN-y to 
ExiT, followed by SecA, Sugl, Mig, and the 19kDa protein, respectively. The majority of 
non-infected cattle produced the highest amount of IFN-y after stimulation with ExiT, 
followed by 19kDa, Sugl, and SecA, respectively. 
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Table 1. Potential antigenic proteins and their proposed function. 
Protein Description 
19kDa Cell wall associated lipoprotein; Generates good humoral and CD4+ immune responses 
ExiT Exochelin excretion on cell surface; Associated with iron acquisition inside the macrophage 
Mce Macrophage Cell Entry; Attachment and entry into macrophages 
Mig Macrophage Induced Gene; Present on surface of bacteria only when inside macrophages 
Mmp Major Membrane Protein; Described by Bannantine et al., 2003 
SecA Protein exporter on cell surface; Associated with export of culture filtrate proteins 
Sugl Sugar transporter on cell surface 
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Table 2. PGR primers used to amplify potential immunogenic genes. 
Primer name Rest, site Primer sequence1 
19kDa-5' Pvu II GCGCCAGCTGACGATCGCGGTCGCGGGCGCGGC 
19kDa-3' Hind III GCGCAAGCTTCAGGTCACATCGATCTCGAAC 
ExiT-5'.l Pvu II GCGCCAGCTGGGCCGCGGCGACCATC 
ExiT-3' Hind III GCGCAAGCTTCTACAGAGTCGCGCCGAG 
Mce-5'A Pvu II GCGCCAGCTGGTGCTGGATGTGGAT 
Mce-3'D Hind III GCGCAAGCTTCAGAACAGTTCGGGGCT 
Mig-5'.l Pvu II GCGCCAGCTGTCCGACACCACAACAG 
Mig-3',2 Hind III GCGCAAGCTTCACTGGGCCGC 
Mmp-5' Stu I GCGCAGGCCTGATCTGGCTGCCAGGCAACTC 
Mmp-3' Hind III GCGCAAGCTTCACTTGTACTCATGGAACTG 
SecA-5' Pvu II GCGCCAGCTGGTTCATGAATTCGTCGAC 
SecA-3' Hind III GCGCAAGCTTCTAGTGGCGAGGTTCGACAGCCA 
SugI-5' Pvu II GCGCCAGCTGGCGACCGTCATCGCCCTG 
SugI-3' Hind III GCGCAAGCTTCAGGACAGGTGCCGCAGCCG 
1 Restriction site encoded by each primer is underlined 
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Table 3. IFN-y response of subclinically infected and non-infected cattle to protein 
stimulation. 
Cow Protein1 
MPS MBP 19kDa ExiT Mig Mce Mmp SecA Sugl 
Subclin. 113 0.275 0.0465 0.0835 0.2445 0.1205 0.0885 0.0725 0.1845 0.144 
Subclin. 116 0.4808 0 0.0075 0.0925 0.015 0.003 0 0.048 0.026 
Subclin. 177 0.2043 0.0148 0.029 0.299 0.1948 0.0435 0 0.1752 0.2083 
Subclin. 153 0.0675 0 0 0.0995 0.019 0 0 0.0315 0 
Subclin. 155 0.099 0.0035 0.0055 0.0215 0.038 0.003 0.008 0.0215 0.027 
Subclin. 156 0.3905 0.0275 0.1065 0.628 0.253 0.1035 0.066 0.362 0.29 
Subclin. 231 0.224 0.009 0 0.247 0.071 0.0175 0.017 0.096 0 
Subclin. 235 0.4435 0.0348 0.1113 0.1545 0.0912 0.0355 0.0463 0.0512 0.0752 
MPS MBP l9kDa Exit Mig Mce Mmp Sec Sug 
Control 109 0 0.095 0.0525 0.045 0.0135 0 0 0.001 0.017 
Control 1 1 1  0 0 0 0.14 0.0155 0.001 0 0.0475 0.05 
Control 182 0 0 0.03 0.018 0 0 0 0.002 0.0075 
Control 183 0.0475 0.0045 0.013 0.1445 0.0135 0.0025 0 0.01 0.0215 
Control 184 0 0.017 0.0415 0.231 0.03 0.028 0 0.0845 0.073 
1 Proteins used for stimulation were M. paratuberculosis sonicate (MPS), maltose binding protein (MBP), 
I9kDa lipoprotein, ExiT, Mig, Mce, Mmp, SecA, and Sugl. 
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Figure 1. Purified proteins were run on a SDS-PAGE gel and Coomassie stained. 
Figure 2. Immunoblot analysis from 8 subclinical^ infected cattle (panels A - H). 
Figure 3. Immunoblot analysis from 4 control, non-infected cattle (panels A - D). 
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